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ABSTRACT
A range of biochemically diverse molecules located in the plasma membrane—
such as proteins, glycans, and lipids—mediate cellular recognition events,
initiation of signalling pathways, and the regulation of processes important for
the normal development and function of multicellular organisms. Interactions
mediated by cell surface receptors can be challenging to detect in biochemical
assays, because they are often highly transient, and membrane-embedded
receptors are difficult to solubilise in their native conformation. The biochem-
ical features of low-affinity extracellular protein interactions have therefore
necessitated the development of bespoke methods to detect them.
Here, I develop a genome-scale cell-based genetic screening approach
using CRISPR-Cas9 knockout technology that reveals cellular pathways re-
quired for specific cell surface recognition events. Using a panel of high-affinity
monoclonal antibodies, I first establish a method from which I identify not only
the direct receptor but also other required gene products, such as co-receptors,
post-translational modifications, and transcription factors contributing to anti-
gen expression and subsequent antibody-antigen recognition on the surface
of cells. I next adapt this method to identify cellular factors required for re-
ceptor interactions for a panel of recombinant proteins corresponding to the
ectodomains of cell surface proteins to the endogenous surface receptors
present on a range of cell lines. In addition to finding general cellular features
recognised by many ectodomains, I also identify direct interaction partners of
recombinant protein probes on cell surfaces together with intracellular genes
required for such associations.
Using this method, I identify IGF2R as a binding partner for the R2 subunit of
GABAB receptors, providing a mechanism for the internalisation and regulation
of GABAB receptor signalling. The results here demonstrate that this single
approach can identify the molecular nature and cell biology of surface receptors
without the need to make any prior assumptions regarding their biochemical
properties.
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CHAPTER 1
INTRODUCTION
Communication between cells is crucial for the normal development and func-
tioning of a multicellular organism. Membrane-compartmentalised cells receive
instructional information from their surroundings by extracellular signalling cues
which are often initiated via specific binding events made by plasma-membrane
embedded receptors. While some extracellular signals are received via soluble
factors (e.g. secreted proteins, hormones, autacoids, and neurotransmitters),
others act through direct cell-cell interactions between specific receptors ex-
posed on the outer surface of apposing cells [1]. Understanding of the molec-
ular basis of cellular recognition events has wide implications as a multitude
of cellular processes such as differentiation, motility and proliferation of cells
depend on inter-cellular communication mediated by membrane receptors.
Interactions between our own cells (e.g. neural and immunological recogni-
tion) as well as between host cells and pathogens also rely on extracellular
recognition and signalling events. This, together with the fact that membrane
receptors are directly accessible to systematically delivered biological reagents
such as monoclonal antibodies [2] and small-molecule antagonists [3], make
the study of membrane receptors therapeutically attractive. In fact, cell surface
receptors currently make up the largest group (44 %) of human drug targets
[4]. Thus, elucidation of cellular recognition processes is of significant interest
for advances in biomedical research.
1.1 Molecules mediating cell surface recognition
A wide range of biochemically diverse molecules located in the plasma mem-
brane of cells such as proteins, carbohydrates, and lipids have the potential to
mediate cell surface interactions that are required for a vast range of biological
processes [5]. In this section, I will review some aspects of each of these in
turn.
1
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1.1.1 Proteins
Nearly a quarter of the human genome encodes for either secreted or membrane-
bound proteins [6, 7]. An intregral membrane protein that is embedded within
the lipid bilayer of the plasma membrane is intrinsically amphipathic in nature.
The domain exposed to the exterior of the cell (ectodomain) is hydrophilic,
often glycosylated and is responsible for binding to the ligand, whereas the
transmembrane region is hydrophobic to allow the receptor to exist within the
plasma membrane. The intracellular domain of membrane receptors is in direct
contact with the components of the cellular cytoplasm, which allows some
membrane proteins to function as ‘signal transducers’ to transmit extracellular
signals across the membrane to influence cellular behaviour in a context (a
cell or signal type) dependent manner [8].
Membrane proteins that behave as signal transducers can be broadly cate-
gorised into three groups: Ion channels, G-protein linked receptors, (GPCR)
and enzyme-linked receptors. Ion channels are usually multimeric and form
an aqueous pore in the plasma membrane that, upon specific perturbation,
allow movement of inorganic ions in and out of the cells [9]. Voltage-gated
ion channels respond to change in membrane potential whereas transmitter
gated channels respond to binding of neurotransmitters [10, 11]. The second
class of signal transducers, GPCRs, are one of the most diverse receptors
that can transmit diverse extracellular signals ranging from peptides, lipids,
neurotransmitters and nucleotides to light, Ca+ and odorants [12, 13, 14, 15].
There are approximately 800 identified members in the GPCR superfamily
in the human genome. Despite the large diversity of GPCRs, they interact
with a relatively small number of heterotrimeric (composed of α, β and γ sub-
units) G proteins to initiate intracellular signalling cascades [16]. GPCRs are
usually characterised by the presence of seven-transmembrane regions and
this includes a class of approximately 140 GPCRs called ‘orphan GPCRs’
whose sequence is known but the endogenous ligands to which they bind are
still largely unknown [17]. The third class of signal transducers are enzyme
linked receptors which, unlike the GPCRs, are usually single transmembrane
proteins that, instead of recruiting a G-protein for signalling activity, usually
contain intrinsic enzymatic activity in their cytoplasmic domain or associate
directly with enzymes with signalling capabilities. Six different classes of en-
zyme linked receptors have been described: (1) receptor guanylyl cyclases,
(2) receptor tyrosine phosphatases, (3) receptor serine/threonine kinases, (4)
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receptor tyrosine kinases, (5) tyrosine kinase-associated receptors, and (6)
histidine-kinase-associated receptors [18].
1.1.2 Glycans
The second class of molecules that mediate cellular interactions are com-
plex carbohydrates or glycans. This is one of the most diverse classes of
macromolecules found in nature. Mammalian glycomes are predominantly
created out of numerous combinations of nine common sugars (Glucose,
N-acetylglucosamine, Galactose, N-acetylgalactosamine, Mannone, Fucose,
Glucosamine, (or isomer L-Iduronic acid), Xylose, and N-Acetylneuraminic
acid). Glycans can be found displayed at cell surfaces, incorporated into the
extracellular matrix and covalently attached to secreted glycoproteins. Most
eukaryotic cells are surrounded with a dense coat consisting of glycans and
glycoconjugates (glycocalyx) that is important not only for providing protective,
organisational, and barrier functions to the cell but also for mediating cellular
communication [19]. Glycans can act as direct receptors for glycan binding
proteins (GBP), which can be broadly classified into two groups: lectins and gly-
cosaminoglycan (GAG) binding proteins. The origins of lectin, a term derived
from the Latin word “legere,” meaning “to select”, dates back to 1888 when
Herrmann Stillmark first described the animal red blood cell agglutination prop-
erties of extracts of castor bean seeds. Subsequently, lectins were identified in
almost every plant species and today the stock of known lectins has increased
vastly to include those from viruses (hemagglutinins), bacteria (adhesins and
toxins), invertebrates and vertebrates. Lectins are usually characterised by
the presence of evolutionarily conserved “carbohydrate recognition domains”
(CRDs) [20]. This is in contrast to GAG binding proteins that are evolutionarily
unrelated to each other and rather than possessing a specific binding domain,
rely on basic residues to mediate interaction with the negatively charged sul-
phated groups of GAGs. An important consideration for the interaction of
GBPs with their glycan ligands is the principle of multivalency. The binding
affinity of a single glycan to GBP is low; thus to achieve biologically significant
interaction, glycans that bind GBPs contain a multiple repeating structure for
increased avidity [21].
1.1.3 Lipids
The third class of macromolecules that mediate cellular recognition and sig-
nalling processes are lipids. Although lipids have been suggested to be as
3
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diverse as proteins, we have a much poorer understanding of their functions.
In the past, lipids were mainly studied in the context of structural components
of the plasma membrane or intermediary metabolites. The initial studies delin-
eating the pathophysiological roles of specific lipid molecules (prostaglandins
and leukotrienes) first suggested a role for lipids as intracellular signalling
molecules [22, 23]. Plasma membrane lipids are mainly composed of phos-
pholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine,
and sphingomyelin) and cholesterol. Since the identification of inositol phos-
pholipids as a plasma membrane lipid crucial for cellular signalling [24], much
research has been devoted to understanding the mechanism by which lipid
molecules carry out signalling functions in cells [25]. The cellular lipid pool
also includes glycans and proteins that are covalently modified by lipids. Both
plasma membrane and intracellular organelle membrane glycans are modified
by lipids to form glycolipids (e.g, glyceroglycolipids, glycosphingolipids, sulfo-
glycosphingolipids and gangliosides), which serve both as signalling molecules,
recognition sites for cell–cell interactions [26, 27, 28], and receptors of bacteria
and bacterial toxins [29, 30, 31].
Similarly, proteins are also post-translationally modified with lipids (e.g,
myristoylation, palmitoylation, geranylgeranylation, GPI (Glycosylphosphatidyli-
nositol) anchored) [32]. Some of these lipid-modified proteins, specifically
those with a GPI anchor, cholesterol-linked and palmitoylated proteins such
as hedgehog, are particularly enriched in the specific micro-environment of
the plasma membrane; these are termed ‘lipid rafts’. Lipid rafts that contain
defined sets of proteins are known to be important for signal transduction
processes in cells [33].
Here, I will mainly focus on extracellular protein-protein and protein-glycan
interactions including those mediated by glycoproteins, glycolipids, proteogly-
cans and lipid modified proteins. I will first discuss some of the challenges
in studying interactions mediated by membrane receptors. Next I will intro-
duce the major methods that have been designed to address some of these
challenges and discuss their applicability and their limitations. Finally, I will
introduce the recent genetic loss-of-function screening approaches including
those using the CRISPR-Cas9 technology and their potential for studying cell
surface interactions.
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1.2 The challenges of studying extracellular ligand-
receptor interactions
Even though extracellular interactions mediated by membrane receptors have
been recognised to be of biological and pharmacological importance, inves-
tigating such interactions remains technically challenging. The inherent bio-
chemical properties of extracellular space exposed membrane proteins, such
as their relatively low abundance (typically 104 to 105 copies per cell) and
amphipathic nature causing poor solubility, make them difficult to isolate, pu-
rify, solubilise, and biochemically manipulate [34]. Advances in approaches
such as (Immuno)affinity-based techniques combined with mass-spectometry
(MS) [35, 36, 37], yeast two-hybrid-based methods (Y2H) [38], and in-vitro
array-based technologies [39, 40], now allow interrogation of protein-protein
interactions at a large scale. However, such approaches are generally consid-
ered unsuitable to study extracellular interactions as the affinities of binding
between two membrane receptor proteins are usually weak (KD in µM to mM
range) with fast dissociation rate constants (half lives of the order of one sec-
ond). This poses challenges in detecting such interactions in approaches that
require stringent wash steps such as affinity purification and MS. Moreover,
membrane proteins are usually post-translationally modified with structurally
critical glycans and disulfide bonds; this limits the use of prokaryotic heterolo-
gous systems or cell-free systems that lack the oxidative environment and the
cellular machinary to generate correctly folded and glycosylated recombinant
membrane proteins [41, 42].
Historically, the study of interactions between glycans and proteins has also
been challenging because of the high diversity of glycans and the difficulties
in obtaining glycans in high quantities in homogenous form [43]. Common
methods to detect the low-affinity monovalent interactions between a single
carbohydrate ligand and a single binding domain of a protein, such as inhibition
studies using soluble mono- and oligosaccharides, isothermal calorimetry,
surface plasmon resonance (SPR), and enzyme-linked lectin assays (ELLA),
require large quantities of purified glycans with precise structures, which are
not always readily available [21]. Unlike proteins, glycans cannot be readily
cloned as they are secondary gene products and are not encoded directly in the
genome. The particularly high diversity of glycans is the result of biosynthetic
enzymes (glycosyltransferases, glycosidases, sulfotransferases, etc.) that
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generate them, which act together in numerous combinatorial possibilities to
generate highly heterogenous glycan chains [44]. These enzymes are dynamic
and respond to environmental cues to act in a context specific manner, which
makes it difficult to predict the exact nature of the glycan generated by cells.
Glycans have also been found to have different roles in cell cultures compared
to whole organisms. In the relatively simple environment of a cell culture
system, genetic defects in glycans usually do not have severe biological
consequences; however, the same defects have been shown to have major
phenotypic consequence in a complex multicellular organism, in which glycans
are involved in mediating important cell-cell and cell-matrix interactions [45, 46].
This has complicated the interpretation of the role of glycans from genetic
studies.
1.3 Methods to study extracellular protein-protein
interactions
1.3.1 General overview
Historically, a range of biochemical and genetic methods have been used to
identify specific extracellular receptor-ligand interactions. Almost four decades
ago, the receptors for platelet-derived growth factor (PDGF), epidermal growth
factor (EGF) and insulin were all isolated using similar biochemical methods
that involved co-purification of chemically cross-linked receptors from cells that
interacted with radiolabelled (Iodine-125) ligand [47, 48, 49, 50]. Upon isolation
of the target receptor, common approaches were to either (i) microsequence
parts of the protein to generate nucleic acid probes to screen a complementary
DNA (cDNA) library generated from the tissue of interest to isolate the cDNA
that encoded for the receptor of interest or, (ii) generate antibodies from the
purified protein to carry out immunoscreening of cDNA expression libraries
(reviewed in [51]). cDNA expression cloning was commonly used especially in
the field of cell surface receptor characterisation of lymphocytes, where cDNA
clones were transiently transfected into cells and screened with monoclonal
antibodies to "pan" for cells that express the receptor [52, 53]. The use of inter-
action blocking monoclonal antibodies has also led to discovery of extracellular
interactions especially in the context of immune cell interactions [54, 55]. Mon-
oclonal antibodies have also contributed majorly to the identification of virus
receptors for human immunodeficiency virus [56, 57] and rhinovirus [58, 59].
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Early methods also included direct cell-cell binding assays using cell types
that either expressed the interacting molecules in their endogenous forms
or that had been transfected to express the receptor (or ligand) of interest.
This was first demonstrated with T-lymphocytes expressing CD2 cell surface
marker that formed “rosettes” with erythrocytes that expressed CD58, the
receptor for CD2 [60]. A variation on this when studying interactions mediated
by non-erythrocytic cells, was the cell aggregation assay, which has been
used to identify both hereophilic [61] and homophilic [62] interactions. Finally,
genetic approaches have also been mainly in the context of neuronal cell inter-
actions to identify receptors using inferences from phenotypes of specific gene
targeted mutants in model organisms (Caenorhabditis elegans and Drosophila
melanogaster ) [63, 64, 65].
The completion of the human genome project was quickly followed by
multiple studies that mapped the human membrane proteome to annotate
proteins that have the potential to participate in extracellular interactions [66,
67, 68]. While the basic principles of the methods used in the post-genomic
era have not changed dramatically compared to the conventional methods,
the knowledge of the cellular secretome has allowed these methods to be
high-throughput. Here I will highlight the key aspects of some of these post-
genomic methods and their utility in understanding molecular mechanisms of
cellular interactions. These will exclude the genetic knockdown or knockout
screening approaches, which will be discussed separately in section 1.6.
1.3.2 Cell-based binding assays
Cell-cell binding assays
Extracellular receptor-ligand interactions can be studied by investigating di-
rect cell-cell adhesion, in which two cell types that express different sets of
membrane proteins are mixed together and the binding is detected with mi-
croscopy or by labeling with a radioisotope or fluorochrome [69, 70, 71]. In
the recent years, efforts have been made to improve such assays in terms of
their sensitivity and quantifiability. For example, in a proof-of-principle demon-
stration of one of the recent approaches, the low-affinity interaction between
the adhesion receptors, JAM-B and JAM-C was detected using a cell–cell
mixing experiment with cDNA transfected CHO cells expressing the receptors
in a GPI anchored form [71]. It was suggested that the addition of the GPI
anchor to the surface receptors aids their lateral diffusion, thereby facilitating
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ligand-induced clustering. The cells were differentially labelled with DiI or DiD
phospholipid binding dyes, which could then be analysed by flow-cytometry,
such that interactions could be readily detected based on the fraction of cells
containing signals from both dyes. While such approaches provide platforms
to study interactions in the context of the plasma membrane, their results
can be confounded by the potential for non-specific cell–cell clustering usually
mediated by endogenous adhesion receptors whose expression can be altered
during the course of the experiment (for example by transfection or signalling
derived from the exogenously expressed genes).
A slightly different approach in this context has been the Baculovirus (BV)
display system, in which a library of BV particles expressing the membrane
protein of interest is used to screen for interactions (reviewed in [72]). For this,
insect cells are transduced with BV encoding for a given membrane receptor
and as the viral particle buds off from the cell membrane it will incorporate the
overexpressed membrane protein. The virions can be used as ‘nanoparticles’
to screen for interaction with whole cells that express the interacting receptor
[73]. This approach has been validated for low-affinity interaction study by
detecting the interaction between BV particles displaying CD58, CD40 and
glucocorticoid-induced tumor necrosis factor (TNF) receptor family-related
protein (GITR) and cells expressing the respective ligands, CD2, CD40 ligand
(CD40L) and GITR-ligand (GITRL), using a flow-cytometry based binding
assay.
Cell-recombinant protein interaction assays
Recombinant proteins are common tools used in many methods designed
to study cell surface interactions. A common theme in any approach that
uses recombinant proteins is the purposeful oligomerisation of proteins, which
generates avid probes, allowing detection of low-affinity interactions. Common
approaches for this include tagging proteins with coiled-coil sequence from rat
cartilage oligomeric matrix protein (COMP)–which causes spontanous protein
pentamerisation or with human immunoglobulin-γ (Fc)-fusion or alkaline phos-
phatase (AP)-fusion proteins– which allows for protein dimerisation. Further
multimerization approaches, for example, conjugating Fc-fusion tagged protein
to protein-A microbeads and conjugating AP to anti-AP antibody to generate
tetramers are also used to achieve even higher avidity [42]. Avid probes gen-
erated in this way can be used to screen for interactions with endogenous or
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over-expressed receptors (for example by cDNA transfection) on the intact cell
surface.
Libraries of cDNAs encoding a broad range of receptors have been widely
used to study extracellular receptor-ligand interactions in the context of immune
regulation, axon guidance mechanisms, ‘de-orphanising’ GPCRs, egg-sperm
interaction, and host-pathogen interactions [74, 75, 76, 77, 78, 79]. In this
method, cDNA expression vectors, with each vector expressing one receptor
protein, are used to transfect cells to generate an ‘expression library’, which
is then screened with avid probes to identify the receptor-ligand interaction.
The clones of interest are then recovered for further analysis. In one of
the comparatively earlier studies, the interaction between a transmembrane
protein netrin-G1 ligand (NGL-1) and netrin-G1 was identified by screening
300 secreted or transmembrane (TM) human proteins expressed as Fc-fusion
proteins with 400 putative cell-surface human proteins that were transiently
expressed in COS7 cells [74]. A focused screen investigating interactions
between TNF ligands and TNF receptors in mouse and human has also used
a similar approach, in which cDNA clones expressing TNF receptors linked to
a C-terminal GPI anchor sequence were individually transfected into HEK293T
cells and and binding with soluble recombinant Fc and FLAG tagged TNF
ligands was investigated using a 96-well format flow cytometry [75]. A slightly
different iterative cDNA cloning approach was used to identify Juno as the
oocyte receptor for Izumo1. In this method, a normalised mouse oocyte cDNA
library was transfected into HEK293T cells in a pooled format and probed with
pentamerised Izumo1. Transfected cells that bound the probe were selected
and cDNAs from the cells were extracted and re-transfected into the cells in an
iterative manner until the single cDNA clone that expressed Juno was identified
[79].
A commercial group (Retrogenix) has designed a cell microarray technology
using a library of cDNA encoding approximately 4500 membrane proteins. The
approach used here is to spot cDNA together with the transfection reagent
in glass slides and overlay mammalian cells such that cells are ‘reverse-
transfected’ to overexpress a wide range of membrane proteins. Such libraries
have been probed with avid reagents to identify low-affinity interactions [77, 78].
1.3.3 Cell-free protein interaction approaches
In the recent years, methods that use cell-free binding assays have been
commonly used to study extracellular protein interactions [80, 81, 82, 83]. The
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ability to generate large libraries of recombinant proteins has allowed for the de-
velopment of methods that can map interaction networks in a high-throughput
manner. In these approaches, soluble recombinant proteins that recapitulate
the ectodomain of the membrane proteins and retain their binding properties
are used. Recombinant proteins can be produced either with cellular systems
or with In Vitro Transcription and Translation (IVTT) system. Here I will be
predominantly focusing on techniques that use mammalian and insect cell
expression systems because these systems are better suited to studying ex-
tracellular proteins as they are better at achieving correct folding, glycosylation
and secretion of recombinant proteins compared to IVTT systems.
AVEXIS
The Wright lab has developed a method for detecting of low affinity protein-
protein interactions, termed ‘avidity-based extracellular interaction screen’
(AVEXIS). In AVEXIS, a mammalian expression system (with HEK293 cells)
is used to produce libraries of soluble ectodomains of membrane proteins
that can be used for interaction screening. The proteins are tagged either
with biotin (‘bait’ protein) or with COMP alongside beta-lactamase tags (‘prey’
protein). Bait proteins are captured on streptavidin-coated plates and the bind-
ing between bait and prey is quantified using the colorimetric beta-lactamase
substrate nitrocefin.The method has been used extensively to characterise
interactions in zebrafish neural system interactions. It was first used to identify
receptor–ligand pairs within the zebrafish immunoglobulin superfamily (IgSF)
[84] and later expanded to screen for interactions mediated by leucine-rich
repeat (LRR) proteins, secreted factors and proteins from floor-plate microen-
vironment in zebrafish [85, 86, 87].
AVEXIS has also been used to identify interactions between malaria caus-
ing parasite P. falciparum and the human red blood cell. In two studies, recom-
binant parasite proteins were used to probe a library of soluble ectodomains
that represented the red blood cell surface protein repertoire to identify host-
pathogen interactions between basigin (BSG)- reticulocyte-binding protein ho-
molog 5 (RH5) and Semaphorin7A-merozoite thrombospondin-related anony-
mous protein (MTRAP) [88, 89]. The interaction between BSG and RH5 was
found to be an essential interaction required by all tested strains of P. falci-
parum in mediating invasion of red-blood cells. Recently, a variation of AVEXIS
has been used to characterise interdependencies of the other parasite proteins
that interact with RH5 and BSG to make up the RH5 invasion complex [90].
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Glass-slide based microarray techniques
Several studies have compiled lists of extracellular proteins to generate re-
combinant protein libraries using mammalian and insect based cell expression
systems to carry out high throughput screens in glass-slide based microarray
format, in which recombinant proteins are captured on a glass slide and inter-
actions are detected using multivalent probes. In this regard, one of the first
demonstrations of protein-microarray approach was the successful detection
of the low-affinity protein interaction between CD200 coupled to multivalent
microbeads and its receptor CD200R [91] immobilized on epoxysilane-coated
glass slides [92, 93]. Subsequently, this approach was used to screen an
array of 1,334 proteins with 89 immunoglobulin superfamily (IgSF) receptor
baits using bait-Fc fusion proteins bound on Protein A coated microbeads
[83]. Recently, this method was also used to describe a virus-host extracellular
interaction map using an array of 1,500 human proteins and human adenovirus
(HAdV) encoded immunomodulatory protein baits [94].
AVEXIS itself has also been miniaturised to a microarray format [95],
in which biotinylated bait proteins are directionally arrayed on streptavidin
coated glass slides and probed with pentamerised probes tagged with FLAG
tag (‘DYKDDDDK’ epitope) for detection using anti-FLAG antibody. This ap-
proach has been utilised to identify FcϵR1α as a receptor for PEAR1 from a
ectodomain library representing the secretome of the human platelet [96].
1.3.4 Mass-spectrometry-based methods
Mass spectrometry (MS) based proteomics is a powerful tool used for the
identification and quantification of peptides, but its application in the analysis of
cell surface receptors has been challenging mainly because of the difficulty in
obtaining homogenous plasma membrane protein regions, low abundance of
membrane proteins, and technical difficulties in identifying hydrophobic regions
of membrane proteins [97, 98]. This has been significantly improved in the
past decade as several approaches have been described, which has allowed
the use of MS in the identification of cell surface proteins [97, 98, 99, 100, 101].
That said, there are still very few mass spectrometry based methods that not
only identify the cell surface molecules but also directly investigate low affinity
interactions mediated at the surface of cells.
One such approach that was recently described is the ligand-based, receptor-
capture (LRC) technology using TRICEPS [102]. TRICEPS is a chemopro-
teomic reagent that consists of three distinct sites: an amine-reactive site
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for non-specific amine conjugation of purified ligand of interest; a protected
aldehydereactive site for covalent conjugation with carbohydrate groups on
glycoproteins under oxidising conditions; and a biotin site purifying the receptor
peptides for identification by quantitative mass spectrometry. In this approach,
ligands conjugated to TRICEPS are added to cells that have been previously
exposed to oxidising conditions. Upon a stable ligand-receptor interaction,
TRICEPS is covalently captured with nearby carbohydrates. After the reaction,
the cells are lysed, trypsinized and the captured glycopeptides are enriched
using the biotin tag and identified using MS. This approach was first validated
by detection of known and novel interaction mediated by extracellular ligands of
diverse nature such as peptides, glycoprotein, therapeutic antibodies and intact
viruses. It has subsequently been commercialised (LRC-TriCEPS; Dualsys-
tems Biotech AG) and used in other studies to identify cell surface interactions
between secreted proteins and membrane receptors [103].
1.4 Methods to study extracellular protein-glycan
interactions
1.4.1 General overview
Studies involving protein-glycan interactions have utilised techniques from
genetics, structural biology, biochemistry, organic, and analytical chemistry.
In the past, plant lectins were crucial tools in the field of glycobiology mainly
because of their high abundance, easy sourceability and ability to mediate
high affinity interactions (KD of nM range) with monosaccarides. Early studies
utilised the agglutination properties of lectins to characterise blood group
antigens, antigenic determinants of which are specified by terminal sugar
residues that are recognised by specific lectins. Plant lectins such as con-
canavalin A, L-phytohemagglutinin lentil lectin (LCA), and Maackia amurensis
leukoagglutinin (MAL) have been used extensively in affinity chromatography
to isolate major glycan structures present in animal cells [104]. Over the years,
a wide range of methods including monoclonal antibody blocking, expression
of glycosyltransferases by transfection with cDNA encoding specific enzymes,
chemical and enzymatic manipulation of carbohydrates and direct binding with
immobilized (glycan arrays and SPR based methods) or soluble (NMR based
methods) glycans have been used to study interactions between glycans and
proteins [105].
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1.4.2 Binding inhibition approaches
In the past, the main method to identify interactions mediated by glycans with
the protein of interest was through binding inhibition studies that used soluble
probes such as monoclonal antibodies and purified mono-(oligo-)saccharides.
One of the best characterised functional evidence for protein-glycan interac-
tions is the low affinity interactions that allow for leukocytes to roll along the
vascular surface. The first indications of such interactions were studied using
the monoclonal antibody (MEL14) that specifically blocked the binding of leuko-
cytes to the high endothelial venules (HEV). Similarly, monoclonal antibodies
were also used to identify ELAM 1 (endothelial-leukocyte adhesion molecule),
which was shown to be expressed on stimulated but not unstimulated human
endothelial cells and gp140, which was expressed in activated platelets. These
molecules were termed as selectins and are known today as L-selectin (MEL
14 antigen), E-selectin (ELAM 1), and P-selectin (gp140). Subsequent binding
inhibition studies with monoclonal antibodies identified sialyl-Lewisx (siaLex)
as the glycan necessary for the interaction of P- and E-selectins with both
fucose and sialic acid residues required for binding (reviewed in [106, 107]).
Chemical or enzymatic manipulation of glycans presented on the cell sur-
face has also been a valuable tool for identification of interactions mediated
by glycans [108]. Tunicamycin, a compound that inhibits N-glycosylation, has
been used extensively for studying the role of N-glycans in mediating interac-
tions. One common approach when studying interactions mediated by sulfated
receptors is the treatment of cells with chlorate, which has been shown to in-
hibit the production of the high-energy sulfate precursor 3’-phosphoadenosine
5’ -phosphosulfate (PAPS). This leads to the generation of undersulfated gly-
coproteins and proteoglycans in cells [109]. The ligand for L-selectin was
determined to be a sulfated version of siaLex based on the decrease in binding
to undersulfated glycoproteins.
Enzymatic deglycosylation is also a common method to study the role
of glycans in mediating interactions. Common enzymes include those that
selectively remove N-linked oligosaccarides (PNGaseF), sialic acid residues
in an O-glycan (sialidase), and core-O-glycans (O-glycosidase) [110]. The
first prediction of the nature of endogenous ligands for L-selectin was made
on the basis of loss of binding of lymphocytes to cells treated with sialidase
[107]. Similarly, neuraminidase (a type of sialidase) treatment of red-blood
cells, which abolished the binding of the malaria causing parasite P. falciparum
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protein EBA175 to these cells led to the discovery of the first host receptor,
glycophorin A, for this parasite [111, 112].
1.4.3 cDNA expression methods
Another approach to studying glycan-protein interactions is to express the
cDNA encoding a glycotransferase in a cell culture system and to detect
the binding mediated by the new glycans (neoglycans) on the cell surface.
This method has been used in studying interactions mediated by selectins
and siglecs (sialic acid-recognizing Ig-superfamily lectins). In the example
of P-selectin, transfecting cDNA encoding a human α-1,3-fucosyltransferase
together with cDNA encoding P-selectin glycoprotein ligand (PSGL-1) into
nonmyeloid cell line (CHO cell line) was shown to confer high affinity bind-
ing of P-selectin to these cells [113]. In another example, one of the early
studies in identifying a receptor for the B cell adhesion molecule CD22 used
a cDNA expression cloning approach, which identified a sialyltransferase
required for adhesion [114]. Although the original study suggested the sialyl-
transferase enzyme to be the direct receptor, further biochemical experiments
soon demonstrated that CD22 bound to a sialic acid residues through its ex-
tracellular domain, the production of which required the enzyme. From there
on, homology based studies led to recognition of a new family protein called
siglecs, which mediate binding in a sialic acid dependent manner [115].
1.4.4 Glycan arrays
Many past methods investigated the glycan binding ability of proteins in
material-intensive assays (e.g. inhibition assays using purified glycans, lectins
and monoclonal antibodies). This was changed when technological advances
in isolating ‘natural’ glycans from sources such as cells, tissues, and pathogens,
and generating synthetic glycans from chemical and enzymatic methods, al-
lowed for the generation of glycan arrays [43]. The two largest mammalian
glycan libraries compiled from natural and synthetic sources are currently
from Consortium for Functional Glycomics (CFG) (∼ 609 glycans) and Feizi
and coworkers (∼ 830 glycans). These arrays have been used to probe for
interactions with plant and microbial lectins, glycan-binding proteins involved
in the innate and adaptive immune system, glycan-specific antibodies, virus
particles, and whole cells (reviewed in [116]).
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1.5 Limitations of the existing methods
While the methods described above have been successful in the past, they
have several limitations:
1. One of the main drawbacks of methods that require large libraries of
cDNA or recombinant proteins is that the initial compilation of libraries
containing hundreds of molecules is resource intensive, and most re-
searchers’ interests are usually focussed on a single or small number of
proteins rather than the networks of interactions within a larger family.
2. The cDNA transfection approach of membrane proteins requires all
expressed proteins to be transported on the surface of cells; however cell
surface targeting of transmembrane proteins is strictly regulated and often
requires cellular accessory factors such as transporters, chaperones and
correct oligomeric assembly. Thus, transfecting a single cDNA might not
be enough to achieve cell surface expression in many cases.
3. Recombinant protein based methods require that the receptor binding
function is retained when expressed by heterologous cells out of the
context of the plasma membrane as a soluble recombinant protein. Whilst
this is generally the case for proteins that span the membrane once
(single-pass (type I, type II) or GPI-anchored), it is not so for receptor
complexes and membrane proteins that span the membrane multiple
times. Therefore, interactions made by these latter classes of complexes
and proteins are usually underrepresented. In addition, although care
can be taken to produce recombinant proteins in heterologous systems
that increase the likelihood of structurally critical post-translational being
added properly, this is not always achieved. An example of this is the
under-glycosylation of HEK-293 expressed recombinant glycophorin A,
which does not retain its property to interact with its known P. falciparum
interaction partner EBA175 [117].
4. While the use of recombinant proteins makes the manipulation of mem-
brane receptors biochemically tractable, it is challenging to investigate
other cellular components required for cellular recognition at the surface
of the cell when interactions are studied in isolation between purified
probes rather than in the context of a cellular system. In a cell, interac-
tions occur in a complex environment, which includes contributions from
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a charged glycocalyx of carbohydrates and lipids displayed on a dynamic
membrane [118, 119, 120]. As a consequence of taking the reduction-
ist approach of studying cell surface molecules as soluble recombinant
proteins, the contribution from cellular factors other than direct receptors
that ultimately contribute in cellular recognition is usually ignored.
5. Mass-spectrometry based methods such as LRC do allow for the inter-
rogation of cell surface interaction mediated by endogenous receptors
in the context of the plasma membrane but they still require chemical
manipulation of the cell surface (e.g, oxidation), which can alter the bio-
chemical nature of the molecules present on the surface of the cells. In
addition, this method relies on the biological properties of the ligand be-
ing preserved during the process of non-specific amine conjugation. This
is difficult to achieve for proteins that rely on lysine residues (residues
where amine conjugation is normally done) to mediate interactions. More-
over, the method requires the receptor to be glycosylated, which is not
always the case.
6. The success of glycan arrays depends on the representation of the
glycans they contain. While there exist multiple efforts to define the
‘glycome’ of an organism using mass-spectrometry, lectin and antibody
array based approaches, due to the very high diversity of glycans, the
size of mammalian glycan array libraries available today still pales in
comparison to the DNA libraries; such mammalian glycan array libraries
may contain a fraction of those glycans present in nature.
7. Methods that tether glycans to a surface such as SPR, glycan array or
ELISA-based methods limit the number of ways in which glycans can
be presented, which can change the binding properties of the isolated
glycans. On the surface of cells, glycans are presented on a glycoprotein
or a glycolipid scaffold in diverse conformations, which can be critical for
ligand recognition.
8. Methods that use isolated glycans require the glycan receptors to inde-
pendently mediate binding with the ligand. This is not always the case as
many glycoprotein backbones also participate in the interaction. The best
known example of this is the interaction mediated by P-selectin, whose
interaction depends both on the glycan and the adjacent sulfotyrosine
residues in the glycoprotein receptor PSGL1 [121].
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1.6 Loss-of-function genetic approaches to study
cellular recognition process
1.6.1 General overview
Genetic mutations can alter cellular processes, therefore a method to study
a function of the gene is to investigate the effect of its absence. Genetic
mechanisms of multiple biological processes can be studied by analysing
loss-of-function (LOF) mutants, in which the altered gene product lacks the
molecular function of the wild-type gene. The underlying principle of a LOF
approach is to ablate the function of a gene by targeting DNA, RNA or protein.
LOF approaches range from non-targeted chemical mutagenesis approaches
to generate mutants, to systematic large-scale generation of mutant libraries for
genetic screens using genome-editing technologies such as short interfering
(si) or short hairpin (sh) RNA, and more recently the CRISPR (clustered
regularly interspaced short palindromic repeats)-Cas9 (CRISPR-associated
protein 9) system (reviewed in [122]). These approaches can be applied both
in a large-scale manner for the identification of novel factors in different cellular
contexts and in a small-scale manner to explore the roles of few candidate
genes usually involved in disease processes that are identified from large-
scale screens. The pioneering works of genome-wide LOF screens carried
out in Caenorhabditis elegans [123] and Drosophila melanogaster [124, 125]
demonstrated how large-scale mutagenesis could be applied to assign gene
function. These approaches have already been applied to many areas of
biological and biomedical research including the investigation into cellular
recognition events, which I will discuss in this section.
1.6.2 Study of naturally occurring mutants
Traditional loss-of-function analysis involved characterising naturally occurring
mutants. For example, in the context of host-pathogen interactions, blood-
group polymorphisms that occur in the human population were used to identify
receptors required for invasion of host cells by malaria causing parasites
P. falciparum and P. vivax. One of the best described examples of this is the
identification of the mutation that abolishes the expression of the Duffy antigen
receptor of chemokines (DARC) on the surface of red blood cells (the so-called
‘Duffy-negative phenotype’) in western and central Africa, which was shown
to confer almost complete protection from P. vivax infection [126, 127]. This
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led to the identification of DARC as a critical receptor for P. vivax invasion
into red-blood cells and the subsequent identification of its parasite binding
partner, Duffy binding protein (DBP). Untill today this receptor-ligand inter-
action remains the only known host-pathogen interaction in the context of
P. vivax infection. Similarly, the studies characterising the host receptors for
P. falciparum merozoite surface proteins have also utilised naturally occuring
erythrocytes with mutations in blood group antigens. For example, the parasite-
host interactions between EBA175 with glycophorin A (GYPA), EBA140 with
glycophorin C (GYPC) and EBL1 with glycophorin B (GYPB) were studied
using blood groups that lacked the respective receptors; En(a-) (absence of
GYPA), Leach phenotype (absence of GYPC) and S-s-U-phenotype (absence
of GYPB) (reviewed in [128]). Another well-known example of this is the study
in individuals resistant to HIV infection, who were found to carry homozygous
mutation in the cell surface receptor protein CCR5, which acts as the viral
co-receptor [129]. While the study of natural mutants using biochemical or
population genetics approach has been useful in the past, the difficulty in ac-
quisition of mutants, the presence of rare alleles in a population, and the limited
shelf life of biological materials makes this approach generally unsuitable for
systematic investigation of cellular recognition processes.
1.6.3 Genetic screening approaches
Chemical and insertional mutagenesis
A different approach to study a gene function is to generate loss-of-function
mutants using genome editing tools. The classical approach of mutant gen-
eration was by random mutagenesis through chemical mutagens (e.g, ethyl
methanesulfonate (EMS)), that can introduce a variety of genetic lesions that
are expressed as complete or partial loss of function of the gene product [130].
Such approaches were commonly carried out in Saccharomyces cerevisiae,
which served as an ideal model organism because of its rapid generation time
and its haploid genome, which permitted efficient generation of homozygous
mutants for the study of recessive phenotypes. This approach served as a fast
and effective method to generate a large number of mutants so that they could
be screened for the phenotype of interest. Genetic screens in yeast using
temperature sensitive mutants served as powerful tools to study cell essential
mechanisms. The early works in yeast temperature sensitive mutants, which
identified components of the SEC genes [131, 132], has been extremely valu-
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able in the field of membrane protein biology as they have shaped our current
understanding of the general secretory pathway that is required for the trans-
port of the majority of membrane and secreted proteins. Similarly, chemical
mutagenesis has also been used to mutate the genome of a hermaphrodite
model organism Caenorhabditis elegans, which has allowed study into, among
other cellular processes, the genetic control of neuronal development. For
example, the molecular basis of UNC-6/Netrin signalling in axon guidance
was first identified by characterisation of mutants generated through random
mutagenesis in this organism (reviewed in [133]).
A different approach of random mutagenesis proceeds through insertional
mutagenesis, which employs the strategy by which exogenous retroviral and
transposable DNA can be inserted randomly into the genome such that if
the insertions is in the coding or regulatory region of the gene, the gene
product will be rendered non-functional. This approach has an advantage over
chemical mutagenesis as it facilitates the identification of the mutated gene
as the inserted DNA, whose sequence is known, serves as a molecular tag.
While powerful, the mutagenesis techniques had limited use for the generation
of homozygous mutants in mammalian cell culture systems mainly because of
the diploid nature of mammalian cells, the lack of strategies to set up genetic
crosses, and the low rates of homologous recombination. One of the strategies
employed to address this limitation was to utilise mouse embryonic stem cell
(ESC) lines that are deficient for Bloom’s syndrome protein (BLM), in which
cells exhibit a high rate of mitotic recombination to generate a genome-wide
library of homozygous mutant cells from heterozygous mutations induced
with insertional mutagenesis approach [134]. Furthermore, the discovery of
haploid human cell lines, KBM7 [135, 136] and HAP1 (a derivative of KBM7)
[137], and haploid mouse embryonic stem cells [138] further facilitated the
use of insertional mutagenesis appraoch in mammalian cell culture system.
The application of random mutations techniques in haploid cells can directly
cause loss-of-function phenotypes, which can be studied in a high-throughput
manner. Such approaches have been used in the context of host-pathogen
interactions mediated by bacteria and viruses (reviewed in [139]). Examples
with the gene trap1 approach in haploid human cell lines include identification
of host factors for bacterial toxins [140, 141, 142], intracellular receptor for the
1A type of insertional mutagenesis using a vector that contains a strong splice acceptor
site, an efficient polyadenylation signal and a marker gene. The insertion of the vector into the
intronic (or exonic) region leads to inactivation of the target gene.
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Ebola virus [137], deciphering the glycosylation of the Lassa virus receptor
α-dystroglycan (α-DG) [143], and receptor switching mediated by the Lassa
virus upon virus internalisation [144]. More recently, the same approach has
been used for the identification of the host receptor for adeno-associated virus
(AAV) serotype 2 [145].
RNAi mediated approaches
During the time when the creation of homozygous mutant libraries for cells
and organisms with diploid genomes was time- and capital-intensive and low
throughput, RNA interference (RNAi) technology provided an alternative ap-
proach to allow high throughput gene silencing through sequence-specific
targeting of mRNAs [146]. In this approach, RNAi reagents (such as synthetic
siRNAs, siRNA precursors (short hairpin RNAs (shRNAs)), or long double-
stranded RNAs (dsRNAs)) are introduced to cells or organisms via methods
such as transduction, transfection, microinjection or, in case of C.elegans,
by simply feeding organisms with E.coli expressing dsRNAs [147]. Once in
the cells, siRNAs are incorporated directly into the RNA-induced silencing
complex (RISC), whereas dsRNAs are processed by DICER to first generate
siRNA. The siRNA-RISC complex can mediate gene silencing by cleaving the
complementary mRNA (when the sequences are perfectly complementary) or
by interfering with translation (when the sequences are partially complemen-
tary). The approach has allowed for the implementation of both small scale
and genome-wide loss-of-function screens in human and Drosophila cell lines
for the identification of genes and gene networks involved in signal transduc-
tion processes [148], identification of regulators of cell adhesion, [149] and
extensively in host-pathogen interactions (e.g. colonisation of Drosophila cells
by sinbad virus [150], dengue virus [151]; mammalian host factors required
by hepatitis C virus (HCV) [152, 153], west nile virus [154], vaccinia virus
[155] and multiple screens for host factors required by HIV (reviewed in [156])).
Similar screens have also been carried out in hematopoietic progenitor cells
that can be differentiated into erythroblasts, thereby allowing forward genetic
screens to be carried out in the otherwise genetically intractable anucleate red-
blood cells. A shRNA mediated genetic screen in such a system has identified
CD55 as a crucial host receptor for P. falciparum invasion into red-blood cells,
although the ligand on the parasite end is still unknown [157].
One of the biggest challenges of using RNAi as a tool to study gene
function involves the sequence-specific off-target effects of siRNA. RNAi uses
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an existing cellular pathway governed by endogenous microRNAs (miRNAs)
that regulate cellular gene expression levels using incomplete complementarity
between the miRNA and its target. Exogenously supplied siRNA can function
as an endogenous miRNA and mediate target recognition by partial sequence
complementarity, which can lead to translational repression and/or degradation
of non targeted mRNAs. Such off target effects can confound the interpretation
of the phenotypic effects and potentially create cellular toxicities [158]. In
addition, the genetic perturbation using RNAi frequently results in incomplete
silencing, which, combined with the off-target effects can lead to a decrease in
sensitivity and inconsistent results. One such example of inconsistent results
is the lack of overlap between three large-scale RNAi-mediated knockdown
approaches conducted by independent laboratories for the identification of
factors responsible for HIV infection, which have identified 842 putative factors
out of which only 37 genes were identified in more than one screen and merely
three genes identified in all three studies [159, 160, 161].
1.6.4 CRISPR-Cas9 approach
Introduction to CRISPR-Cas9
CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR
associated) systems are adaptive immunity strategies developed by bacteria
and archaea to protect themselves against foreign genetic elements such
as viruses and plasmids [162, 163]. The system involves three key steps:
(i) spacer acquisition, during which small DNA fragments from foreign DNA
elements are inserted into the CRISPR locus; (ii) crRNA (CRISPR RNA) ex-
pression, during which the CRISPR locus is transcribed to generate a long
primary CRISPR transcript (the pre-crRNA); (iii) target interference, during
which the target is detected and degraded by the crRNA and Cas9 protein(s).
Depending on the architecture of the interference molecules, the system can
be divided to two main classes, consisting of six types (type I-VI) and 16
subtypes. The CRISPR-Cas9 technology is derived from type II CRISPR-Cas
system, which utilises crRNA, tracrRNA (trans-activating crRNA2), and a single
large multi-domain effector protein (Cas9) to mediate target recognition and
cleavage. Under this system, the Cas9 protein, which is an endonuclease,
is loaded with RNA duplex (tracrRNA:crRNA) and this riboprotein complex is
directed to the target site (i.e., the site complementary to the guide sequence
2These are short sequences that are complementary to the corresponding crRNA. They
are required for Cas9 to correctly recognise the target DNA.
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from crRNA), enabling the Cas9 protein to introduce double stranded breaks
(DSBs) in the DNA. Target recognition by Cas9 also requires the protospacer
adjacent motif (PAM), which is a species-dependent short (2-6 nucleotide se-
quences (nts)) DNA sequence immediately following the target DNA sequence
(reviewed in [164, 165]). The majority of the current CRISPR-Cas9 systems
use the Cas9 protein from Streptococcus pyogenes (henceforth referred to as
SpCas9), which uses 5′-NGG and 5′-NAG (although at less efficient rates) as
the PAM sequence (figure 1.1).
Fig. 1.1 Overview of type II CRISPR-Cas9 mediated gene editing. Cas9 can
be programmed either with RNA duplex generated from crRNA and tracrRNA or
with a single chimeric RNA, which mimics the RNA duplex. Once loaded with the
RNA duplex or the chimeric RNA, the Cas9 protein is targeted to the region of the
genome that is complementary to the 20 nts sequence of the crRNA (or the gRNA)
where it mediates double stranded DNA cleavage. The Cas9 protein contains two
endonuclease domains, the HNH and RuvC domains that either cleave the strand
complementary to the guide sequence, or the strand matching the guide sequence.
Once a double stranded break is generated the cellular DNA machinery repairs it
either with the NHEJ pathway or the HDR pathway (if homologous donor template is
present). NHEJ pathway is error-prone and can lead to generation of indel mutations,
leading to inactivation of the gene [165]. Figure adapted from [166].
Gene targeting using the CRISPR-Cas9 system
One of the major findings in the field of CRISPR-mediated gene editing has
been the observation that the tracrRNA:crRNA duplex can be engineered
as a single piece of chimeric RNA (termed as single guide RNA (sgRNA) or
gRNA) [167]. Immediately following this observation, CRISPR/Cas9 system
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was adapted for genome engineering in human cells, where by changing the
20 nucleotide guide sequence of the gRNA, the DNA sequence of interest
could be efficiently targeted by the Cas9 endonuclease to generate double
stranded breaks (DSBs) [168, 169]. DSBs in cells are repaired using two major
pathways: (i) the error-prone Non-Homologous End Joining (NHEJ) pathway;
and (ii) the high-fidelity Homology Directed Repair (HDR) pathway. In higher
organisms, the NHEJ pathway, which does not require specific sequence for
ligation of DNA, is the major method for repairing DSBs and unlike HDR, this
pathway is active during all stages of the cell cycle [170]. DNA repair using
the NHEJ pathway is prone to insertion and/or deletion (indel) mutations at the
junctional site, which in coding exons can introduce premature stop codons or
frameshift mutations, leading to disruption of the targeted gene. This system
therefore provides a convenient way to generate loss-of-function mutations in
the mammalian genome.
Overview and basic principles of a knockout screen using the CRISPR-
Cas9 system
Given the ease of generating libraries containing thousands of gRNAs that
could be used to create large knockout collections, CRISPR-Cas9 technol-
ogy quickly became the method of choice for genome-wide loss-of-function
screening approaches. The first genome-wide loss-of-function screens were
carried out in human [171, 172] and mouse [173] cells using cell growth as a
phenotype and showed successful application with both positive and negative
selection results. All the initial screens and the majority of the genome-scale
screens that have been described up to now have used a pooled screening
approach, the basic principles of which are summarised below.
In a pooled screening approach, gRNA oligonucleotides are synthesised
as a pool and cloned to create plasmid library that is used for virus production.
The viral library is then used to transduce Cas9-expressing cells3 at a low
multiplicity of infection (MOI) to generate a library of knockout cells. Ensuring
a low MOI (usually MOI of 0.3) is a crucial step in pooled screens to reduce
the probability of more than one gRNA being transduced and stably integrated
into one cell. The mutant library thus generated is subjected to positive (e.g,
3In a single vector approach such as the LentiCRISPR used in [171], both Cas9 and gRNA
are encoded from a single plasmid; thus the cells do not express Cas9 prior to transduction with
the virus generated from this plasmid. In a dual vector approach, stable cell lines expressing
Cas9 are first generated and then transduced with the gRNA library to generate knockout
libraries.
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drug, toxin resistance), negative (e.g. proliferation) or marker gene selections
(expression of surface markers) and the cells of interest are recovered (will be
discussed in detail below). The integrated virus serves as a molecular tag for
each mutated gene and this can be read-out by isolating genomic DNA from
the cell population, sequencing (using next-generation sequencing (NGS))
across the gRNA-encoding regions, and then mapping each sequencing read
to a pre-compiled list of designed gRNA library. Computational analysis is then
carried out to determine the differences in the abundance of gRNAs between
the control and the phenotyped sample to identify the gene product involved
[174].
A pooled screen can be carried out with negative, positive or marker gene
selection. The goal of a negative selection screen is to identify perturbations
that affect the survival or proliferation of cells, which cause the perturbed cells
to be depleted during selection. The approach here is to transduce two sets
of cell populations and subject one set to the selection while the other serves
as a non-selected control. The gRNA abundance in both populations is then
analysed to identify gRNAs that have been depleted because of the selection.
One of the simplest form of a negative selection screen is the continued growth
of cells for an extended amount of time to identify genes that are required for
the proliferation of cells. Such screens have been used to identify essential
genes for several cell lines [171, 175, 176, 177]. In a positive selection screen,
a strong selective pressure is introduced such that the probability of cells being
selected without the genetic perturbation is low. These screens have been
used to identify perturbations that confer resistance to drug [171, 173], toxin
[173, 178, 179], hypoxia stress [180], and pathogen infection [181, 182, 183].
Unlike negative selection screens, the signal for a positive selection is usually
strong, as the abundance of relevant gRNAs in such screens increases relative
to the rest of the gRNAs, which allows for easy detection of resistant cells [184].
A third type of selection is the marker gene selection in which the phenotype is
not based on lethality of the cells but rather on mutations that change marker
gene protein expression. In this type of screen, the marker gene is either
endogenously-tagged with fluorescent proteins [185] or labelled with highly
specific antibodies [186, 187] and cells with gRNAs that target genes whose
perturbations contribute to the expression of marker gene are captured using
fluorescence-activity cell sorting (FACS)-based approaches.
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1.6.5 The scope of CRISPR-Cas9 knockout screening sys-
tem in the context of cellular interactions
Over the last decade, technological advancements in gene annotation and
gene synthesis have facilitated the generation of libraries of recombinant
proteins to carry out numerous cell-based or cell-free assays, as discussed
here (figure 1.2). The recent development of the genetic-screening method
using the CRISPR-Cas9 system has the potential to utilise these libraries of
recombinant proteins that could potentially be involved in cellular interaction
within different biological contexts (e.g. neural and immunological recognition,
and host-pathogen interactions). By using the ‘binding’ of recombinant proteins
to cell lines as a measurable phenotype, a positive selection genome-scale
knockout screen can be designed, in which cells within the knockout library
that can no longer bind the protein they previously bound can be selected for
the identification of the perturbations, which led to the loss in binding. Within
those perturbations should, in principle, lie the receptor of the recombinant
protein and any components that alter the expression of that receptor. This
approach could be used for the study of cellular recognition events and has
the following potential advantages over the previously discussed pre-existing
methods:
1. Screening on cells that express a wide range of endogenous proteins
in the context of a plasma membrane, which contain appropriate post-
translational modifications, avoids the necessity of recombinantly gen-
erating a large number of proteins. This facilitates the investigation of
proteins that are normally difficult to study with biochemical approaches
(e.g, large proteins, multi-pass membrane receptors and protein com-
plexes).
2. Genome-scale screens provide a unique platform to study interactions
mediated by glycans as the identity of a glycan receptor can be readily
inferred by identifying enzymes and intracellular transporters involved in
their biosynthesis.
3. The use of an unbiased genome-wide approach to study receptor-ligand
interactions on the cell surface facilitates the identification of cellular
factors that are not necessarily direct receptors but are involved in their
expression on the surface of cells.
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4. One important advantage of this approach is that it should be able to
identify all gene products required for extracellular interactions without
the need to make any prior assumptions regarding the biochemical na-
ture of the receptor.
Fig. 1.2 Outline of the major approaches that are utilised for the study of extra-
cellular interactions. Current high throughput approaches utilise compiled libraries
of cDNA clones or protein/glycan libraries to investigate protein interactions. Gain-of-
function approaches such as cDNA-mediated over-expression strategies have been
used in cell-cell binding assays or cell-probe binding assays for the identification
of novel extracellular interactions (‘probe’ in this context refers to avid recombinant
proteins or glycans). A genome-scale loss-of-function screening approach has the
potential to utilise the avid recombinant proteins or glycans in a cell-binding assay to
complement the pre-existing methods to identify direct receptor-ligand interactions.
In addition, a genome-scale knockout approach would, in principle, also allow for the
identification of intracellular pathways contributing to the biology of the receptor.
1.7 Thesis aims
In this work, I explore whether genome-scale cell-based CRISPR-Cas9 knock-
out screens can be used to determine the molecular basis of cell surface
recognition events. The aim is to develop an approach that utilises the com-
monly used tools in receptor discovery, monoclonal antibodies and recombinant
proteins, to reveal direct receptor-ligand interactions, and assess the feasi-
bility of such an approach to identify other important cellular factors required
for the interaction, such as posttranslational modifications, co-receptors, and
cytoplasmic proteins involved in receptor trafficking.
26
CHAPTER 2
MATERIALS AND METHODS
2.1 Buffers/Media/Solutions
The composition of the buffers and solutions used in this study are described
as follows:
• TAE buffer-10x: 2 M Tris, 57.1 mL acetic acid (100%), 100 mL EDTA (0.5
M, pH 8.0 ) in MiliQ water
• LB media: 1% tryptone, 0.5% Yeast extract, 1% NaCl in MiliQ water.
• Diethanolamine buffer, pH 9.2: 10% diethylamine and 0.5 mM MgCl2 in
MliQ water
• HBS buffer (10x) pH 7.4: 1.5 M NaCl and 200 mM HEPES in MiliQ water
• PBS buffer (10x), pH 7.4 : 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4 and 2.4
g KH2PO4 in MiliQ water
• Nitrocefin solution: 5 mg Nitrocefin was dissolved in 500 µL DMSO and
added to 39.5 mL PBS to reach 40 mL final volume (concentration: 242
µM); filtered through 0.2 µm filter and stored in dark.
• RPMI culture media: RPMI 1640 (Life Technologies) supplemented
with 10% heat-inactivated (50◦C for 20 minutes) FBS, 1 mM sodium
pyruvate (Life Technologies), 10 mM D-glucose (Sigma) and 1% peni-
cillin–streptomycin (100 units/mL).
• DMEM/F12 culture media: DMEM/F12 media supplemented with 1%
penicillin-streptomycin (100 units/mL) and 10% heat inactivated FBS
• IMDM culture media: IMDM media supplemented with 1% penicillin-
streptomycin and 10% heat inactivated FBS
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• Sodium phosphate buffer (80mM stock), pH-7.4 : 7.1 g Na2HPO4.2H2O,
5.55 g NaH2PO4
• His-tag purification- binding buffer: 20 mM Sodium Phosphate Buffer, 0.5
M NaCl and 20 mM Imidazole, filtered and degassed
• His-tag purification- elution buffer: 20 mM Sodium Phosphate Buffer,
0.5M NaCl and 400 mM Imidazole, filtered and degassed
2.2 Generation of expression plasmids
All expression plasmids used for protein production via transient transfection
of EBNA1 expressing HEK-293-6E cells was based on the pTT3 plasmid
backbone, which features an EBV origin of replication that allows increased
expression of transgenes in these cells [188] (figure 2.1A). While the endoge-
nous signal peptide was included in the insert for the expression of mammalian
proteins, an exogenous N-terminal signal peptide from a mouse immunoglobu-
lin κ-light chain (VkSP) was cloned into the vector backbone for the expression
of Plasmodium falciparum proteins (figure 2.1B). Additional processing of Plas-
modium ectodomain coding sequences included trimming of the endogenous
signal peptide, codon-optimisation for mammalian cell expression and mutation
of N-linked glycosylation sequences from NXS/T to NXA (where X is any amino
acid except Proline) in order to prevent inappropriate glycosylation.
All ectodomains were chemically synthesised together with the flanking
NotI and AscI sites and cloned into either of the following vector(s) (also see
figure 2.1C).
1. the ‘pentameric vector’ containing N-terminal signal peptide, and C-
terminal tags in the following order: rat Cd4 domains 3 and 4 tag (hence-
forth referred to as the Cd4 tag), a pentamerization sequence from the
cartilage oligomeric matrix protein (COMP), sequence for β-lactamase
enzyme, 3× FLAG tag and a terminal hexa-his tag. All proteins generated
via this plasmid were expressed as pentamers.
2. the ‘monomeric biotinylation vector’ containing N-terminal signal pep-
tide and a C-terminal Cd4 tag followed by an E.coli BirA biotin ligase
sequence motif and a hexa-his tag. This was used for the production
of his-tagged monomeric protein with a mono-biotinylation on a specific
lysine residue.
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3. ‘monomeric β-lactamase vector’ containing N-terminal signal peptide and
a C-terminal Cd4 tag followed by sequence for β-lactamase enzyme.
Fig. 2.1 Schematic diagram representing the plasmids used for protein produc-
tion using the HEK-293-6E protein expression system. A. Generalized map of
pTT3-based expression plasmids. EBV: Epstein-Barr virus, AmpR: Ampicillin re-
sistance cassette, oriP: pBR322 origin of replication, CMV: Cytomegalovirus pro-
moter, SP: signal peptide, CDS: protein ectodomain-coding sequence, polyA: poly-
adenylation site. B. The arrangement of restriction cloning sites were different in
respect to the start of the signal peptide for Plasmodium and human proteins. C. All
vectors contain a cytomegalovirus (CMV) promoter driving the transcription of the
desired transgene. The pentameric vector construct contains the ectodomain followed
by the Cd4 tag, a region from the cartilage oligomeric matrix protein (COMP) that
forms pentamers, a β-lactamase enzymatic tag, a 3 ×FLAG-tag for immunological
detection and a C-terminal 6 ×His tag for purification. The monomeric biotinylation
vector contains the ectodomain followed by the CD4 tag, a biotinylation sequence and
a his-tag (BLH), whereas the monomeric β-lactamase tagged vector is the same as
the biotinylation vector but consists of β-lactamase tagged instead of the BLH tag.
All plasmids except those relating to IGF2R expression were obtained
from the laboratory database. Transformation of the recombinant DNA was
done with 1 µg of DNA using chemically competent Escherichia coli (E. coli)
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cells (‘Top10’, Invitrogen) using manufacturers recommendation. Maxi-prep kit
(Invitrogen) was used to purify the DNA and the concentration was adjusted to
1 mg/mL.
2.2.1 Cloning of IGF2R expression construct
PCR amplification of ectodomain of IGF2R
A plamid for the expression of full length IGF2R was obtained from Origene
(SC300143). Region representing M1-2306V (the ectodomain) was amplified
from this construct using IGF2R-fwd and IGF2R-rev primers (refer to appendix
table A.1) with Q5 Hot Start High-Fidelity 2×Master Mix. NotI and AscI restric-
tion sites were added to forward and reverse primers correspondingly, in order
to facilitate sub-cloning into the expression vectors. The PCR reaction was
performed in a thermocycler with the following set up: Initial denaturation for 5
minutes at 95 ◦C; 25 cycles of denaturation at 95 ◦C for 20 s, elongation at 68
◦C for 7 minutes and annealing at 72 ◦C for 90 s; and final elongation for 10
minutes at 72 ◦C. After finishing the run, the samples were cooled to 4 ◦C.
DNA samples (5 µL/sample) from the PCR reaction were analysed on a
1 % (w/v) agarose gel prepared in TAE buffer. After verifying the size of the
amplified fragment, the remaining PCR product was cleaned using Qiagen
PCR purification kit. In the final elution step, DNA was eluted in 30 µL EB
buffer.
Restriction digest and ligation
The purified PCR fragments were digested with NotI and AscI enzymes. For
each sample, a 50 µL reaction mixture was set up with the following com-
ponents with the indicated volumes and concentrations: 30 µL purified PCR
product, 1 µL NotI enzyme (10000U/mL), 1 µL AscI enzyme (20000U/ mL), 5
µL CutSmart (NEB) buffer (10×) and 13 µL MiliQ water. The reaction mixture
was incubated for 24 hours at 37 ◦C following which all 50 µL from each sample
was run on a 1% agarose gel. The corresponding fragments were excised
from the gel and purified using Qiagen gel extraction kit. DNA was eluted in 20
µL EB buffer and the concentration was measured using spectrophotometer.
The insert (restriction digested, purified and gel extracted PCR product)
was next ligated with the desired vector backbone (also restriction digested,
purified and gel extracted) using T4 DNA ligase in the presence of T4 DNA
ligase buffer containing ATP (NEB). Ligation mixture was incubated for 16
hours at room temperature and transformed into chemically competent E.coli
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(Top 10, Invitrogen) according to manufacturers recommendation and plated
on a LB-agar plate supplemented with 100 µg/mL ampicillin.
Plasmid extraction
Randomly selected bacterial colonies from the LB plate were inoculated in 8
mL Falcon tubes with 2 mL LB media supplemented with ampicillin (100 µg/mL)
and cultured overnight at 37 ◦C and 225 rpm for up to 24 hours. Plasmid from
the bacterial culture was isolated using miniprep from Qiagen miniprep kit
using manufacturer’s recommendation. The insert sequence was verified by
sanger sequencing using sequencing primers OL497 and OL4006 (refer to
table A.1, appendix section). The DNA obtained from clones with the correct
insert were re-transformed and re-purified using maxi-prep kit (Invitrogen) and
the DNA concentration was adjusted to 1 mg/mL.
2.3 Recombinant protein production using HEK-
293-6E cells
All proteins were expressed in HEK293-6E cells maintained in Freestyle media
(Life Technologies) supplemented with 50 µg/mL G418 and 0.1 % Kolliphor
P188. For routine culture, 2.5 x 107 cells were seeded in 500 ml Erlenmeyer
culture flasks containing 100 mL culture media and cultured in a shaker set at
37 ◦C, 5 % CO2, 70% humidity and 125 rpm. To maintain a logarithmic growth
phase, cells were diluted into fresh media every 2-3 days when the cell density
reached approximately 2 ×106/mL.
The cells were transfected with plasmids carrying the desired inserts using
polyethylenimine (PEI) as the transfection reagent. The cell culture was pre-
pared 48 hours prior to transfection by seeding cells at a density of 5 × 105
cells/mL in 125 mL, 250 mL or 500 mL Erlenmeyer culture flasks with 25 mL,
50 mL or 100 mL culture media respectively. For the production of biotinylated
protein, the cells were grown in culture media supplemented with D-biotin (100
µM) [80]. On the day of transfection, cells were counted to ensure that the
desired density of 1.5 -2 × 106 cells/mL was reached.
Table 2.1 summarises the amounts of each component added to form
DNA/PEI complexes. For each indicated transfection scale reaction, two sepa-
rate tubes containing transfection media (unsupplemented Freestyle media)
were prepared. Next, plasmid DNA was added to the one tube and PEI was
added to the other. When expressing biotinylated proteins, plasmid encoding
a secreted E.coli BirA enzyme was added together with the plasmid DNA in
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1:10 ratio. Both tubes were immediately vortexed and the PEI solution was
added to the DNA solution. The contents were incubated for 3 minutes at room
temperature and the whole mixture was added to the pre-prepared cultures.
The cells were grown for 5 days in order to achieve maximum protein yield.
Table 2.1 Summary of reagent quantities for transfection of HEK-293-6E cells.
Transfection
scale/volume
Volume of transfection
media
Amount of
Expression
plasmid
Amount
of PEI
Amount of BirA
plasmid
Small (25 mL) 1.25 mL + 1.25 mL 25 µg 50 µg 2.5 µg
Medium (50 mL) 2.5 mL + 2.5 mL 50 µg 100 µg 5 µg
Large (100 mL) 5 mL + 5 mL 100 µg 200 µg 10 µg
As all the constructs contained either an exogenous or an endogenous
signal peptide, all recombinant proteins produced by the cells were released
into the culture media. The proteins were harvested by spinning down the
culture for 20 minutes at 3320 ×g and filtering the cell supernatant through a
0.2 µm filter. Supernatants containing pentameric recombinant proteins were
stored at 4 ◦C until further use.
2.4 Protein purification and quantification
2.4.1 Immobilized metal ion affinity chromatography
The six-times his-tagged proteins were enriched from cell culture supernatants
either on HisTrap HP columns (GE Healthcare) using an ÄKTAxpress (GE
Healthcare) or on unpacked nickel-sepharose beads. In both case the same
binding and elution buffer was used (see section 2.1)
Enrichment of his-tagged proteins using ÄKTAxpress
The culture supernatant containing the proteins were supplemented with 500
mM NaCl and 20 mM imidazole prior to enrichment to decrease non-specific
protein binding. The HisTrap column was equilibrated with 20 mL of binding
buffer and the protein was slowly loaded at the rate of 1 mL/min. The proteins
were eluted from the column with 10 mL elution buffer and all 20 elution
fractions were collected (0.5 mL/fraction). The readout from the machine was
an absorbance curve based on the 280 nm absorbance of each eluted fraction.
The fraction with the highest absorbance was collected to achieve maximum
protein yield.
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Enrichment of his-tagged proteins using Nickel beads
The culture supernatant containing the his-tagged proteins were enriched
using Ni2+-NTA sepharose beads using gravity-flow chromatography with
Polypropylene columns (Qiagen). In brief, beads were first added to the
supernatant in a 1:1000 ratio (i.e. 50 µL of 50% sepharose slurry into 50 mL
supernatant) and binding to the beads was carried out overnight at 4 ◦C or for
at least for two hours at room temperature on a rotating platform. The beads
were washed once with wash buffer before the samples were eluted with 300
to 500 µL of elution buffer.
2.4.2 Determination of protein expression and quality
Determination of protein concentration
The 280 nm absorbance of the enriched proteins was measured with a bench-
top spectrophotometer. The extinction coefficients of the proteins were calcu-
lated using Snapgene software and the protein concentration was determined
using the Beer-Lambert law. This method of concentration determination was
carried out only for protiens that had been buffer exchanged into PBS. Buffer
exchange of purified proteins were carried out using PD-10 desalting columns
(GE-healthcare) using the manufacturers ‘Gravity’ protocol.
SDS-PAGE
The expression of recombinant proteins were detected by SDS-PAGE under
reducing conditions to confirm their size and integrity. Culture supernatants
(10-15 µL) or purified protein samples (5-10 µL) were mixed with NuPAGE LDS
Sample Buffer (4×) sample buffer NuPAGE Sample Reducing Agent (10×)
(Thermo-Fisher) and heat denatured by boiling the mix at 95 ◦C for 10 minutes.
The entire sample together with pre-stained gel marker were loaded on a
4-12% pre-cast gradient gels (Thermo-Fisher). The gel chamber was filled
with NuPAGE running buffer and the separation was carried out for an hour
at 200 V. The proteins on the gel were stained with InstantBlue Protein Stain
(Expedeon) using manufacturers recommendation.
Western blotting
Following SDS-PAGE, the proteins were transfered to a PVDF (GE Healthcare)
membrane using a wet transfer method with NuPage transfer buffer (Life
Technologies) supplemented with 10 % methanol, an XCell II blot module
(Novex) and 30 V voltage for an hour at room temperature. The membrane
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was blocked with blocking buffer (PBS supplemented with 2.5% milk powder) for
1 hour in order to avoid spurious binding and was then probed with 200 ng/mL
of appropriate HRP-conjugated antibody diluted in blocking buffer (anti-FLAG-
HRP for pentamers and Streptavidin-HRP for the biotinylated monomers) for 1
hour. Finally, the blot was washed 3 times with PBST (PBS with 0.1% Tween
20). The signals from the proteins were detected on Hyperfilm (GE Healthcare)
in the presence of SuperSignal West Pico enhanced chemiluminiescent HRP
substrate (Thermo-Fisher). The reagent was used according to manufacturer’s
recommendation.
Quantification of pentameric proteins with β-lactamase tag
Prey protein expression was quantified by measuring the turnover rate of
nitrocefin solution by the β-lactamase enzyme activity associated with the
expressed proteins. First, 20 µL culture supernatant containing the prey protein
was aliquoted on a 96-well plate. Next, 60 µL of 125 µg/mL nitrocefin solution
(Calbiochem) was added to each well. Absorbance readings were taken
15-20 minutes post-substrate addition at 485 nm on a Pherastar plus (BMG
laboratories). The proteins were normalised to enzyme activity corresponding
to approximately 1 nmol/min, which corresponds to complete hydrolysis of 14.5
nmol nitrocefin in approximately 15 minutes.
Quantification of monomeric proteins with biotin tag with ELISA
Biotinylated bait proteins were detected by enzyme-linked immunosorbent
assay (ELISA). Proteins were captured on 96-well streptavidin-coated plates
(NUNC) for one hour before adding 10 µg/mL primary antibody recognising
the rat Cd4 tag (mouse anti-rat Cd4, clone OX68) common to all recombinant
proteins, for another hour. Plates were washed 3x in PBS/0.1% Tween-20
(PBST) before adding 100 µL of an anti-mouse alkaline phosphatase conjugate
(Sigma) at 0.2 µg/mL. Plates were washed 3× PBST and 1× PBS before
adding 100 µL p-nitrophenyl phosphate (Sigma 104 alkaline phosphatase
substrate) at 1 mg/mL in diethanolamine buffer. Absorbance readings were
taken 15-20 minutes post-substrate addition at 405 nm on a Pherastar plus
(BMG laboratories).
2.4.3 Plate-based direct protein interaction assay
A biotinylated ‘bait’ protein consisting of the entire ectodomain of GABBR2
and controls were first immobilised in a well of a streptavidin-coated 96-well
microtitre plate (NUNC) at a concentration that saturated the biotin binding ca-
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pacity of the well and probed for direct interactions with the entire ectodomain
of IGF2R expressed as a β-lactamase-tagged ‘prey’. The plate was washed
2× in PBST after which normalised β-lactamase-tagged ‘prey’ (IGF2R and
controls) proteins were added to the wells for one hour. Following another
wash step (2× with PBST and final wash with only PBS), 100 µL of 125 µg/mL
nitrocefin was added and prey capture was quantified by measuring the ab-
sorbance of nitrocefin hydrolysis products at 485 nm on a Pherastar plus (BMG
laboratories). Biotinylated Cd4 tag alone was used as a negative control bait
and a biotinylated anti-Cd4 monoclonal antibody (anti-prey) used as a positive
control as required. Where soluble monosaccharides were used in blocking
experiments, prey proteins were first incubated with a range of concentrations
(10 mM- 0.04 mM) of mannose-6-phosphate or mannose for one hour, prior to
incubation with bait proteins. To remove N-linked glycans from soluble recom-
binant GABBR2, 1500U of PNGaseF (New England Biolabs) were added to 10
µg of GABBR2 and incubated for duration ranging from 1-16 hours at 37 ◦C.
2.5 Human Cell line culture
All cell lines except HEL, HEK-293-E and HEK-293-6E were obtained from the
Sanger Institute cell line database. HEK-293-E/6E cells were obtained from
Yves Durocher [188] and HEL cells were purchased from DSMZ. All cell lines
were tested and found to be mycoplasma free. The growth conditions for all
cell lines are listed in table 2.2. For some lines, Cas9 expressing versions were
made and therefore were grown with supplemented Blasticidin to the indicated
concentration.
All cell lines were maintained in a static incubator at 37 ◦C in humidified
atmoshere with and 5% CO2. All suspension lines were passaged every 2-3
days or when the density reached 1.5 million/mL by diluting the confluent
culture with fresh media to obtain a final density of 0.4 million/mL. To passage
the adherent cell lines, the cells were first briefly rinsed with 1 × PBS. Pre-
warmed (37 ◦C) Trypsin solution (TrypLE, Gibco) was next added for 5 – 7
minutes and the plate was incubated at 37 ◦C. Once the cells were lifted off
from the plate, Trypsin was deactivated by adding equal volume of complete
growth medium. The cells were then seeded at a final density of 0.1 million/mL.
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Table 2.2 Growth condition for cell lines used in this study
Cell-line Origin Media∗/Growth condition Blasticidin
concentration
NCI-SNU-1 Human gastric carcinoma RPMI- Suspension 20 µg/mL
NCI-SNU-16 Human gastric carcinoma RPMI-Suspension 20 µg/mL
COLO-320-
HSR
Human gastric carcinoma RPMI-Suspension 20 µg/mL
KBM7 Human Chronic myeloge-
nous leukemia (CML)
IMDM- Suspension 10 µg/mL
HEL Human erythroleukemia RPMI- Suspension 15 µg/mL
HL-60 Human promyelocytic
leukemia
IMDM- Suspension 15 µg/mL
HepG2 Human liver hepatocellu-
lar carcinoma
DMEM/F12- Adherent 20 µg/mL
HEK-293-E Human embryonic kidney
cells 293
Freestyle 293- Suspen-
sion
20 µg/mL
SK-MEL-1 Human melanoma DMEM/F12-Suspension 10 µg/mL
Lu-65 Human lung carcinoma RPMI-Suspension 15 µg/mL
∗The full composition of each media is listed in section 2.1
2.6 Flow cytometry based cell binding assay
Binding assay with streptavidin-PE conjugated proteins
To increase binding avidity, biotinylated monomeric Cd4-tagged proteins were
multimerized around streptavidin-phycoerythrin (PE). To ensure all biotin bind-
ing sites on the streptavidin were occupied and yet to minimise the presence of
excess monomer, serial dilutions of biotinylated protein samples were titrated
against a fixed concentration of streptavidin-PE (100 µL of 0.1 µg/mL) for
20 minutes at room temperature before transferring to a streptavidin-coated
plate and assaying for the capture of any excess biotinylated Cd4-tagged
proteins using the OX68 ELISA. The minimal dilution at which all biotinylated
Cd4-tagged protein was captured was subsequently used to create tetramers.
A 10× tetramer staining solution was prepared using 4 µg/mL streptavidin-PE
and the appropriate biotinylated protein dilution by incubating for 30 minutes at
room temperature, then diluted to 1× and 100 µL added to 0.5-1×106 cells in
an U-bottomed 96-well microtiter plates and incubated for one hour at room
temperature. Where the anti-BSG antibody was used in blocking experiments,
cells were first incubated with 10 µg/mL antibody (or isotype matched control)
for one hour, prior to incubation with the RH5-streptavidin-PE complex. Cells
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were washed once with wash buffer (PBS with Ca2+/Mg2+ (Hyclone, Sigma)
supplemented with 1 % BSA) and analysed by flow cytometry.
Binding assay with pentameric proteins
The 3× FLAG and β-lactamase-tagged pentameric proteins were quantified
directly from supernatants and normalised to approximately 1 nmol/min using
the β-lactamase enzyme activity. Next, 100 µL of diluted proteins were added
to 0.5-1×106 cells in a U-bottomed 96-well microtiter plates for 1 hour at room
temperature. Following a wash with the wash buffer, 100 µL PE-conjugated anti-
FLAG antibody (0.5 µg/mL, Abcam) was added to the samples and incubated
for 1 hour. The cells were again washed once in wash buffer and analysed by
flow cytometry.
Binding assay with antibody specific to the cell surface proteins
For antibody staining of cell surface proteins, 50 µL of 1 µg/mL primary antibody
was incubated with 1×106 cells in 96-well U bottom plates. The cells were
washed after 1 hour of primary antibody incubation after which 100 µL of
an appropriate secondary antibody, also conjugated to PE, was used at 0.1
µg/mL.
Binding assay with transiently transfected cells
Human IGF2R was expressed on the surface of transfected cells using an
expression construct in which its cytoplasmic region was replaced by eGFP,
as previously described [85]. NCI-SNU-1 cells, which do not have detectable
levels of plasma membrane IGF2R expression, were transiently transfected
with either IGF2R-TM-eGFP or CD200R-TM-eGFP as a control, and probed for
binding interactions with either GABBR2 ectodomain presented as a tetramer
around streptavidin-PE or with an anti-IGF2R mAb.
All flow cytometry was performed on a Becton-Dickinson (BD) LSR Fortessa
flow cytometer, collecting between 10,000 to 30,000 events; live cells were
gated using forward and side scatter. PE was excited at a wavelength of 561
nm and emission detected using a 582/15 band pass filter; BFP was excited at
405 nm and the emission detected using a 450/50 band pass filter. Analysis
was performed using FloJo software (Treestar Inc.)
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2.7 Genome-wide screening and validation
2.7.1 Construction of gRNA expression vector
The Human Improved Genome-wide Knockout CRISPR Library v1 consisting
90,709 sgRNAs targeting 18,010 human genes (Addgene: 67989), lentiviral
Cas9 reporter plasmids : pKLV2-U6gRNA5(gGFP)-PGKBFP2AGFP-W (Ad-
dgene: 67980) and pKLV2-U6gRNA5(Empty)-PGKBFP2AGFP-W (Addgene:
67979), lentiviral vector expressing Cas9 fused with the Blasticidin resistant
gene at the C-terminus pKLV2-EF1a-Cas9Bsd-W (Addgene: 68343) and lentivi-
ral CRISPR gRNA expression vector pKLV2-U6gRNA5(BbsI)-PGKpuro2ABFP-
W (Addgene: 67974) were obtained from Kosuke Yusa [176].
To target a particular gene of interest, 20 base pair constructs were cloned
into the lentiviral CRISPR gRNA expression vector. For each of the targeting
sequence, BbsI sites were introduced and the oligos were ordered from Sigma
(table A.2, appendix section). Sense and antisense 24-nt oligonucleotides (10
mM each) were mixed in oligo annealing buffer (10 mM Tris-HCl (pH8.0) and 5
mM MgCl2) in a total volume of 100 µL. The mixture was incubated at 95 ◦C for
5 min and cooled to room temperature. The double stranded oligonucleotides
were then cloned into the BbsI site of the backbone vector.
2.7.2 Lentiviral production
Lentivirus was produced by transfection of HEK-293-FT cells. These cells were
cultured in RPMI 1640 media supplemented with 10% FBS. The cells were
seeded one day prior to transfection such that they would be approximately
80% confluent on the day of transfection. For the generation of lentivirus from
transfection of cells in 10 cm dish, 3 µg of a lentiviral vector, 9 µg of ViraPower
Lentiviral Packaging Mix (Invitrogen) and 12 mL of the PLUS reagent were
added to 3 mL of OPTI-MEM and incubated for 5 min at room temperature. 36
mL of the LTX reagent was then added to this mixture and further incubated for
30 min at room temperature. The transfection complex was added to the cells
and incubated for at least 4 hours after which the media was replaced with
fresh media. Media was again refreshed after 18 hours and finally 48 hours
later, the viral supernatant was harvested and stored at –80 ◦C.
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2.7.3 Lentivirus transduction
Lentivirus transduction for stable Cas9 line generation
All Cas9-expressing human cell lines were selected following transduction
of cells with lentivirus prepared from the pKLV2-EF1a-Cas9Bsd-W plasmid.
Polybrene (8 µg/mL) was added for the transduction of all cell lines expect
HEK293-E cell lines. Cells were selected using the indicated blasticidin con-
centration (see table 2.2) two days following transduction. Clonal high Cas9
activity cell lines were established by sorting individual blasticidin-resistant
cells into wells of 96-well plates (MoFlo XDP) which were further expanded
and tested for Cas9 activity using the GFP-BFP system [176]. In brief, cells
were transduced with lentivirus encoding GFP, BFP and a gRNA targeting GFP
(pKLV2-U6gRNA5(gGFP)-PGKBFP2AGFP-W) or the same construct with an
‘empty’ gRNA (pKLV2-U6gRNA5(Empty)-PGKBFP2AGFP-W) as a negative
control. High activity Cas9 stable cell lines were selected by examining the
ratio of BFP only to GFP-BFP-double positive cells transduced by the two
lentiviruses. These clonal cell lines were expanded and further tested by
targeting an endogenous gene encoding the BSG cell surface protein using
lentivirus prepared using a plasmid encoding puromycin, BFP and a gRNA tar-
geting BSG (pKLV2-U6gRNA5(BbsI-gBSG)-PGKpuro2ABFP-W). The surface
expression of BSG was quantified by flow cytometry using an anti-BSG mAb
(MEM-M6/6) eight days post-transduction to validate high Cas9 efficiency.
Lentivirus trasduction of HEK-293-E cells for knock-out library genera-
tion
A genome-scale ‘knockout’ library of HEK-293-E-Cas9 cells was produced
by transducing 3×107 cells such that ∼30% of the total cell population were
transduced to increase the chances that each cell just received a single
gRNA. The transduced (BFP positive) cells were harvested three days after
transduction using a cell sorter (MoFlo-XDP), and libraries containing at least
5x106 cells were selected. The libraries were cultured in media containing 2
µg/mL puromycin to remove the non-transduced cells and at every passage, at
least 10× the initial library (starting cell number on day three) for each library
were seeded into new culture flasks, thereby generating a sampling size of
at least 50x106 cells for each screen. Phenotyping screens for cell surface
binding events were carried out between 9 and 16 days post transduction.
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Lentivirus transduction of other human cell lines for knock-out library
generation
A spinoculation protocol was used to infect other human cells as they were
more difficult to transduce than HEK-293-E cells. For this, 2 mL of 5× 106
cells/mL were aliquoted in 8× 15 mL Falcon tubes, and mixed with lentivirus
together with 8 µg/mL polybrene and incubated at room temperature for 30
minutes followed by centrifugation for 100 min at 800×g at 32 ◦C. The super-
natant was removed, and the cells from each Falcon tube were resuspended
in 50 mL culture media. As with HEK-293-E cells, cells were sorted on day
three post transduction to generate control and sample libraries and grown
further in media supplemented with 1 µg/mL puromycin.
Lentivirus trasduction of human cells for a targeted gene knock-out
For targeted gene knockout in cancer cells, 1× 106 cells were seeded in one
well of a 6-well plate. 100 µL virus was added to the cells for at least 5 hours.
Polybrene (8 µg/mL) was added to all cells except HEK-293-E cells during
virus infection. The virus containing media was removed after the infection
period and fresh culture media was added to the cells. 48 hours post infection,
the cells were selected with puromycin (2 µg/mL for HEK-293-E cells and 1
µg/mL for all other cell lines). Polyclonal lines were used for initial validation of
the screen results. For the generation of clonal knockout lines of SLC35B2 and
IGF2R, the transduced cells were left to grow under selection for additional
10 days after which, the cells were single-cell sorted into 96-well plates (BD-
MoFlo-XDP). Clonally derived lines of IGF2R were analysed for gene knockout
using antibody staining with an anti-IGF2R antibody, from which clones lacking
surface staining of IGF2R were chosen. Gene disruption of SLC35B2 was
verified by first isolating genomic DNA from 500,000 cells using a commercial
kit (Blood and tissue miniprep kit, Qiagen), and then amplifying approximately
300 base pairs on either side of the expected cut site (gRNA targeted region)
with the following primers: forward primer- 5‘ TGCTGCAGGAAAGAGTGAT-
GACC3’; reverse primer- 5‘GCATGGGCAGCAAACTCACT3’. PCR products
were sequenced by Sanger sequencing. Insertions and deletions were anal-
ysed by sequence alignment and Tracking of Indels by DEcomposition (TIDE)
[189].
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2.7.4 Cell surface phenotyping, selection and amplification
of selected gRNAs
Genome-scale knockout libraries were phenotyped by cell surface staining
using flow cytometry between 9 and 16 days post-transduction. The mutant
library was divided into two parts: at least 5×107 cells from the mutant library
were collected as ‘control’ population for later analysis whereas 5×107 - 15
×107 cells from the library were stained with appropriate reagent (recombinant
protein or antibody) using the binding assay protocol as described above with
minor modifications: cells (5×106 cells/mL) were stained in 15 mL Falcon
tubes with gentle rotation (6 rpm), and the stained cells were then analysed
using an flow sorter (BD-MoFlo-XDP) and the BFP+/PE- cells were collected.
The percentage of the total library population that was collected in each screen
varied between 0.2% to 4%. Sorting threshold and the approximate number of
cells sampled and collected for each screen is listed in appendix table A.3. All
genetic screens performed in this study were carried out once.
Amplification of gRNA from control mutant cells
The human genome-wide lentiviral gRNA library has a high complexity as it
contains approximately 91,000 different sequences. To capture every guide in
the library, each mutant library was composed of at least 50 million transduced
cells (500x of the gRNA library). However, it is not feasible to extract gRNA
from all of 50 million cells therefore, gRNAs from at least 10 million cells
(approximately 72 µg) were sampled from the control library. The genomic
DNA from the cells were isolated with a commercial kit (Blood and tissue Maxi
kit, Qiagen) using manufacturer’s recommendation. gRNA was then amplified
using the isolated genomic DNA (2 µg DNA/PCR reaction), primers (U1 and L1,
refer to table A.4, appendix section) and Q5 Hot Start High-Fidelity 2 × Master
Mix. The detailed protocol for PCR amplification of gRNAs from genomic DNA
is provided in the appendix section A.1. The PCR products were cleaned with
Qiagen PCR purification kit.
Amplification of gRNA from screened cells
For samples where the sorted cell number was less than 100,000, a cell lysate
protocol was used to isolate guides prior to PCR enrichment. Cell lysates
were prepared from sorted cells by boiling samples (10,000 cells/sample) at
95 ◦C with 25 µL water for 10 minutes. Next, 5 µL of 2 mg/mL freshly diluted
Proteinase K was added to each well for 1 hour and incubated at 56 ◦C, after
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which the enzyme was inactivated by boiling the sample for 10 minutes at 95
◦C. The gRNAs were then amplified using 10 µL cell lysates/PCR reaction. For
larger cell number, genomic DNA was isolated using a commercial kit (Blood
and tissue miniprep kit, Qiagen) using manufacturer’s recommendation. 100
ng DNA was used for each PCR reaction and the guides were amplified with
the same L1 and U1 primers.
Illumina Hi-Seq sequencing of gRNA
The PCR amplified guides were diluted to 40 pg/µL in EB and tagged with
illumina index primers using second round of PCR with using 200 pg template,
PE 1.0 as forward primer, appropriate index tags as reverse primers and KAPA
HiFi HotStart ReadyMix polymerase (also refer to appendix section A.1 for
detailed protocol and table A.4 for primer information). The PCR products
were cleaned using SPRI beads (Agencourt AMPure XP beads). When the
samples were multiplexed, qPCR was conducted by the Sanger DNA pipelines
to load equivalent molar quantities of differently tagged samples. 4 nM of mul-
tiplexed sample was prepared and loaded Hi-Seq 2500 rapid run sequencing
machines and single-end sequencing (19bps) was performed with the custom
sequencing primer, 5‘-TCTTCCGATCTCTTGTGGAAAGGACGAAACACCG-3’.
Approximately 300 million reads were obtained from each sequencing run in
two lanes of Hi-seq 2500. Between 10-15 samples were multiplexed in each
sequencing run, providing a read depth of at least 20 million for each sample.
2.7.5 Data analysis
The read count for each gRNA and gene level enrichment analysis was carried
out using the MAGeCK statistical package (version, v0.5.5) [190]. Briefly,
the software package was used to first convert the fastq files obtained from
sequencing machines into a count file (csv format) using the "–count" function,
which maps the 19 bps sequencing reads to the sequences of each gRNA.
Thus obtained count files contained the read counts for each gRNA, which
were used in the "–test" function to perform the gRNA and the gene ranking
for both negative and positive selections. In this step, MAGeCK first performs
a median normalisation of the read counts from treatment sample (sorted pop-
ulation in this case) and control sample. Next, a negative binomial (NB) model
is applied to investigate the significant differences in the gRNA abundance
between the control and treatment samples. The individual gRNAs are ranked
based on the on P-values calculated from the NB model and the enriched
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genes are identified using a modified robust ranking aggregation (RRA) algo-
rithm which investigates whether gRNAs targeting the genes are consistently
ranked higher than expected. Pathway analysis was also carried out using
the RRA algorithm of the MAGeCK software using the ranked gene list with
default settings and KEGG annotated pathways [191]. Full documentation re-
garding installation of MAGeCK and application of each function is provided in
https://sourceforge.net/p/mageck/wiki/usage/. All further analysis was
carried out using R [192]. Gene annotations were obtained from Uniprot [193].
43

CHAPTER 3
DEVELOPMENT OF A CRISPR-CAS9 BASED KNOCK-
OUT SCREEN FOR CELLULAR RECOGNITION
3.1 Introduction
This chapter describes the design of a genome-scale knockout (KO) screening
approach using the CRISPR-Cas9 system in human cell lines. The approach is
subsequently used to screen a panel of monoclonal antibodies targeting struc-
turally diverse membrane receptors to assess the potential of the approach and
to determine the experimental parameters to identify cellular factors mediating
cellular recognition events at the cell surface.
3.1.1 Monoclonal antibodies are ideal probes for the study
of cell surface recognition
To first assess the feasibility of genome-scale KO screens for the identification
of factors required for cell surface recognition events, I focused initially on
the interactions mediated by monoclonal antibodies (mAbs). mAbs have
already been established as powerful tools to investigate various aspects of
receptor biology as exemplified by their use in the past to isolate, localise,
and biochemically characterise membrane receptors, as described in Chapter
1. As mAbs are selected to bind specifically to a single epitope within a
receptor with a high avidity (KDs in the nM to pM range), the binding of mAbs
on a cell surface that abundantly expresses the corresponding antigen often
leads to a bright staining with a high signal to noise ratio. In a CRISPR-
Cas9 screen, this can be the basis for Fluorescence Activated Cell Sorting
(FACS)-based phenotypic selection, allowing identification of factors, which
if disrupted causes a decrease in the cell surface expression display of the
mAb epitope. Strong phenotypic selections are usually desired in a pooled
screening approach as they allow for the identification of candidate genes with
45
Chapter3
high confidence, thus the use of mAbs as probes will be ideal to determine the
parameters of CRISPR-KO screens.
3.1.2 Genome-scale knockout screening approach has the
potential to determine the specificity of mAbs.
The use of mAbs in a genome-scale KO screening approach in itself has the
potential to become a novel means of determining the specificity of a given
antibody. High quality antibodies should recognise their targets specifically
but the batch-to-batch variability of the commercially available antibodies
can lead to poor specificity, and has caused concerns in the research field
[194, 195, 196, 197]. The need for target validation of mAbs is even higher
now as there is a growing use of mAbs as therapeutics in human diseases
such as cancer, rheumatoid arthritis and Crohn’s disease [198]. Common
methods to characterise antibody specificity involve immunoassays such as
immunohistochemistry (IHC), immunoprecipitation (IP), Western blotting (WB),
and mass spectrometry (MS) analysis [199, 200]. However, such approaches
are not always applicable, especially if the mAbs are raised against the correctly
folded protein epitopes such that they do not react to denatured or detergent-
solubilised antigens. The genetic strategies discussed earlier in Chapter 1 to
identify binding partners, such as the gain-of-function approach using a cDNA
library and the loss-of-function screens using RNAi-mediated knockdown, have
been used to identify targets of mAbs that recognise folded epitopes that are
correctly expressed on the surface of cells [201, 202, 203]. However, the high
off-target effects of RNAi systems that often lead to inconsistent results and
the resource- and time-intensive nature of expression cloning approaches
using cDNA libraries pose potential challenges in their applications. Genetic
screening methods using the CRISPR-Cas9 KO system holds potential for
identification of receptors targeted by mAbs, which could be valuable in the
field of antibody characterisation. This will be explored in detail in this chapter.
3.1.3 Considerations for knockout screening approach to
identify directly interacting receptors
One of the considerations for the use of genome-scale KO screens to identify
directly interacting receptors is the possibility that cellular processes that con-
tribute to general protein transport, would dominate the identified genes in all
the screens and decrease the likelihood of identifying the direct receptor. Some
of the cellular factors that transport plasma membrane-destined membrane
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receptors from the endoplasmic reticulum (ER) lumen via the Golgi to the cell
surface include: proteins of the signal recognition particle (SRP)-dependent
protein targeting pathway, which mediates co-translational targeting of newly
synthesised polypeptides into the ER; enzymes within the ER, which modify
the polypeptides through signal peptide cleavage and initial glycosylation (also
called ‘core glycosylation’); and proteins that package folded polypeptides
into specific vesicles for intracellular transport between organelles [204]. The
disruption of these factors would affect the membrane expression of a large
number of membrane proteins and therefore these factors are expected to be
identified in the majority of the screens. However, many genes involved in these
pathways (specifically the genes encoding the SRP-dependent protein translo-
cation pathway proteins and the core glycosylation pathway proteins) are also
known to be essential for the cells, and multiple negative selection CRISPR-KO
based screens have shown that gRNAs targeting these genes usually drop-out
of the mutant pool as the cells are continually grown [175, 176, 177, 205].
This would instead decrease the likelihood of these genes dominating the
identified hits in the screen. In this chapter, I investigate how the experimental
parameters in terms of the timing and the stringency of selection can influence
the identification of genes that generally contribute to receptor expression
versus genes that encode the directly interacting receptor.
3.1.4 Knockout approach used in this study
A dual vector approach is used in this study to generate genome-wide mutants.
In this approach, stable Cas9-expressing cell lines are first created and then
transduced with the lentiviral knockout library to generate the cell mutant
library. The lentiviral library is generated from a plasmid pool obtained from
Kosuke Yusa (‘Yusa library’). This library consists of 90,709 gRNA targeting
18,009 genes (approximately five gRNAs/gene). The library was designed with
features that have been shown to improve gRNA efficacy, such as the improved
scaffold (iscaffold) on the gRNA. The conventional scaffold of a chimeric gRNA
consists of a stretch of thymidines (T), which acts as a pause signal for RNA
polymerase III that can potentially reduce the transcription efficiency [206]. The
improved scaffold on the Yusa library is longer than the conventional scaffold
by five nucleotides and avoids T stretches by mutating a single T residue within
the stretch. The library has already been used for the study of essential genes
in cells for the identifcation of genetic vulnerabilities in acute myeloid leukemia
[176].
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3.1.5 Scope of this chapter
In this chapter, I first describe the generation of a ‘toolkit’ required for setting up
a genome-scale KO screening technology. This toolkit consists of: (a) human
cell lines expressing highly efficient Cas9, and (b) a quality-controlled genome-
scale library generated from the Yusa plasmid library. I next proceed to describe
the optimal strategy for FACS-based phenotypic selection, before going on to
describe multiple screens carried out with mAbs targeting structurally diverse
membrane receptors, to identify cellular factors required for mAb binding to
the cell lines. Finally, I will summarise the lessons learnt from this initial study.
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3.2 Results
3.2.1 Generation of stable cell lines expressing Cas9
Determination of protein turnover time
To carry out CRISPR-Cas9 mediated KO screens, I first generated a sta-
ble Cas9-expressing HEK-293-E cell line using lentiviral transduction. I next
designed a method to measure the Cas9 efficiency by making a gRNA con-
struct expressing a single gRNA targeting BSG, which could be introduced
to Cas9-expressing cells via lentiviral transduction (scheme for vectors used
in figure 3.1A). Using this system, the decrease in cell surface expression of
BSG in the transduced cells is readily established by flow cytometry using an
anti-BSG mAb, which is then used as the measure of Cas9 efficiency. This
flow-cytometric approach allows for rapid assessment of the efficiency of the
individual cells in a pool rather than efficiency of the ‘bulk’ population. An
important consideration in using this system is to wait long enough to allow
complete protein turnover so that the previously transcribed mRNA and the
translated protein is degraded. To determine the earliest timepoint where loss
of the protein could be observed, polyclonal Cas9 cells infected with gRNA
targeting BSG were checked for cell surface BSG expression on days 6, 8,10,
15 and 20, post transduction. While only a very small loss of cell surface
BSG was observed at day six post infection, a clear population lacking the
surface staining for BSG was observed from day eight onwards, demonstrating
the expression of functional Cas9 in the cell line. However, approximately
25% cells retained surface expression of BSG on day eight and this knockout
refractory population did not change even when examined at day 20 (figure
3.1B).
To assess whether eight days was a typical turnover time for other surface
receptors, three more guides targeting SDC1, CD55, and CD44, as well as
an empty construct with no targeting gRNA were cloned in the BbsI site of the
reporter vector and was used to infect the Cas9-expressing HEK-293-E cells.
The level of the respective surface proteins was also tested on day eight post
transduction. A clear loss of the surface proteins were observed in all cases.
Cells refractory to gene knockout were also observed in all cases (figure3.1C).
Collectively, day eight was determined to be the earliest time-point that could
be used to test the efficiency of Cas9 using the endogenous gene knockout
system.
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Fig. 3.1 Time- dependent decrease in cell surface expression of membrane re-
ceptors is observed in Cas9-expressing cells that are transduced with gene
specific gRNAs. A. Schematics of lentiviral vector encoding Cas9 together with the
blasticidin resistant gene at the C-terminus used to create stable Cas9 expressing
lines (left panel) and Cas9 activity reporter with an improved scaffold and puro/BFP
markers targeting BSG (right panel). B. Viruses with the activity reporter were used to
quantify genome editing efficiency in Cas9-expressing HEK-293-E cell line. A small
decrease in the surface expression of BSG was seen on transduced cells on day
six post transduction. From day eight onwards, a very clear double population was
observed. Approximately 25% of cells retained BSG expression on the cell surface
by day eight and the frequency of this population did not change even at day 20.
C. The surface expression of three other cell surface receptors (CD55, SDC1, and
CD44) also decreased on day eight. Control: parental cell line stained with secondary
anti-mouse(ms)-PE alone; Uninf: parental cell line stained with anti-BSG antibody,
Empty: parental cell line stained with the indicated primary antibody. Both B and
C are representative of two technical replicates. CMV: Cytomegalovirus promoter,
RU5: 5’ long terminal repeat lacking the U3 region, EF1a: intron-containing human
elongation factor 1a promoter, Cas9: codon-optimised Streptococcus pyogenes Cas9,
Bsd: Blasticidin resistant gene, W: Woodchuck Hepatitis Virus posttranscriptional
regulatory element, SIN: ∆U3RU5 (self-inactivating 3’ LTR); hU6: human U6 promoter,
gBSG: gRNA targeting BSG, Iscaffold: Improved scaffold, 2A: self cleavage peptide,
PGK: PGK1 promoter, puro: puromycin-resistant gene, BFP: blue fluorescent protein.
Cloning Cas9-expressing cell lines increases Cas9 cleavage efficiency
Having established the protocol to measure Cas9 efficiency, I proceeded to
make stable Cas9 lines for a cell line originating from a different tissue source
(colorectal carcinoma, NCI-SNU-1). The level of BSG expression on the
surface of cells was analysed eight days post-infection by flow cytometry using
an anti-BSG mAb. While the Cas9-mediated gene inactivation was evident
from loss of BSG from the cell surface upon infection with gRNA targeting BSG,
approximately 30% of cells that retained BSG expression were again observed
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(figure 3.2B). One of the reasons for this incomplete knockout of BSG is likely
to be the variability in expression of efficient Cas9-nuclease in a polyclonal cell
population. In a polyclonal Cas9 line, it has been shown that some cells acquire
mutations in the proviral Cas9-coding sequence with APOBEC3 mutational
signature that can lead to Cas9 inactivation and decrease the overall efficiency
[176]. Such inactivations within a population can potentially cause problems
in genome-scale screens where Cas9 is assumed to be 100% efficient and
the incorporation of a gRNA in a cell is equated to the complete loss of the
targeted gene product. To reduce the heterogeneity and to select the cell with
the highest Cas9 efficiency, single cells of the polyclonal line were sorted using
a MoFlo-XDP sorter into 96-well tissue culture plates. Colonies appeared
approximately two weeks later and as an initial test, 23 clones were tested. All
except one clone had an increased population of cells that had lost surface
BSG compared to the polyclonal line (five best clones depicted in figure 3.2B).
The clone with the largest refractory population (clone 22) showed a broad
surface expression profile with no clear population lacking cell surface BSG
(figure 3.2C). In a polyclonal Cas9 line, cells with lower cleavage efficiency
would decrease the overall Cas9 efficiency.
The loss of cell surface BSG expression as an indicator of Cas9 activity
is useful for estimating efficiency for targeting endogenous genes but is time-
consuming requiring steps involving antibody staining, and waiting for at least
eight days to ensure complete protein turnover. A faster method (a GFP-BFP
system) to check Cas9 efficiency has been developed using an exogenous
system in which cells are transduced either with a construct expressing GFP
with a gRNA targeting GFP or an empty gRNA as a control (vector schematics
in 3.2 D) [176]. The expression of GFP can be monitored as early as three days
post-transduction to determine the nuclease cleavage efficiency. To directly
compare the BSG KO method with the GFP KO method, the five best clones of
NCI-SNU-1 cells selected for the lowest refractory population of BSG surface
expression were checked with the GFP-BFP system. All five clones showed a
very high efficiency of GFP targeting compared to the polyclonal line (figure
3.2D). The fraction of cells from the polyclonal line that remain refractory to
gene KO was lower using this system compared to the BSG KO system (6%
compared to 30%). That said, the clone with the lowest refractory population
under the BSG KO system (clone 4) also had the lowest refractory population
with the GFP-BFP system.
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Fig. 3.2 Selecting clonal cell lines with high Cas9 activity for efficient genome-
scale genetic screening. A. The Cas9 activity of polyclonal Cas9-expressing NCI-
SNU-1 was tested by lentiviral transduction with a BSG-KO reporter: approximately
70% decrease in surface expression of BSG was observed. B. Clones of stable Cas9-
NCI-SNU-1 showed variation in the fraction of the population that remained refractory
to BSG inactivation. All five clones depicted a population that was approximately
threefold lower compared to that from the polyclonal line. C. Comparison between the
best and the worst clones from the same polyclonal line (23 clones tested). Clone
22 showed a small decrease in surface expression of BSG with no evident negative
population as observed in clone 4. Control: parental NCI-SNU-1 cell line stained
with secondary anti-mouse-(ms-) PE alone; WT: NCI-SNU-1 cell line stained with
anti-BSG antibody. D. Viruses with a gRNA-targeting plasmid encoded GFP or without
(‘empty’) (schematic depicted) were used to quantify genome editing efficiency of
both polyclonal and cloned lines of Cas9-expressing NCI-SNU-1 cell line. The cells
were tested for both BFP and GFP expression by flow cytometry after infection with
lentivirus, or left uninfected. BFP expression marks transduced cells and the loss of
GFP expression was used to quantify Cas9 activity. The profile for uninfected and
‘empty’ infected cells looked similar for all clones; representative profiles are depicted
in the left panel. All five clones of the NCI-SNU-1 cell line show a higher loss of GFP
compared to the polyclonal line (right panel), with clone 4 having the lowest refractory
population.
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Taken together, the GFP-BFP system used to assay Cas9 efficiecny cor-
related well with the BSG KO system, but a direct comparison between the
assays suggested that the GFP-BFP system overestimates the Cas9 efficiency,
whereas the BSG KO system provides a more realistic estimation of the effi-
ciency of the targeting of endogenous genes. Taking this into consideration,
the strategy I subsequently employed to create other stable Cas9-expressing
lines was to initially use the GFP-BFP system to clone the high efficiency lines,
and then to check the clone with the highest GFP cleavage efficiency with
the BSG KO system to obtain a more accurate estimate of Cas9 efficiency.
Five clones of HEK-293-E and HEL cells were each tested, and the clone with
the lowest refractory population expressing GFP upon infection with gRNA
targeting GFP was chosen to re-test with the BSG KO system (figure 3.3A).
The chosen clones of HEL and HEK-293-E cell lines exhibited approximately
91% and 92% loss of BSG from the cell surface respectively, when transduced
with a gRNA targeting BSG (figure 3.3B).
Fig. 3.3 Cas9-expressing human cell lines generated in this study demonstrate
high GFP and BSG cleavage efficiency. A. Cloned Cas9-expressing HEK-293-E
and HEL cell lines were tested for both BFP and GFP expression by flow cytometry
after transduction with GFP-BFP reporter viruses, or alternatively left uninfected. BFP
expression represents transduced cells (note the transduction rate for HEL cells was
lower compared to the HEK-293-E cells). As before, the loss of GFP expression is
used to quantify Cas9 activity; the line exhibiting the greatest loss of GFP expression
out of at least five clones tested are shown. B. The cloned cell lines selected using the
GFP-BFP assay were additionally tested for their ability to target an endogenous locus
by infecting them with a lentivirus encoding a gRNA targeting BSG and quantifying
expression of BSG on the cell surface with an anti-BSG mAb; both cell lines exhibited
loss of BSG from >90% of the population. Control: parental cell line stained with
secondary anti-ms-PE alone; Uninf: parental cell line stained with anti-BSG antibody.
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3.2.2 Quality control of the genome-scale mutant cell library
Reproducible mutant cell libraries with a uniform coverage of the gRNAs
can be created from plasmid gRNA library
I next set out to explore the optimal parameters to perform a pooled KO screen
using the Cas9 cell lines that were generated. In the intended genome-scale
screening setup, in which approximately 91,000 gRNAs are used, the library
complexity plays a role in determining the success of a screen. The population
of cells that are to be screened should be large enough to capture all gRNAs
in the library. Usually, libraries that have high complexity (500-1000-fold
representation of each guide) are used to screen for the desired phenotype.
To obtain this representation, it is common to transduce 30-100 million cells at
MOI of 0.3 to reduce the chance of more than one gRNA per cell [207]. The
transduced cells make up the initial library. As a guiding principle, a library at
least five fold larger than this library should be maintained while passaging the
cells over the time that is required for the complete turnover of the proteins (at
least eight days).
To ensure that gRNA representation is maintained using the cellular KO
library preparation protocol, I first quantified the individual gRNA abundances in
at least 5×107 cells on different days after transduction from two independent
NCI-SNU-1-Cas9 libraries and one library of both HEK-293-E-Cas9 and HEL-
Cas9 cells. The gRNA abundances in the libraries were quantified by deep
sequencing and a high correlation between the biological replicates of NCI-
SNU-1-Cas9 libraries and amongst the three different cell line libraries at
equivalent time points was observed (figure 3.4A). This indicated that using
this protocol, it was possible to reproducibly create mutant cell libraries with
good representation of all gRNAs. Compared to the correlation between the
different mutant cell libraries, the correlation between the original plasmid
population and the mutant cell libraries was lower. This suggested that the
most appropriate control for gRNA enrichment analysis was the cell line on
that particular day rather than the population of gRNAs in the original plasmid
population.
To further investigate the difference between the plasmid pool and the
mutant cells in terms of their gRNA abundance, I next analysed the distribution
of all gRNAs in each cell line and compared it to the distribution in the plasmid
pool. In the plasmid library, while a small fraction of gRNAs were under- or
over-represented, approximately 82% of gRNAs were uniformly distributed
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with only 8-fold increase in abundance between the 10th and 90th percentiles.
The mutant libraries generated from this plasmid library also showed a uniform
coverage, but a small drop in the overall representation of the gRNA library
was observed in all cell lines; this decrease was more evident for libraries on
day 16 compared to those on day 9. (figure 3.4B).
Fig. 3.4 Mutant cell libraries can be created reproducibly by transduction with
the lentiviral gRNA library. A. Matrix plot depicting the correlation between nor-
malised read counts of all gRNAs in the original plasmid library and gRNAs in the
indicated cellular mutant libraries on the indicated days. Correlation between bio-
logical replicates of NCI-SNU-1 and between any cell line on any day was higher
than when compared to the original plasmid pool. B. Cumulative distribution function
plots comparing the gRNA abundance in the plasmid library to the mutant libraries of
HEK-293-E and NCI-SNU-1 cells on day 9, 14 and 16 days post transduction. The
differences in the curves from the mutant cell populations represent the depletion in a
subset of gRNAs compared to the plasmid library.
Negative selection screens reveal essential genes
In a negative selection screen, in which the mutant cells are continually grown
for an extended period of time, the cells that carry mutations in the genes that
are essential for cell proliferation will deplete, which makes the corresponding
gRNA to ’drop-out’. Therefore, when comparing the mutant gRNA abundance
to the plasmid gRNA abundance, gRNAs that target fundamental cellular
processes should, in principle, be depleted. These screens are sensitive to the
library representation as losing the representation of gRNAs due to technical
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reasons- such as the need to passage the library because of cell growth, which
may create population restriction points, reducing gRNA library representation.
Thus, investigating the depleted genes under negative selection can provide
valuable insights into the quality of the mutant library.
To check whether the depleted gRNAs targeted essential genes, I next
carried out a gene-level negative selection enrichment analysis to identify
genes that were depleted in the mutant library compared to the plasmid library.
As a quality control, I first analysed ribosomal genes (annotations from KEGG-
Ribosome), which are known to be essential and are often identified robustly in
similar negative selection screens [175, 176, 177]. Reassuringly, the majority
of the ribosomal genes were amongst the most significantly depleted genes
(False discovery rate (FDR) <10%) in all three days and in both HEK-293-E
and NCI-SNU-1 cell lines (figure 3.5A). Next, I carried out pathway analysis
using KEGG annotated pathways; among the most depleted pathways were
essential biological processes such as the spliceosome, cell cycle, proteasome
and DNA replication processes. The number of relevant genes (‘hits’) in these
pathways was similar between the biological replicates and also between cell
lines (figure 3.5B). These results provided further confidence that the cellular
mutant libraries generated using the protocol retained their gRNA complexity
and could be used for genome-scale screening.
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Fig. 3.5 gRNAs targeting genes involved in essential biological processes were
depleted during culture of the mutant cell library. A. Gene-level enrichment anal-
ysis revealed genes involved in ribosomal biosynthesis to be among the most sig-
nificantly depleted genes in NCI-SNU-1, HEL and HEK-293-E cell lines on all three
time-points, days 9,14 and 16. For NCI-SNU-1, representative analysis from one
of the two experiments is shown. B. Five KEGG-annotated pathways known to be
involved in essential cell processes that were significantly depleted in all the samples
are shown. The numbers under each pathway represents the total number of genes
in the group. The number of genes involved in each pathway identified as being
significant was similar for the replicates of NCI-SNU-1 and between the HEK-293-E,
HEL and NCI-SNU-1 cell lines.
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3.2.3 Genome-scale screens using monoclonal antibodies
Design of a genome-scale KO screening platform to investigate cellular
recognition events at the cell surface
To identify factors required for molecular recognition events at the cell surface
in the context of a plasma membrane, I initially designed a genome-scale
KO screening system in human cell lines. A flow-cytometry based binding
assay was initially used to identify a high-efficiency Cas9 expressing cell line
that stained brightly with a mAb. I then created a genome-scale mutant cell
library for the chosen cell line using a library of lentiviruses, each encoding a
single gRNA from a pool of 90,709 individual gRNAs (gRNA expression vector
depicted in figure 3.6A). Transduced cells that had lost the antibody epitope
at the cell surface were isolated through fluorescence-activated cell sorting
(FACS) and the genes responsible for this loss of binding were identified by
comparing the relative abundance of the different gene-specific gRNAs present
in the sorted cells compared to the total unsorted population using deep
sequencing of PCR products and enrichment analysis (schematics depicted in
figure 3.6).
Fig. 3.6 Schematic of the genetic screening approach. A. Schematic of lentiviral
single gRNA expression vector with BFP and puromycin selection cassettes with
gRNAs cloned into the BbsI site. The backbone is the same as the reporter vector
with gRNA targeting BSG described earlier (figure 3.1A). B. Strategy used to perform
genome-scale KO screens using mAbs as selection reagents. The initial mutant library
is generated by infecting cells at a low MOI of 0.3 and the infected cells expressing
BFP are selected by FACS. The sorted library is kept in culture between 9 and 16
days. The total cell population on the screen day is divided into two; one half is kept
as control population and the other half is selected for mAb binding. The cells from the
mutant library that are refractory to binding are sorted using FACS and the abundance
of gRNAs in the sorted population is compared to the control population to identify
genes contributing to binding of the mAb to the cells.
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A proof-of-principle screen using anti-BSG antibody identifies BSG and
a chaperone required for BSG trafficking to the plasma membrane.
To test the use of the genome-scale screening approach, I carried out a proof-
of-principle screen on HEK-293-E cells with an anti-BSG mAb as the selection
reagent. BSG was a good model to test this system as the antibody provided a
clear bright signal on the Cas9-expressing HEK-293-E cell line with a very high
signal to noise ratio (figure 3.7A). The mutant library was screened 16 days
post transduction and 0.22% of the population that expressed gRNA (BFP+)
and lacked BSG on the surface (PE-) was sorted (figure 3.7B). Unsorted cells
also from day 16 post-infection were used as a controls. gRNAs from both
sorted and control populations were isolated and deep sequenced to quantify
their abundance.
Fig. 3.7 Cell sorting strategy for a proof-of-principle genome-scale screening
for recognition of BSG in HEK-293-E cells by an anti-BSG mAb A. BSG was
highly expressed in HEK-293-E cells as indicated by the clear separation of cells
stained with anti-BSG antibody versus secondary-only stained samples. B. Gating
strategy for screen carried out with anti-BSG mAb in HEK-293-E cells. A very small
fraction of PE-negative and BFP-positive cells were sorted. Approximately 60 million
cells were sampled and 40,000 cells were collected during this screen.
A preliminary analysis using the raw abundance of gRNAs in the sorted
population revealed a high enrichment of gRNAs targeting BSG, as expected,
but also gRNAs targeting a gene encoding a monocarboxylate transporter,
SLC16A1 (or MCT1). Within the top ten most abundant gRNAs, four targeted
BSG and four targeted SLC16A1—which is a known chaperone required for
maturation and surface expression of BSG (3.8A). BSG is an unusual protein
for a single transmembrane protein as it contains a charged glutamic acid
residue within the transmembrane region. It has been suggested that this
charged residue is important for the lateral association of BSG with the multi-
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pass protein MCT1 on the plasma membrane (Schematics in figure 3.8B)
[208, 209].
I next carried out a enrichment analysis using the MAGeCK software
and identified four genes (BSG, SLC16A1 and two novel factors SPPL3 and
WDR48) that were significantly enriched (FDR <0.05) in the sorted population
compared to the control population (figure 3.8C). SPPL3 is a Golgi-resident
intramembrane-cleaving protease that has been shown to regulate the activity
of N-glycosylation related glycosyltransferases such as MGAT5, B3GNT5
and B4GALT1 [210]. The three N-glycosylation sites (N44Q, N152Q, and
N186Q) of BSG are known to contain complex-type carbohydrate groups
generated in the Golgi by the action of multiple glycosyltransferases, including
MGAT5, thus it is possible that the loss of SPPL3 causes the generation
of abnormal carbohydrate chains in BSG, which could lead to disregulated
surface expression [211]. WDR48 is a regulator of deubiquitylating complexes,
and, in this case also, there has not been a reported direct association of this
protein with BSG. However, it has been suggested that BSG recruitment to the
surface of the cell membrane is induced upon K63-linked ubiquitylation [212].
Therefore, it is possible that WDR48 has an effect on the pathway leading to
BSG ubiquitylation thereby affecting its surface localisation. Further validation
experiments are required to investigate these hypothesised roles.
This proof-of-principle study demonstrated that genome-scale KO screening
approach was a suitable method to identify not only the gene encoding the
antibody epitope, but also reveal factors such as chaperones that are important
in expression of the receptors. However, one limitation of the method was
that very few genes were identified as being significantly enriched. This was
surprising because I was expecting that genes encoding proteins within the
secretory pathway would be enriched in the sorted non-binding population
as they would affect the surface expression of BSG. While a few members
of the general secretory pathway are known to be essential, and by the day
the screen was carried out, cells with mutations in those genes would have
dropped-out of the mutant pool, it was surprising that none were identified. A
likely explanation for the low number of significant genes could be the stringent
gating threshold and the low number of cells (∼40,000) that were collected,
resulting in lower number of gRNA being represented in the sorted population.
This could be observed by comparing the gRNA abundance in the control
and sorted sample, which revealed a clear loss of many gRNAs in the sorted
sample (figure 3.8D). Upon a closer look, only approximately 16,300 gRNAs
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had representation (count above 10) in the sorted population compared to
the 86,000 in the control population. Within the represented gRNAs, the
abundance of gRNAs targeting the four significant hits were clearly higher in
the sorted population compared to the control population. This suggested that
using a highly stringent sorting threshold would result in the identification of few
genes that have strong effects on binding loss. However, such a strategy might
not be ideal for the identification of genes that have comparatively weaker size
effects.
Fig. 3.8 A positive selection screen using anti-BSG mAb demonstrates the suc-
cessful application of a CRISPR-based loss-of-function screen to identify fac-
tors required for epitope recognition by a mAb A. Top ten gRNAs with the highest
raw read counts in the sorted non-mAb binding population. Four out of nine gRNAs
targeting BSG and four out of five gRNAs targeting SLC16A1 were represented in
the top ten list. B. Schematic representation of cell surface interaction between 12-
transmembrane transporter protein MCT1 and the single pass type I protein BSG. C.
Enrichment analysis using MAGeCK. The y-axis represents the Robust Rank Aggre-
gation (RRA) scores of genes calculated by comparing the gRNA abundance in sorted
vs control cells. Genes are ordered by their RRA-score. D. Comparison between nor-
malised read counts in control versus treatment (sorted) population. Individual gRNAs
targeting the four significantly enriched genes but no gRNAs targeting the secretory
pathway genes (KEGG-protein export) were enriched in the sorted population.
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An improved screen identifies cellular pathways required for receptor
expression in addition to genes directly encoding for the mAb epitope
I next explored ways to improve the screen to increase its sensitivity and identify
not only the direct receptor, but also the pathways required for the expression
of the receptor on the cell membrane. To test if the stringency of sorting
was the reason for the low number of significant genes being identified in the
screen, I aimed to decrease the stringency and to increase the mutant library
size, in order to increase the number of sorted cells, thereby increasing the
representation of the gRNAs. I carried out the screen using these parameters
with an anti-CD59 mAb antibody. CD59 was chosen to test this system
for various reasons. First, the anti-CD59 provided a bright stain on Cas9
expressing HEK-293-E cells (figure 3.9A); second, as CD59 is a GPI-anchored
protein, its expression on the plasma membrane depends on the components
of the cellular GPI anchor biosynthesis pathway [213]. The GPI anchor pathway
is known to be non-essential for cell lines and has been robustly identified in
genome-scale loss-of-function screens [173]. For this experiment, I screened
100 million cells from the mutant library and sorted 0.45% of the non-binding
and BFP expressing cells (figure 3.9B). For increased representation of the
library in the sorted population, I aimed to collect up to ten times more cells in
the non-binding population compared to the screen with anti-BSG mAb.
When comparing the overall abundance of gRNAs in the sorted population
to that from the control population, I immediately observed a strong enrichment
for individual gRNAs targeting CD59, the GPI anchor biosynthesis pathway and
the secretory pathway in the sorted population (figure 3.10A). Next, I applied
gene-level enrichment analysis using the MAGeCK software and observed
that CD59 itself and 25 genes directly related or contributing to the GPI anchor
biosynthesis pathway were significantly enriched (FDR <0.05) in the sorted
population (figure 3.10B, GPI anchor biosynthesis schematic depicted in figure
3.10C).
Upon a closer look at the secretory pathway genes, only one member of
the protein export pathway, SLC61A1, was identified as being significantly
enriched in the sorted population. All other genes corresponded to the initial
stages of the N-linked glycosylation pathway or the ‘core glycosylation’ pathway
(identified genes in figure 3.11). The early steps in N-linked glycosylation
involves the generation of a unique 14- monosaccaride (Glc3Man9GlcNAc2)
structure, which is a conserved feature of eukaryotic cells and is used as
62
CRISPR-Cas9 knockout screens for cellular recognition
a signalling molecule in the protein folding pathway for a wide range of N-
glycosylated proteins such as CD591 [215]. Thus, the genes in this pathway are
likely to have contributed to the proper folding of CD59 ensuring its transport
to the surface of the cells.
Fig. 3.9 Cell sorting profile for flow-cytometry based CRISPR-Cas9 screen in
HEK-293-E cells with an anti-CD59 antibody. A. CD59 was highly expressed on
the surface of HEK-293-E cells as indicated by the clear separation of cells stained
with antibody compared to the secondary only stained sample. B. Gating strategy
used in a genome-scale screen carried out using an anti-CD59 mAb. Approximately
100 million cells were sampled and 350,000 cells were collected during this screen.
The mutant cell library has a clear BFP negative population as the library was made
with only BFP sort and no puromycin was added to remove the contaminating non-
transduced cells. The screen was carried out 15 days post infection with the gRNA
lentiviral library.
The data here demonstrated that sampling enough cells from a high com-
plexity library increases the sensitivity and allows for the identification of
general and protein specific pathways required for transport of receptor to the
surface in addition to the receptor itself. Increasing the sorting threshold did
not influence the confidence with which the target receptor was identified as
CD59 was the still the most enriched gene in the sorted population.
1CD59 has two N-linked glycosylation sites and it mainly consists of a family of biantennary
complex-type structures with and without lactosamine extensions and outer arm fucose
residues. It has been shown that CD59 transport to the surface of the cells does not rely
on this glycan being present on the protein [214]. Consistent with this, no genes in the later
processing steps, which make these complex type structures were identified in the screen.
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Fig. 3.10 An Improved CRISPR-mediated forward genetic screen identifies the
genes required for the trafficking of the receptor in addition to the gene encod-
ing the antibody epitope. A. Comparison of gRNAs abundance in sorted samples
versus the control samples. Multiple gRNAs targeting the GPI-anchor pathway and
CD59 were clearly enriched in the sorted population. B. The enrichment of gRNAs
targeting each gene (ordered alphabetically) is quantified as the RRA-score. Each
circle represents a specific gene and the size corresponds to the FDR (large circle:
FDR<1%, small circle: 1% < FDR < 5%). Only genes with FDR < 5% are labelled
and the colors represent genes related by function. For better clarity, enlarged version
of B. is also depicted in Appendix section figure A.1. C. Schematics of cellular GPI-
anchor biosynthesis pathway (adapted from [216]). The genes that were significantly
enriched are highlighted in red. Key enzymes along the pathway are labelled. PMM2
catalyses the isomerisation of mannose 6-phosphate to mannose 1-phosphate, which
is a precursor to GDP-mannose necessary for the synthesis of dolichol-P-mannose
by the members of dolichol-phosphate mannose (DPM) synthase complex (DPM1,
DPM2 and DPM3). MPDU1 is required for the utilisation of the mannose donor
dolichol-P-mannose by mannosyltransferase PIGM. Figure modified from [216].
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Fig. 3.11 Several genes involved in the early stages of N-glycan biosynthesis
pathway were identified in the screen using an anti-CD59 mAb. Pathway de-
picting the core glycosylation that occurs in the ER to generate a 14-sugar-glycan
precursor (dolichol-P-P-GlcNAc2Man9Glc3), which is transferred ‘en-bloc’ to the N-
glycosylation consensus sequence (Asn-X-Ser/Thr) by the oligosaccharyltransferase
(OST). The first committed step of the core glycan assembly is catalysed by a well-
conserved essential gene DPAGT1 (or ALG7) [217]. The enzymes that catalyze
each step in the biosynthesis have been identified mainly from studies carried out in
mutants of the yeast Saccharomyces cerevisiae. The gene affected by each yeast
mutation is known as an ALG gene (for altered in glycosylation). NUS1 together
with DHDDS, forms the dehydrodolichyl diphosphate synthase (DDS) complex, an
essential component of the dolichol monophosphate (Dol-P) biosynthetic machinery.
Inhibition of protein N-glycosylation has been shown to cause cellular stresses that
disrupt the ER leading to the induction of an unfolded protein response (UPR) and
ER-assisted degradation (ERAD) [218]. Figure modified from [216]
Application of the screening method on a panel of antibodies reveals
cellular factors required for receptor expression.
To determine whether the high sensitivity of the genome-scale method could
be exploited to understand the other components of receptor biology, I next
selected six mAbs targeting structurally diverse cell surface proteins expressed
on either HEK-293-E or HEL cells and applied the method (summarised in
table 3.1). All screens were carried out with libraries created from independent
lentiviral transductions and for all screens, approximately 0.8-1% cells (250,000-
400,000 cells) that had lost the ability to bind to the mAbs were collected.
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Enrichment analysis using MAGeCK was carried out by comparing the gRNAs
in the sorted population and the control population.
Table 3.1 Summary of mAbs used for genome-scale loss-of-function screening.
Cell line/Screen day Antibody Target receptor Receptor feature
HEK-293-E cells (9 days p.i)
BRIC125 CD47
5-TM membrane proteinBRIC126 CD47
B6H12 CD47
BRIC5 CD58 Single-Pass type I
HEK-293-E cells (10 days p.i) P16 GP1a/IIa (αIIβ1) Integrin heterodimer
HEL- (14 days p.i) BRIC216 GYPA O-glycosylated protein
Genome-scale screens carried out using mAbs identify SRP dependent
ER translocation pathway. Three screens, using independently created
knockout libraries, were performed with three different monoclonal antibodies
targeting CD47 (BRIC125, BRIC126 and B6H12) on day nine post mutant
library generation using lentiviral transduction. These screens were designed
to (i) gain insights into the repeatability and robustness to biological variation
in using the KO screening approach, and (ii) to assess the effect of screen day
on genes that are identified in a genome-scale screen.
Enrichment analysis of the sorted population in all three screens revealed
CD47 among the most significantly enriched genes (FDR <0.01 in all cases),
(figure 3.12A, B and C), demonstrating the robustness of the genetic screening
method using the CRISPR-Cas9 system in identifying the gene encoding the
direct receptor. In all three cases, multiple members of the general protein
export pathway were also identified within FDR <0.05 (summarised in table
3.2). Excluding CD47, 16 genes were identified in at least two of three screens
and nine of these common genes encoded the proteins involved in the general
protein export pathway, specifically the components of the ER translocon
protein complex (SEC61A1, SEC61G), the signal recognition particle (SRP)
proteins (SRP19, SRP14, SRP54, SRP68, SRPR), and the members of the
signal peptidase complex (SPCS2 and SPCS3) (figure 3.12 D).
The general protein export pathway is the cellular machinery by which the
majority of newly synthesised membrane and secreted proteins are folded and
transported, thus in this context, their identification is to be expected. That
said, it was interesting that these genes were mainly identified repeatedly in
this set of screens, and not in the one with anti-CD59 antibody (where only
SLC61A1 was identified). A likely explanation for this is the day the screens
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were carried out— day 9 here, versus day 15 post transduction in case of
anti-CD59 mAb screen. Many identified genes along the general protein export
pathway, including the ones identified here, such as SLC61A1, SRPR, SPCS3,
SRP54, have been described as ‘core fitness genes’ that are essential for
cellular proliferation in every cell [175]. Thus, the gRNAs targeting these genes
are very likely to ‘drop-out’ as the cells are continually grown. Hence, the
chance of identifying them could be time-dependent, as the longer the mutant
library is kept, the higher the chance that the cells with mutations in essential
genes will be non-viable and drop-out of the mutant pool, causing the signal to
dilute.
Table 3.2 Genes involved in protein export (KEGG annotation) identified in screens
carried out using anti-CD47 mAb on day nine post mutant library generation
Description Protein Number of genes(s) identified using mAb
Translocation channel constituents
SEC61A1 BRIC125, BRIC126, B6H12
SEC61G BRIC125, BRIC126
Components of SRP
SRP14 BRIC125, BRIC126, B6H12
SRP19 BRIC125, BRIC126, B6H12
SRP54 BRIC125, BRIC126, B6H12
SRP68 BRIC125, BRIC126
SRP72 B6H12
SRP-ribosome complex receptor
SRPR BRIC126, B6H12
SRPRB BRIC126
Signal peptidase complex
SPCS2 BRIC125, BRIC126
SPCS3 BRIC125, BRIC126
The other gene that was identified in all three screens was ASCC3, which
has been recently identified to regulate gene expression after UV-induced
DNA damage [219]. The role of ASCC3 in relation to CD47 expression on the
cell surface is not known, but this gene has also been identified in CRISPR
mediated KO screen carried out for host factors required by DENV virus [220],
so it is possible that it plays a regulatory role for general protein expression
rather than a CD47-specific role. Further studies would have to be done to
confirm this.
The data presented here demonstrate that this method is reproducible and
can tolerate biological variation especially for the identification of the direct
target of the mAb. In addition, it can also repeatedly reveal both essential and
non-essential cellular factors that contribute to the expression of the target
receptor on the surface of the cell.
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Fig. 3.12 Genome-scale CRISPR-Cas9 screen using anti-CD47 mAbs targeting
cell surface protein reveal members of SRP dependent ER protein translocation
pathway. Gene-level RRA-score calculated using MAGeCK in a genome-scale KO
screens using anti-CD47 mAbs: B6H12 mAb (A), BRIC 125 (B) and BRIC126 (C).
Each circle represents a specific gene and the size corresponds to the FDR (large
circle: FDR<1%, small circle: 1% < FDR < 5%). Only genes with FDR < 5% are
labeled and the colors represent genes related by function. In all cases, CD47 was
identified amongst the most enriched genes, as expected; however, in the case of
mAb clone BRIC125, an additional gene encoding for a different cell surface protein,
EPHB3, was also identified with same the FDR as CD47. EPHB3 was not enriched
for two other anti-CD47 mAbs, suggesting the BRIC125 epitope was present on both
CD47 and EPHB3. D. Venn-diagram representing the genes identified with FDR < 5
% in the three screens. Six genes were common to all screens. These included genes
of the SRP-dependent protein export pathway, CD47 and ASCC3. All three screens
were performed nine days post infection with the gRNA lentiviral library. For better
clarity, an enlarged version of this figure is also depicted in Appendix section figure
A.2.
Genome-scale screen using an anti-GYPA mAb reveals post-translational
modifications present on GYPA required for the mAb epitope. Genome-
scale screening methods provide a unique potential to study the enzymes
required for cell surface post-translational modifications such as glycans. With
the method described here, it should, in principle, be possible to identify ge-
netic pathways leading to the biosynthesis and the subsequent positioning of
the receptor glycans on proteins or lipids, thereby facilitating their identification.
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The human erythrocyte protein, GYPA, serves as a good model to study post
translational glycan modifications as it is one of the most heavily glycosylated
proteins with 15 O-linked glycans, which consists predominantly of disiaylote-
trasaccharide linked to a serine or threonine residue and one N-linked glycan
[221]. To investigate this further, an anti-GYPA antibody (BRIC256), which
recognises the extracellular epitope amino acids 41-58 on GYPA where three
O-linked glycans are present (position 44, 47 and 50) [222] was used as a
probe to carry out a genetic screen. The expression of GYPA is restricted to
the cells of erythroid lineage, thus in this case, the screen could not be carried
out in HEK-293-E cells. For this purpose, I selected the HEL cell line as these
cells resemble erythroblasts (nucleated immature erythrocyte) and are known
to express GYPA [223].
The gene-level enrichment analysis of the gRNAs in the cells that had lost
binding the anti-GYPA antibody revealed GYPA as one of the most-enriched
genes, as expected (figure 3.13A). In addition, genes required for the gen-
eration of the core-O-glycan structure (C1GALT1, C1GALT1C1) and genes
involved in the addition of terminal N-acetyl neuraminic acid (Neu5Ac) modifica-
tions (CMAS, SLC35C1) were also identified. Schematics of the predominant
O-glycan found on GYPA and the roles of the identified enzymes in generating
this structure are depicted in Figure 3.13B. This suggests that the loss of GYPA
itself or the loss of enzymes required for the generation of the disialotetrasac-
caride present on GYPA leads to the loss of the mAb epitope. This could
either happen if GYPA expression on the surface of the cells depended on the
presence of O-linked glycans on the protein or if the O-linked glycans together
with the protein backbone form the antibody binding epitope. As BRIC256
recognises the region of the protein where O-linked glycosylation sites are
present, the latter seems more likely in this case. These results demonstrate
that in situations where the interaction is mediated by glycans, the screen is
able to identify the cellular pathways that are required for the biosynthesis of
the glycan, thereby providing clues to the identify of the glycan.
The screen additionally identified an erythroid-specific transcription factor
GATA1, which is presumably required for GYPA transcription in HEL cells. In
addition, two genes, CDIPT and SACM1L were also identified. Both of these
genes are required for metabolism of phosphatidylinositol (PtdIns). CDIPT
protein is required for biosynthesis of phosphatidylinositol whereas SACM1 is
a phosphoinositide lipid phosphatase. GYPA has been shown to be associated
with PtdIns(4,5)P2 in the cytosol [224], which suggests that the loss of phos-
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phoinositides would adversely affect its membrane positioning. Additionally,
the identification of TNNT3, a gene that encodes for the tropomyosin-binding
subunit of troponin, was intriguing as tropomyosin has been previously shown
to associate with the major proteins of the erythrocyte membrane skeleton
(spectrin, actin, and 4.1R (human erythrocyte protein 4.1)) to form a mem-
brane complex that includes glycophorins [225]. Further studies will have to
be carried out to verify the role of TNNT3 in regulating GYPA expression.
Fig. 3.13 Genome-scale KO screen using an anti-GYPA antibody reveals mAb
epitope and factors required for the cell surface GYPA display. A. Enrichment
analysis using MAGeCK revealed nine genes that were enriched in the sorted popula-
tion compared to the control population (FDR< 5%). The number of cells sampled in
this screen was lower compared to the previous screens carried out with HEK-293-E
cells (50 million vs 100 million). The screen was performed on day 14 post infection
with the gRNA lentiviral library. Genes relating to the post-translational modification
present on GYPA and the gene encoding for erythroid specific transcription GATA1
are labelled in red. B. GYPA on the cell surface exits in either the M or N form with
the M phenotype characterised by Ser-1, Gly-5 and the N-phenotype by Leu-1 and
Gly-5. Schematics of the N-type GYPA is depicted in the left panel and the detailed
structure of the predominant O-linked tetrasaccaride present in the protein is depicted
in the upper right panel. The function of the GYPA specific genes identified in (A) are
detailed in the lower right panel.
A Genome-scale screen using an anti α2β1 mAb identifies the subunit
encoding the antibody epitope and the critical requirement of actin reg-
ulation. A genome-scale screen was carried out in HEK-293-E cells using a
monoclonal antibody (P16) targeting integrin α2β1 (ITGA2/ITGB1) ten days
post mutant library generation. Enrichment analysis revealed the gene en-
coding only the β1 chain (ITGB1) of the integrin heterodimer in the sorted
population demonstrating the epitope of this mAb is located within the β1
and not α2 chain. In addition, genes of the general secretory pathway (SEC
translocon complex and SRP components) were also significantly enriched in
the sorted population and similar to the screen with anti-CD59 mAb, genes
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required for early steps of N-linked glycosylation in the ER were also identified
(figure 3.14A).
Fig. 3.14 Genome-scale loss-of-function screen using an anti-integrin αIIβ1
mAb identifies the subunit encoding the antibody epitope and components of
the cytoplasmic Arp2/3 complex. A. Gene-level enrichment analysis on a screen
carried out using an anti-αIIβ1 antibody. Only the β1-subunit encoding gene, ITGB1,
was identified to be significantly enriched in the sorted population (FDR= 0.024).
B. Schematics depicting the ARP2/3 complex, which consists of seven members,
three of which were identified in the screen to be statistically significant (FDR <0.05)
(highlighted in red, figure adapted from [226]). Depending on the combinations of
α and β subunits, the extracellular domains of integrin heterodimer interact with the
components of the extracellular matrix (ECM). This link between the intracellular
cytoskeleton to the ECM via integrins has been shown to be important in cell motility,
cell polarity, cell growth and survival (figure adapted from [227]). The screen was
performed ten days post infection with the gRNA lentiviral library. For better clarity, an
enlarged version of A. is also depicted in Appendix section figure A.3.
An interesting observation in this screen was also the identification of three
genes relating to the members of Arp2/3 complex (ARPC4, ACTR2, APRC3).
Arp2/3 protein complex consists of seven members and it is essential in the
nucleation and assembly of branched actin filaments (figure3.14B) [226]. The
cytoplasmic tails of β-subunits have been shown to be necessary and sufficient
to link integrins to the actin cytoskeleton [228]. Actin binding proteins such
as α-actinin, filamin and talin bind to actin filaments and mediate their link
with cell surface integrin heterodimers (schematic depicted in figure 3.14C).
Such interactions at the cytoplasmic domains of integrins have been shown
to induce conformational changes in integrin extracellular domains (from a
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‘bent’ (inactive) to ‘extended’ (active) conformation) that result in increased
affinity for ligand in a process described as ‘inside-out signalling’ [229]. The
screen here demonstrated that the components of the Arp2/3 complex were
important for the recognition of ITGB1 at the cell surface by the mAb. This
finding can be interpreted in two ways: (i) the expression of ITGB1 on the
surface of cells depends on its interaction with the members of the Arp2/3
complex or (ii) the interaction with Arp2/3 complex with the cytoplasmic domain
of ITGB1 changes the integrin subunit conformation that is required for the
mAb epitope binding. The latter scenario is consistent with the presence of
other mAbs for integrins that have been previously described to specifically
recognise epitopes that are only present in the active conformation [230]. It is
therefore likely that P16 falls into this class of integrin mAbs.
Summary of the genetic screens
All enrichment analysis here was done using MAGeCK software, which can
use a single dataset to estimate a read count variance to determine the
significantly enriched genes. I used a FDR of less than 0.05 as the cut-off point
and estimated the biologically relevant genes that could be identified within
that threshold. In all the screens that were carried out, the target receptor was
identified with a very low FDR and well within the threshold (summarised in
table 3.3).
Table 3.3 FDR of identification of the genes encoding direct receptor in a genome-
scale screening approach using monoclonal antibodies targeting cell surface recep-
tors.
Antibody Day of screen Target receptor Target FDR Genes (FDR<5%)
MEM6/6 Day 16 BSG 0.0012 4
BRIC222 Day 15 CD59 0.0002 58
BRIC125 Day 9 CD47 0.001 15
B6H12 Day 9 CD47 0.001 27
BRIC126 Day 9 CD47 0.004 35
P16 Day 10 ITGB1 0.024 52
BRIC256 Day 14 GYPA 0.001 9
BRIC5 Day 9 CD58∗ 0.001 14
∗Full screen result for this screen is available in appendix section figure A.4
The number of significantly enriched genes identified in each screen de-
pended on the quality of the screen performed in terms of the library size
and the representation of the gRNA in the sorted cells. In the example of an
72
CRISPR-Cas9 knockout screens for cellular recognition
anti-BSG antibody where a stringent sorting threshold was used, very few
genes were identified. This was improved when the number of sorted cells
was increased in the subsequent screens.
Apart from the identification of the direct target receptor, specific cellular
pathways required for the ligand recognition such as the GPI-anchor pathway
(in anti-CD59 screen) and the O-glycosylation pathway (in anti-GYPA screen)
were also identified. In addition, a pathway analysis of all enriched genes that
were shared between antibody selections encoded proteins required for protein
secretion and glycosylation, as expected, but also identified housekeeping
pathways such as ribosome biosynthesis and RNA metabolism; genes iden-
tified in these pathways were grouped and labelled as ‘other factors’ (figure
3.15, also refer to table A.5 in the appendix section for specific ‘other factors’
that were enriched in at least two out the seven screens with FDR<0.05). I
observed that the representation of these general pathways was often reduced
when selections were performed several days later (day 15-16 rather than day
9), suggesting these genes are required for long-term cell viability in culture,
and that antibody staining was reduced on moribund cells.
Fig. 3.15 Genes required for protein export, N-glycan biosynthesis and general
housekeeping functions were enriched in, and shared between, cells selected
for the loss of cell surface mAb staining. Pathway analysis on genes enriched in
cells selected with the indicated mAbs identified some pathways shared between more
than one antibody including protein export, N-glycan biosynthesis as well as more
general housekeeping functions. No significantly enriched pathway was identified in
the anti-BSG screen.
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3.3 Discussion
In this chapter, I have demonstrated the use of a cell-based genome-scale
CRISPR screening approach to identify genes encoding proteins required for
extracellular recognition. I first generated high efficiency Cas9 cell lines by iso-
lating stable clones grown from single cells within a polyclonal Cas9-expressing
population. This approach allowed for the removal of cells which contained
Cas9 with decreased efficiency resulting presumably from the acquisition of
mutations that led to the inactivation of Cas9. I utilised two different methods
to measure the Cas9 efficiency: (i) an endogenous gene KO method in which
endogenous BSG was targeted, and (ii) a rapid exogenous method in which
GFP, together with gRNA targeting GFP, was introduced to the cells and the
efficiency of GFP targeting was measured. The exogenous approach provided
a rapid means of determining the presence of functional Cas9 in the cells and
was particularly useful during the single cell cloning steps, during which many
clones had to be tested. However, targeting the single integrated GFP can
be considerably more efficient than targeting both alleles of an endogenous
gene (as exemplified by the lower efficiency observed for the same clonal line
for BSG KO compared to GFP KO), so this approach usually represents the
best-case-scenario for targeted gene KO. Additionally, endogenous targeting
also depends on other factors, such as the protein-turnover time, the copy
number of the target gene in a cell, and the targeting efficiency of the gRNA.
To account for these factors, I opted to estimate the ‘realistic’ Cas9 efficiency
based on the decrease in cell surface expression of BSG upon transduction
with gRNA targeting BSG, rather than the GFP targeting approach.
In this work, I utilised the Yusa library to conduct genetic screens. There are
several genome-wide libraries that have been described to date, which can be
used to perform genome-wide KO screens [175, 176, 177, 205, 231, 232, 233].
Of these, four libraries are considered to be second generation libraries as they
feature improved gRNA efficacy [234]. These are the ‘Human V1 library’ or the
‘Yusa library’ [176], the ‘Whitehead library’ [177], the ‘Brunello library’ [205] and
the ‘Toronto knockout libray version 3.0 (TKO3.0) library’ [233]. The Whitehead
library is the largest consisting of 10 gRNA/gene (182,134 gRNAs) compared
to the 5 gRNAs/gene of the Yusa library (90,709 gRNAs) and 4 gRNAs/gene
of the Brunello library (77,441 gRNAs) and the TKO3.0 library (71,090 gRNAs).
The Yusa library differs from the other libraries as it uses the improved gRNA
scaffold to avoid the T stretches as discussed in section 3.1.4. The design
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of the gRNAs in the Yusa library, unlike those in the other three libraries, is
not based on an on-target prediction for gRNA selection. However, this does
not seem to affect the screening results as a recent comparison between the
performance of these libraries in negative selection screens has shown that
that these libraries identify genes with similar false discovery rates (between
14 % and 23 %) [234]. The same study has also suggested that while the
higher number of gRNAs per gene, for example that of the Whitehead library,
allows for better statistical confidence, this can also cause over-sensitivity
of the analysis programs such as MAGeCK to call genes that have lower
fold change values as statistical hits. In addition, as the number of gRNAs
increases, the complexity of the library also increases, maintainance of which
over an extended period of time can be practically challenging. This could
instead lead to poor screen outcome. For second generation libraries it has
been suggested that libraries with 6 gRNAs per gene are likely to be optimal
for genome-wide CRISPR-KO screens [234]. While I only used the Yusa library
in the study here, given the similarity of performance with the other libraries, it
is unlikely that the other libraries would yield vastly differing results.
The genetic approach described in this chapter provides a valuable alter-
native to existing biochemical methods which must account for the largely
insoluble nature of membrane-embedded receptors. An advantage of this
method over existing methods is its ability to reveal the receptor protein at the
cell surface which directly interacts with a presented ligand, but also identify
other gene products that are required for the cell biology of the receptor. The
screens carried out with the panel of mAbs demonstrated the ways in which
the method can be used to identify the protein/glycan receptors and cellular
factors such as chaperones, transcription factors, and cytoskeletal elements
that are involved in the expression or correct positioning of the receptors on
the surface of the cells.
The application of a genome-scale screening approach in the identifica-
tion of monoclonal antibody targets can be a valuable tool for monoclonal
antibody characterisation. A similar approach for this purpose has been de-
scribed recently by others [235], where the cells refractory to antibody binding
were enriched using two rounds of sorting and few gRNAs present in this
enriched population were analysed using Sanger sequencing to identify the
target receptor. Here I have extended the use of the genome-scale screening
approach by using a single sorting approach that can not only capture gRNAs
targeting genes encoding the antibody epitope, but also the gRNA targeting
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genes contributing to the cell biology of the antibody epitope. In the example
of an anti-integrin mAb, this included identifying the specific subunit of the
heterodimer encoding the antibody epitope and components of the cytoplas-
mic Arp2/3 complex and for an anti-Glycophorin A mAb, a required role for
enzymes involved in O-linked glycosylation in antibody binding.
In the genetic screens carried out here, I often identified genes that are
required for the ‘house-keeping’ of receptors, including those involved in the
secretory and glycosylation pathways. However, this did not greatly influence
the confidence with which the receptor was identified. The target receptor
was revealed in every case attempted within the FDR threshold of 0.05, with
seven out of eight screens identifying the receptor with a very low FDR of
under 0.005. The highest FDR of 0.024 was observed in the screen with the
anti-ITGA2/B1 integrin antibody where admittedly, genes of the secretory and
glycosylation pathway were enriched more than the target receptor. But even
in such a scenario, assuming that the target of this antibody was unknown, the
observation that (i) ITGB1 was the only cell surface receptor encoding gene
identified in the screen within the given threshold of 0.05; (ii) components of
the Arp2/3 complex that fit with the integrin biology were identified among the
most enriched genes and; (iii) the fact that genes that contribute to general
receptor house-keeping can be ruled out as specific factors, suggest that it
would have been possible to identity ITGB1 as the target receptor.
One of the challenges of loss-of-function screen studies is the investigation
of the effect of the genes, which are essential for cell growth and viability, on
the phenotype being tested. Comprehensive studies carried out out using
CRISPR–Cas screens on multiple cell lines have identified approximately 2000
‘core-genes’ that are designated to be ‘essential’ for optimal growth of the cells
[175, 176, 177, 205]. Identifying the role of cell-essential genes on cellular
recognition can be challenging as cells that contain mutations in essential
genes become non-viable and are no longer represented in the mutant library.
However, it has been suggested that the number of genes thought to be
‘core-essential’ could be overestimated as this includes genes that not only
affect viability of the cells but also moderately affect cell growth [236, p. 357].
CRISPR-Cas9 KO screens carried out recently in the context of virus-host
interactions have shown that it is possible to identify the effect of genes that
have been categorised as core-essential genes in genome-scale KO screens
(for example, the role of oligosaccharyl transferase complex (OST) in dengue
virus infection [220]). The data here demonstrated that such screens can
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indeed identify the core-essential genes involved in general protein export
and glycosylation pathways, but unlike the direct receptors, genes in these
categories were not identified in every case (e.g., not identified in anti-BSG
and anti-GYPA screens). The timing (early time points rather than later) and
the quality of the screen parameters in terms of the day post transduction
the screening was carried out, the number of cells in the sorting population
and the sorting stringency seemed to influence the successful identification of
essential genes in such screens.
In summary, I have developed and applied a cell-based genetic method
based on CRISPR-KO technology using mAbs to identify genes that mediate
high affinity interactions at the cell surface. The method is able to identify the
direct receptors at the cell surface robustly with high confidence and often also
identifies cellular components that are related to the biology of the receptor.
77

CHAPTER 4
APPLICATION OF THE GENETIC SCREENING APPROACH
TO IDENTIFY INTERACTIONS MEDIATED BY RECOMBI-
NANT PROTEINS
4.1 Introduction
This chapter describes the application of the genome-scale KO screening
approach that was developed in Chapter 3 to identify interactions between
soluble recombinant proteins and the receptors on the surface of human cell
lines.
While high affinity monoclonal antibodies are useful research tools and
important therapeutic reagents, I sought next to determine whether this ap-
proach could be used to identify receptors for recombinant proteins. The use of
recombinant proteins in the genetic screening approach designed here would
open up the possibility to identify directly interacting receptors in wide range of
biological contexts. In addition, a genome-scale approach could also reveal
cellular factors required for the receptor to be correctly presented on the cell
surface allowing novel insights into the biology of the receptor.
The interactions mediated by recombinant proteins, unlike mAbs, are usu-
ally of low-affinity. Therefore, to detect the interactions mediated by recombi-
nant proteins with the cell surfaces, it is important to use oligomeric proteins
that have increased avidity compared to their monomeric forms. In this work,
I utilised two approaches for oligomerisation of the recombinant probes: (i)
proteins were produced in monomeric biotinylated forms and conjugated to
streptavidin-PE to generate fluorescent tetrameric avid probes; (ii) proteins
were produced as pentamers using the COMP tag. The pentameric proteins
also carried a FLAG-tag, which could be detected using an anti-FLAG-PE
antibody.
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To adapt the screening system to use recombinant proteins as screening
probes, I utilised the protein resources that were already available in our
laboratory. Below I will highlight the two main classes of protein libraries from
which I selected primary candidates for the screening approach.
4.1.1 P. falciparum ‘merozoite’ protein library
P. falciparum is an obligate intracellular parasite that causes malaria in humans.
The parasite has a complex life cycle that involves two organisms (humans as
‘hosts’ and mosquitoes as ‘vectors’) and three life-cycle stages (‘sporozoites’,
‘merozoites’ and ‘gametocytes’). The blood stage of the infection, during which
the merozoite invades erythrocytes, accounts for the majority of the symptoms
and pathology of malaria. As the merozoites are briefly exposed to the host
immune system between invasion cycles, merozoite ligands responsible for
invasion are considered an attractive target for a vaccine intervention. The
merozoite contains more than 100 proteins on its surface and intracellular
vesicular organelles, most of which have been suggested to be involved in
binding to the erythrocyte surface for mediating invasion [237]. Despite signifi-
cant research efforts, less than ten of these interactions between merozoite
protein ligands and human erythrocyte receptors have been described to date
(figure 4.1).
Our laboratory has compiled a list of more than 60 proteins representing
the ectodomains of abundant cell surface and secreted merozoite proteins
of the 3D7 strain of P. falciparum [238, 239]. This protein library has already
been used to identify some of the host-pathogen interactions such BSG-RH5,
Semaphorin 7A- MTRAP, and P-selectin- MSP-7 [88, 128, 240]. Here, I mainly
focused on 11 merozoite proteins from this library (highlighted in figure 4.1A).
The proteins were selected on the basis of (a) known biology (i.e. previous
reports indicating that they could be involved in host-parasite interactions;
this includes proteins mainly located in the micronemes and rhoptries [241]);
(b) proteins that interact with the invasion-related proteins (CyRPA, which is
known to interact with RH5 to form an invasion complex [90, 242]); (c) proteins
encoded by blood-stage essential genes (e.g. MSP1, which is also the most
abundant protein on the surface of the parasite, [237]); and (d) parasite proteins
against which in-vitro invasion blocking antibodies have been raised: MSRP5,
SERA9 [243].
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Fig. 4.1 Cellular organization and invasion process of P. falciparum merozoite. A. Schematics of cellular organisation of the merozoite.
The merozoite is eukaryotic Apicomplexan parasite consisting of eukaryotic organelles such as a nucleus, a single mitochondrion, and an
apicoplast together with specialised apicomplexan secretory organelles such as rhoptries, micronemes and dense granules. The secretory
organelles contain distinct sets of proteins as labelled. The surface of the merozoite consists of a large number of invasion-related proteins
making up the ‘fuzzy surface coat’. The proteins labelled in red were investigated in this study, whereas the proteins labelled in green have
been studied in the past and their host receptors already identified. B. Schematics of the process through which the merozoite enters a
red blood cell (RBC). At the start of invasion, the merozoite interacts with the RBC in a reversible process called ‘primary attachment’,
during which the surface proteins from any surface of the merozoite mediate low affinity interactions with the surface of RBC. The process
is followed by ‘re-orientation’, during which the parasite juxtaposes the apical surface towards the erythrocyte surface and releases the
contents of its micronemes and rhoptries to mediate host cell surface interactions. Many proteins from these internal secretory organelles
have been shown to be important for the host-pathogen interactions (some of the known interaction partners and proteins that are believed
to have a host receptor are listed). This strong attachment leads to a non-reversible commitment towards invasion and formation of a ‘tight
junction’. As the parasite utilises the actin/myosin motor to force its way into the RBC, the tight junction moves along the length of the
parasite. The surface proteins of the parasite are also cleaved by parasite proteases and shed off during the process. Eventually, the
merozoite is engulfed by the erythrocyte and the parasite resides within the parasitophorous vacuoles [241]. Figure A is adapted from [244].
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4.1.2 The platelet receptor library
Platelets are small anucleated cells in blood that play an important role in
regulating hemostasis and thrombosis. Platelet-mediated thrombosis requires
a large number of proteins present both on the platelet plasma membrane
and within the secretory vesicles (also known as ‘platelet granules’). Platelet
functions are mediated by the important cell-cell and cell-subendothelial matrix
interactions carried out by these receptors [245]. A protein library representing
the cell surface receptor and secretome of the human platelet has also been
compiled in our laboratory. This library includes roughly 200 proteins, which
includes a diverse set of receptors such as integrins, leucine-rich repeats
receptors, selectins, and immunoglobulin superfamily receptors. Many proteins
in this library are not restricted only to platelets but are also found on many
different cell types such as erythrocytes, leukocytes, and endothelial cells [96].
This library will be referred to as the ‘human protein library’.
4.1.3 Scope of this chapter
In this chapter, I will first describe a successful proof-of-principle demonstration
for the use of recombinant proteins as screening probes for the CRISPR-Cas9-
based KO screening system. This demonstration uses the known interaction
between RH5 and BSG. I will then describe the attempts made for the identifi-
cation of host receptors for other merozoite proteins and optimisation steps
made in the method to address some of the generic binding behaviour ex-
hibited by recombinant proteins. Finally, I will use the human protein library
to demonstrate how this method can be applied to robustly identify specific
receptors and non-receptor cellular factors contributing to cellular recognition.
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4.2 Results
4.2.1 Proof-of-concept study: BSG and RH5 interaction
Recombinant RH5 binds to BSG and an unknown factor on the cell sur-
face of HEK-293-E cells
To assess whether recombinant proteins could be used as screening probes
in this system, I initially selected the interaction between RH5 and its host
receptor BSG. This served as a good model system because it is a low affinity
interaction (KD ∼1µM); is biochemically and structurally well characterised;
and BSG is highly expressed on the Cas9-expressing HEK-293-E cell line
[88, 246]. In a flow-cytometry based binding assay, I observed direct binding
of the avid RH5 reagent (streptavidin-PE conjugated biotinylated RH5) to the
surface of HEK-293-E cells, as expected (figure 4.2A). To test whether this
binding was specific to BSG on the cell surface, I pre-incubated the cells
with an anti-BSG antibody; however, the antibody, which has previously been
shown to completely block this interaction in an in-vitro ELISA-based assay,
did not prevent all RH5 binding on the cell surface even at 15 µg/mL final
concentration. This additional binding was not due to a subfraction of inactive
protein in the RH5 preparation since all binding could be prevented by heat
treatment of the recombinant protein (figure 4.2B, figure 4.2C depicts the RH5
preparation that was used in the experiment). This observation suggested that
there was an additional receptor/s for RH5 on HEK-293-E cells.
Genome-wide screens reveals BSG and heparan sulphate as indepen-
dent receptors of RH5 on the cell surface.
To identify the receptor/s for RH5 other than BSG in the HEK-293-E cell context,
I carried out a genetic screen with the avid-RH5 probe and compared the genes
required for RH5 binding with those necessary for surface expression of BSG
(data from the anti-BSG antibody screen that was carried out earlier- figure
4.3A). The enriched gRNAs common to both selections beyond those targeting
general secretory pathway genes, corresponded to BSG, and the chaperone
SLC16A1, as expected. In the case of RH5, the most highly enriched gene
in the cells sorted using RH5 compared to anti-BSG mAb was SLC35B2
(solute carrier family 35 member B2), which encodes a protein that transports
3’-phosphoadenosine-5’-phosphosulfate (PAPS), from the cytosol into the
lumen of the Golgi apparatus where sulfotransferases use it as a universal
83
Chapter4
Fig. 4.2 RH5 binding to HEK293 was not completely dependent on BSG but was
heat labile. Biotinylated RH5 was clustered around a streptavidin-PE conjugate and
binding to HEK293 cells analysed by flow cytometry. A. RH5 binding was only partially
blocked by an anti-BSG mAb relative to controls. B. Heat treatment (80◦C for 10
minutes) of biotinylated RH5 abrogated all binding back to a negative control. In both
cases a representative of three independent experiments is shown. Control represents
binding of biotinylated protein tags (Cd4 alone) clustered around streptavidin-PE
(henceforth referred to as Cd4-Strep-PE) to the HEK-293-E cell line. C. A coomassie
stained (under reducing conditions) gel depicting the RH5 and the Cd4 used in A and
B. Both bands are observed at the expected sizes (RH5- 88 kDa and Cd4- 28 kDa).
sulfuryl donor for the sulfation of major constituents of the glycocalyx including
glycoproteins, glycolipids and glycosaminoglycans (GAGs) [247]. A broader
pathway analysis using KEGG-annotated pathways identified the heparan
sulphate (HS) but not chondroitin sulphate (CS)1 biosynthesis pathway as
significantly enriched (FDR < 0.05). Consistent with this, when I increased the
FDR threshold to 0.25, I could identify two more genes (NDST1 and EXTL3)
encoding for enzymes that are critical for HS biosynthesis but not the genes
critical for CS biosynthesis (CSGALNACT1 and CSGALNACT2) (schematics
depicted in figure 4.3B). Furthermore, RH5 binding to HEK-293-E cells could
be inhibited to a threshold value by heparin2, but not by CS (figure 4.3C). This
is in agreement with the reported presence of heparin binding motifs in RH5
and its ability to bind heparin-coated agarose [248]. The role of SLC35B2 and
HS in RH5 binding was independent of BSG as the surface expression of BSG
was not affected in cells in which genes required for GAG biosynthesis were
targeted (figure 4.3C).
1HS and CS are types of GAGs. The HS biosynthesis pathway will be discussed in detail
in figure 4.3B and again in section 4.2.2
2Heparin is commonly used as a model compound for the sulfated, protein-binding regions
of HS. It is generally easier to obtain in higher quantities than HS.
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Fig. 4.3 Cell-based genetic screens identified BSG and heparan sulfate as in-
dependent receptors for P. falciparum RH5 on HEK293 cells. A. Rank-ordered
genes identified from gRNA enrichment analysis required for cell surface display of
an anti-BSG mAb (left panel) and RH5 binding (right panel). Significantly enriched
genes with a FDR<0.05 and FDR<0.25 are marked separately (note that there were
no additional genes identified in the anti-BSG screen with the increased threshold so
the higher threshold value is not marked). Genes contributing to the HS-biosynthesis
pathway were identified only in the RH5 screen. The full list of enriched genes for the
RH5 screen is available in the appendix section table A.6. B. Schematic depicting
the general GAG biosynthesis pathway with the relevant genes mapped to the corre-
sponding steps. The general GAG biosynthesis pathway bifurcates into HS and CS
biosynthesis pathway after the formation of a linkage tetrasaccharide structure [249]
C. Clustered RH5 binding probe was pre-incubated with the indicated concentrations
of either heparin or chondroitin sulfate (CS) prior to presentation to HEK-293-E cells
and binding quantified by flow cytometry. Preincubation of RH5 with heparin showed a
dose-dependent inhibition of binding up to a threshold; preincubation with CS showed
no inhibition of RH5 binding, even at the maximum concentration of 2.5 mg/mL. The
control represents binding of Cd4-Strep-PE to the cell line. A representative of three
independent experiments is shown. D. Cells transduced with lentivirus-encoding
gRNAs targeting enzymes in the heparan sulphate biosynthesis pathway show no al-
teration in surface BSG expression. Cell surface levels of BSG were quantified by flow
cytometry on parental HEK-293-E cells or those transduced with lentivirus encoding
single gRNAs targeting SLC35B2 or EXTL3 (genes required for HS biosynthesis), or
BSG, as a control. Cells were stained with an anti-BSG mAb; control cells are stained
with secondary antibody alone. A representative of two independent experiments is
shown.
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RH5 binding to HS was additive rather than co-dependent on BSG
To investigate further the role of SLC35B2 and HS in RH5 binding, I first tested
the binding of an RH5 probe to cells targeted either for genes required for
HS biosynthesis (SLC35B2 and EXTL3), or for the known receptor BSG. In
all three scenarios, I could only observe a partial reduction in RH5 binding
(figure 4.4A). The residual binding in the case of cells lacking SLC35B2 was
specifically due to BSG because it could be completely blocked by the anti-
BSG antibody (figure 4.4B). Whereas, in the case of cells lacking BSG, the
residual binding was specifically due to HS because soluble heparin, but not
soluble CS, could block all RH5 binding (figure 4.4C). This suggested that the
RH5 binding to HS was additive rather than co-dependent on BSG.
Fig. 4.4 The total observed binding of RH5 to HEK-293-E cell surface is the
sum of independent contributions from BSG and HS. A. Binding of RH5 to cells
is partially reduced when transduced with lentiviruses encoding gRNAs targeting
either the receptor (BSG) or enzymes required for HS synthesis (SLC35B2, EXTL3)
relative to controls. Transduced polyclonal lines were used for this experiment. B.
RH5 binding to SLC35B2-targeted HEK-293-E cells could be completely blocked if
preincubated with an anti-BSG mAb but not an isotype-matched control. C. RH5
binding to BSG-targeted HEK-293-E cells could be completely blocked if preincubated
with 200 µg/mL heparin but not 200 µg/mL CS. A representative of three technical
replicate experiments is shown in all three cases.
These experiments revealed a role for HS within the glycocalyx for interac-
tions at the cell surface. Using the genetic approach, I was able to identify both
the direct receptor of low affinity ligands (including the chaperone required
for the receptor) and the contribution from HS in a single experiment. Further
investigation showed that the binding contributions from the independent re-
ceptors could also be separated experimentally. I next proceeded to apply this
approach to a panel of merozoite recombinant proteins with an aim to identify
novel receptors and associated factors contributing to the receptor biology.
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4.2.2 Heparan sulphates serve as common factors for cel-
lular recognition
Initial screen of the protein library to identify candidates for screening
A pre-requisite for the screening approach designed here is the ability of a
soluble probe to bind a cell line. Therefore, to first identify candidate proteins
that bound to cell lines, I first tested the binding of a total of 11 avid monomeric
biotinylated recombinant merozoite proteins clustered around PE (together
with RH5 as a control) to a panel of six cell lines originating from different tissue
sources (see figure A.2 in appendix section). From this initial screening list, I
short-listed three merozoite proteins (SERA9, EBA181 and MSRP5), based
on their bright staining on multiple cell lines tested (HEK-293-E, NCI-SNU-1,
and KBM7).
The binding of multiple merozoite proteins to the cell surface is depen-
dent on the cell surface HS
To identify the cellular factors mediating the binding of the merozoite proteins
to the cell lines, I carried out the cell-based genome-scale KO screens in HEK-
293-E cells using the avid monomeric protein probes. Notably, gRNAs targeting
genes encoding for GAG (specifically HS) biosynthesis enzymes were found
to be highly enriched in all three screens (figure 4.5A-EBA181, 4.5B-SERA9,
4.5C-MSRP5). I next mapped the genes identified in these screens to the HS
biosynthesis pathway, from which I could clearly identify the majority of the
pathway genes to be significantly enriched (figure 4.5D). The biogenesis of
HS begins with the generation of a tetrasaccharide linkage on serine residue
of the protein backbone through the sequential addition of four monosaccha-
ride residues by glycosyltransferase enzymes. Commitment towards the HS
pathway occurs via the EXTL3 enzyme, which adds the N-acetylglucosamine
(GluNAc) residue to the existing polysaccharide chain. Within the Golgi, two
enzymes EXT1 and EXT2 catalyse the initial chain polymerisation, during
which multiple GluNAc and Glucuronic acid (GluUA) residues are added. A se-
ries of modifications to the growing polymer includes epimerization of GluUA to
Iduronic acid (IdoA) by GLCE; N-sulfation by NDST family of sulfotransferases;
and O-sulfation by and 2-O, 3-O and 6-O sulfotransferases [249]. Except for
GLCE, genes encoding for the majority of these steps were identified in every
screen. In all three cases, genes encoding for a candidate cell surface receptor
proteins were not identified even at FDR<0.05.
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Fig. 4.5 All three genome-wide screens using merozoite proteins revealed the role of HS-biosynthesis pathway in mediating cell
surface interactions. Gene level enrichment analysis on sorted mutant cells refractory to binding recombinant proteins- A-EBA181,
B-SERA9 and C-MSRP5. Only genes with FDR<0.05 are labelled and the genes are ordered alphabetically. The highly enriched genes
in all three cases correspond to the genes involved in HS-biosynthesis (labelled in red). This includes genes encoding enzymes directly
catalysing each step of the pathway (pathway schematics with the corresponding enzymes depicted in D with the identified gene products
from the screens highlighted in red); genes encoding enzymes that generate the activated monosaccharide precursors required for the
generation of the initial tetrasaccharide structure, specifically UDP-xylose (UXS1) and UDP-glucuronate (UGDH); and genes encoding for a
kinase that regulates the amount of mature GAG chains in a cell (FAM20B).
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To validate the screen findings, I next investigated the extent to which the
binding of the recombinant proteins depended on the presence of sulfated
glycans on the surface of cells. I tested the binding of the three proteins in cell
lines where SLC35B2 was inactivated as SLC35B2 was amongst the most
enriched genes in all screens (FDR< 0.01). Unlike the case with RH5, in
which SLC35B2 inactivation led to partial loss of binding, in this case, there
was a complete loss of binding of all three tested probes (figure 4.6A). This
seemed to be a recurring theme in the interactions mediated by merozoite
proteins as binding of two more merozoite ectodomains, CyRPA and RAMA, to
HEK-293-E cells could also be completely abrogated by inactivating SLC35B2
(figure 4.6B).
Fig. 4.6 The binding of multiple merozoite proteins to HEK-293-E cell surface
can be completely abrogated by inactivating SLC35B2. Biotinylated ligands
oligomerised around streptavidin-PE were tested for binding to an unmodified parental
cell line (black histograms) or polyclonal SLC35B2-targeted cells (red histograms). A.
All three proteins used for screening showed a complete loss in binding when tested
on SLC35B2-targeted cells. In the case of RH5, a partial loss in binding was observed,
as expected. B. RAMA and CyRPA demonstrated binding to HEK-293-E cells in the
initial cell-binding assay. The binding of these two proteins were also completely
dependent on SLC35B2.
Heparan sulphate proteoglycans are highly negatively charged biopolymers
that have been known to bind to many ligands (e.g., growth factors, extracellular
matrix proteins, chemokines, morphogenes, and cell surface proteins) usually
via the sulfated domains within the HS chains. The interactions are largely
electrostatic, with the brush-like negatively charged surface HS forming salt
bridges with surface-exposed basic residues, and are generally thought to
provide a suitable scaffold to present ligands to receptors in an appropriate
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manner by regulating their orientation, oligomerisation and establishing local
concentration gradients [21]. In the cell binding assay designed here, the
contribution of HS towards binding was identified to be additive rather than
co-dependent on other receptors, which suggested that HS may represent
a factor responsible for cell surface binding for a range of ligands, even in
the absence of another receptor. Given the observation with the merozoite
proteins in which targeting SLC35B2 was sufficient to inhibit all binding to the
cell line, the presence of another receptor for these proteins in this cell line
was unlikely. This posed a challenge in the screening strategy as binding to
the cell line alone could no longer be the only pre-requisite for the screen as
this binding could be due to proteins adsorbing into HS without binding to a
specific receptor.
Development of a pre-screening approach to determine the fractional
contribution of HS towards binding
To discriminate between proteins that only adsorb into HS versus those that
interact with a specific receptor (with or without the contribution from HS), I took
advantage of the SLC35B2-targeted cell line to rapidly determine the fractional
contribution of HS adsorption to cell staining by comparing ligand binding
events between the SLC35B2-targeted and the parental line (summarised in
figure 4.7).
While using SLC35B2- targeted cells provides a rapid and consistent way
to determine fractional contribution from HS, it is important to consider that
SLC35B2 is involved in sulfation of other glycans, lipids and proteins in a cell,
and thus its removal could have adverse effects to molecules other than HS.
To address this, the approach I took was to first quickly assess binding on a
cell line in which SLC35B2 was targeted and upon observing a loss in binding
confirm that this was specifically due to HS by either re-testing binding on cell
lines where EXTL3 (gene encoding for HS-specific enzyme) was targeted or
with blocking experiments using soluble heparin. For the merozoite proteins
for which I had not carried out the genetic screens (CyRPA, RAMA), I took
the latter biochemical approach, in which I pre-incubated the recombinant
proteins with a range of soluble heparin and demonstrated that concentrations
above 200 µg/mL of soluble heparin led to a complete loss in binding to the
parental cell line (appendix figure A.3). This indicated that all the five tested
merozoite proteins from the initial screening list adsorbed into HS and this
genetic approach would not be feasible to identify receptors for them.
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Fig. 4.7 Schematics for the approach to determine the fractional contribution
of HS towards binding. Cell surfaces contain a range of receptors including heparan
sulphate proteoglycans (HSPGs) such as syndecans and glypicans (represented in
green) [250]. In the parental line, an observation of binding can be misleading as
both proteins that bind to a specific receptor (represented in red) and proteins that
adsorb into HS (represented by the chains emerging from HSPGs) display the same
binding phenotype. However, the binding of a protein to the cell line that contains its
specific receptor will be unaffected or only partially affected by targeting SLC35B2 (as
observed with RH5- represented by red triangles), whereas the binding of a protein
which does not contain a specific receptor but adsorbs into HS will be predominantly
lost in SLC35B2 targeted cell line (as seen with all other tested merozoite proteins
except RH5- represented by grey polygons). This approach would provide a basis
for choosing candidates for the genome-scale screening system to identify receptors
beyond HS. The genetic screen itself would be carried out on the parental cell line
and not on the SLC35B2 targeted line.
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4.2.3 Investigating extracellular interactions mediated by
human proteins
Application of the pre-screening approach to a panel of human proteins
identifies the contribution of SLC35B2 in binding.
To assess whether the pre-screening approach on cell lines lacking the GAG-
biosynthesis enzymes would provide a rapid way to identify proteins that bind
specifically to cell surface receptors, I next tested the binding of a panel of
51 human proteins, produced as recombinant pentamers from the platelet
library, with the parental HEK-293-E cell line and HEK-293-E cell line in which
SLC35B2 was targeted (figure 4.8). From this panel of proteins, I identified six
proteins that demonstrated binding to the parental cell line. Next, I categorised
the six proteins into three classes, based upon their binding behaviour to
cells with inactivated SLC35B2 as compared with their binding behaviour to
wild-type cells. The three categories were proteins with: (1) a small loss in
binding (< 20%, CD226, EPHB1, LPHN1) ; (2) a moderate loss in binding
(>50%, G6B); and (3) a severe loss in binding (>80%, APLP2, APP).
Fig. 4.8 The pre-screening strategy identifies human proteins whose binding is
not solely dependent on SLC35B2. Pentameric ligands were tested for binding to
either the unmodified parental cell line or to the polyclonal SLC35B2-targeted cells.
The number in each grid represents the percentage of cells that fell within the ‘binding’
gate, which was drawn on the histogram obtained from control protein binding to
the parental HEK-293-E cell line (depicted in the right panel). From the panel of 51
proteins, only six exhibited a clear binding (‘binding’ population higher than 25%).
While CD226, EPHB1 and LPHN1 (category 1) retained more than 80% binding in
the SLC35B2-targeted cells, APP and APLP2 (category 3) almost completely lost the
binding. G6B (category 2) exhibited an intermediate phenotype in which more than
50% binding was lost.
To assess whether the loss of binding observed in the pre-screening step
translated to the identification of the HS pathway in a genome-scale screen,
I next carried out screens to identify the factors contributing to the binding of
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proteins that exhibited a moderate or a severe loss (APLP2, APP, G6B) upon
SLC35B2 inactivation (figure 4.9A). A brief introduction to the investigated
proteins is provided in table 4.1. In all three scenarios, the enriched genes
contained enzymes required for HS biosynthesis as predicted (figure 4.9B).
Other than the GAG biosynthesis pathway, a number of genes identified in
these screens also overlapped with the screens carried out with merozoite pro-
teins before (appendix figure A.4, genes identified in more than one screen are
labelled in figure 4.9B as ‘overlapping factors’). This included genes involved in
processes such as the general secretory pathway, core glycosylation pathway,
vesicular transport pathway, subunits of V-type ATPases, general transcription
factors, elongation factors, and mRNA processing enzymes. In addition, genes
encoding the proteins TMEM165 and PTAR1, the loss of both of which has
been suggested to affect global glycosylation in cells [251, 144], were also
identified in the majority of the screens. No specific cell surface receptor was
identified in any of the screens. This demonstrated the applicability of the
pre-screening step in rapidly determining HS contribution towards binding and
showed that when the binding of the protein is mostly dependent on HS, this
approach may have limited ability to identify a specific receptor.
Table 4.1 Background of the ligands that demonstrated dependency on SLC35B2 for
binding to HEK-293-E cells.
Ligand Protein function Known cell surface receptors Ref.
APP
and
APLP2
Amyloid-beta precursor proteins
(APPs) consist of APP, APLP1 and
APLP2. All three are type I trans-
membrane proteins that are cleaved
by secretases to form a number of
peptides. The cleavage of APP
leads to generation of the Aβ pep-
tide, which is the major component
of amyloid plaques found in the
brains of Alzheimer’s patients.
Both APP and APLP2 have been
suggested to interact with HSPGs.
APP interaction with HS on glypican
1 has been demonstrated in-vitro but
the function of the interaction in-vivo
is unclear. An ectodomain of APP,
which is generated by cleavage with
β-secratase has also been shown
to bind to death receptor 6 (DR6)
to activate intracellular caspases in
axons.
[252,
253]
G6B Cell surface receptor of the im-
munoglobulin superfamily that has
been implicated to function in cel-
lular recognition and signal trans-
duction. It is expressed in platelets
where it acts as a negative regulator
of platelet function.
The ectodomain of G6B interacts
with soluble heparin; however, it has
been suggested to have a specific
binding partner on the cell surface.
[254,
255]
93
Chapter4
Fig. 4.9 Genome-scale screens identify HS-biosynthesis pathway when ligands
that lose majority of binding upon targeting SLC35B2 are used as screening
probes. A. Pentameric ligands were tested for binding to unmodified parental cell
lines or to polyclonal SLC35B2-targeted cells. The HEK293 cell line was used for
all proteins. B. RRA-score rank-ordered genes identified from gRNA enrichment
analysis from sorted cells which had lost binding to APP, APLP2 and G6B; in all
three cases, genes encoding the cellular factors required for HS-biosynthesis pathway
were identified. Multiple genes identified in this screen were also identified in screens
carried out before with merozoite proteins. Overlapping factors represent genes that
have been identified in at least any two out of the six screens, which have identified
the HS-biosynthesis pathway.
Genome-scale cell-based CRISPR screens using recombinant protein
probes identify directly interacting receptors
I next carried out genetic screens with ligands, which showed no (CD226,
EPHB1) or merely fractional (<10-20%) decrease in binding upon targeting
SLC3B2, to evaluate whether the screening approach would be able to identify
specific receptors on the cell surface (figure 4.10A). Where the overall binding
of the ligand had been established to have no contribution from SLC35B2, the
gene with the most enriched gRNAs corresponded to a known receptor (refer to
table 4.2) in every case: EFNB2 was the top-ranked gene when selected with
the EPHB1 ligand and PVR for CD226 (figure 4.10B). In the case of LPHN1, the
binding of which had a partial contribution from SLC35B2, the most enriched
genes included a known receptor - TENM4 - as well as SLC35B2 (figure
94
CRISPR-Cas9 knockout screens for cellular recognition
4.10C). These experiments demonstrated that the pre-screening approach is
a useful way to rapidly establish whether the protein contains a receptor on
the cell line, and that the directly interacting receptor in such cases can be
determined with the genome-scale screening approach.
Fig. 4.10 Cell surface receptors were identified using cellular genetic screens.
A. Pentameric ligands were tested for binding to the unmodified parental cell line, or to
the polyclonal SLC35B2-targeted cells. The HEK293 cell line was used for all proteins.
B. RRA-score rank-ordered genes identified from gRNA enrichment analysis from
sorted cells which had lost binding to CD226 and EPHB1; in both cases, the gene
encoding the known receptor was identified as the most significantly enriched gene
with no contribution from HS, as expected. C. Rank-ordered genes identified from
gRNA enrichment analysis from sorted cells which had lost binding to LPHN1. The
top four genes were identified with the same FDR: these included a gene encoding a
known receptor TENM4, SLC35B2, and two genes relating to global glycosylation in
cells (PTAR1 and TMEM165, which were also identified previously in the screens that
identified the HS-biosynthesis pathway). The list of all identified genes with FDR<0.05
in each case is provided in appendix section table A.6.
95
Chapter4
Table 4.2 Background of the identified receptor-ligand interaction partners. The three
detected receptor ligand-pairs in this genetic screening approach were identified in the
past using distinct biochemical and genetic methods. The interactions represent both
low (CD226-PVR) and high (EPHB1-EFNB2 and LPHN1-TENM4) affinity interactions.
Ligand Receptor FDR Approach used in the past Reported KD Ref.
CD226 PVR 0.005 Expression cloning with cDNA li-
brary using CD226 conjugated to
Fc domain as a probe.
2.3x10−7 M [256]
EPHB1 EFNB2 0.005 Ephrin B2 (EFNB2) was initially
identified as an ephrin ligand
as it shared sequence homology
with then known ephrin ligand,
EFNA2. Identification of EPHB1
as one of the binding partners
was done through cDNA overex-
pression and cell binding assay.
0.78 x10−9 M [257]
LPHN1 TENM4 0.005 Affinity purification from rat brain
with the ectodomain of LPHN1
fused to the Fc domain followed
by mass-spectrometry.
1.07x 10−9 M [258]
Having established a system from which I could pre-screen for candidate
proteins that bind to specific receptors on the cell surface, I next established a
screening pipeline (summarised in figure 4.11) through which I could ‘feed in’
recombinant proteins to identify candidates that could be used in a genome-
scale screening approach to identify novel receptors and non-receptor cellular
factors that contribute to the biology of the receptor.
Fig. 4.11 Strategy for genetic screening using recombinant proteins. The strat-
egy is based on the retention of binding on SLC35B2-targeted cell lines. A conclusive
test for HS-adsorption is carried out with a blocking assay with soluble heparin.
Where the receptor was already known, genetic screens were carried out to iden-
tify additional information regarding the biology of the receptor. For this purpose,
SLC35B2-deficient versions of six different cell lines (HEK-293-E, HEL, NCI-SNU-1,
KBM7, HL-60, HepG2) were produced and an additional ∼80 human proteins were
screened. The binding of the merozoite proteins were also re-tested on the SLC35B2-
KO versions of the cell lines generated here and in all cases, binding was completely
abrogated (data not shown).
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Genome-scale cell-based screens using recombinant protein probes also
identify intracellular pathways required for receptor expression on the
surface of cells
One of the ligands from the screening pipeline that I next investigated was
TNFRSF9 (also known as CD137 or 4-1BB-receptor), which demonstrated
SLC35B2-independent binding on the NCI-SNU-1 cell line (human colon
cancer cell line). TNFRSF9 belongs to the tumor necrosis receptor family
primarily present in T cells where its expression is up-regulated upon receiving
antigen-specific signals. TNFRSF9 is a well-characterised co-stimulatory
molecule on T cell and is known to interact with TNFSF9 (or CD137L), which
is primarily expressed on antigen-presenting cells (APCs). The stimulation of
TNFRSF9 has been shown to suppress tumour growth in murine models of
sarcoma, mastocytoma, and glioma, which has made this antigen an attractive
target for cancer immunotherapy [259, 260]. The expression of both TNFRSF9
and its ligand TNFSF9 is not restricted to the cells of the immune system: a
number of non-lymphoid cell lines have also been shown to express these
proteins on their surface. Human colon carcinoma lines have been shown
to constitutively express varying levels of TNFSF9 that is able to functionally
interact with TNFRSF9 on anti-CD3 activated T-cells [261].
To investigate the factors contributing to the interaction of TNFRSF9 with
the NCI-SNU-1 cell line, I carried out a genome-scale screening approach
using a monomeric biotinylated TNFRSF9 clustered around streptavidin-PE as
the selection ligand. Enrichment analysis using cells refractory to binding the
ligand revealed genes corresponding to the known interaction partner TNFSF9
as the most enriched gene. In addition, several genes involved in the p53
pathway (CDKN2A, CDC37, STK11 and DYRK1A) and TP53 itself were also
enriched in the non-binding population, suggesting a role for the p53 pathway
in presenting TNFSF9 in a ligand-binding form on the cell surface (figure 4.12B-
see figure 4.12C for the relationship of these genes toTP53). I validated this
by independently targeting TP53, which resulted in a decrease in the binding
of the TNFRSF9 ligand (figure 4.12D).
These experiments further demonstrated that where binding is not largely
dependent on adsorption into HS, the directly interacting receptor and the cellu-
lar pathways responsible for the cell biology of the receptor can be determined
using this method.
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Fig. 4.12 Genome-scale screen using TNFRSF9 ectodomain as a sorting ligand
identifies the interaction partner along with the p53 pathway. A. Monomeric
biotinylated TNFRSF9 conjugated to streptavidin-PE binds to NCI-SNU-1 cell line;
this binding was not affected by targeting of SLC35B2. B. RRA-score for genes that
were identified to be enriched in the sorted cells that were refractory to binding to
the TNFRSF9 probe. Genes are ranked according to the RRA-score. The known
interaction partner TNFSF9 and genes related to the TP53 pathway (labelled in red)
were identified in the screen. C. The relationship of genes identified in B with TP53.
Identified gene products are highlighted in red. D. TNFRSF9 binding to NCI-SNU-1
cells was reduced in TP53-targeted cells relative to a non-targeting control; targeted
cells were maintained as polyclonal lines. A and C show representative experiments
of three technical replicates. Refer to table A.6 in the appendix section for identity of
all genes identified with FDR<0.05.
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4.3 Discussion
In this chapter, I demonstrated how the genome-scale screening approach
can be used to investigate interactions with cell lines mediated by recombinant
protein probes. In the proof-of-principle demonstration using RH5 ectodomain
as a screening probe, I was able to clearly identify, in a single experiment,
both the direct receptor BSG (and the associated chaperone SLC16A1) and
the contribution from the component of the cellular glycocalyx, especially HS.
Further experiments with RH5 interaction with the surface of cells showed that
the contributions to RH5-binding by its specific receptor and HS, at least in this
context, were independent and could be experimentally separated.
When the approach was used subsequently to identify receptors for five
other merozoite proteins, I consistently observed complete dependence of the
proteins on the cellular HS-biosynthesis pathway to mediate binding to the cell
lines. The role of sulfated glycans in the context of host-parasite interactions
has been studied in the past: the addition of heparin to in-vitro cell cultures of
P. falciparum has been shown to block the invasion of merozoites into the red-
blood cells. It has been suggested that heparin like molecules could be involved
in the initial attachment of the parasite to the host cell [262, 263, 264], as has
been shown for the attachment of various viruses, bacteria and other parasites
to the host cells [265, 139, 266, 267]. Heparin or heparin-like molecules have
been shown to interact directly with recombinant or native merozoite proteins
[268, 269, 248]. One such study, which used pull-down experiments with
heparin affinity chromatography, has even suggested that almost all of the
erythrocyte-binding proteins of P. falciparum (for example EBA140, RH2, RH4,
and RH5) have the capacity to bind to heparin-like molecules [270]. It is not
always easy to predict whether proteins have the ability to interact with HS,
as there does not exist a specific protein fold or recognizable amino acid
sequence patterns that determines the binding of proteins to HS3. Rather,
the majority of the HS interactions are mediated by the negatively charged
sulfated groups on the polysaccharides with the positively charged amino acid
residues (such as lysine and arginine or protonated histidine residues at low
3Attempts to identify HS-binding domains in proteins have been made with suggestions
of XBBXBX or XBBBXXBX, where B is lysine or arginine and X is any other amino acid
as potential sequences. Such sequences can be identified in multiple merozoite proteins,
including RH5; however, it is now suggested that such sequences merely imply a possible
interaction with heparin and should not be taken as a proof for interactions under physiological
conditions [271].
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pH values) present on the external surface of the folded proteins [271]. Based
on the observations here and from the studies from before, it is possible that a
number of merozoite proteins possess such charged surfaces enabling them
to interact with HS.
However, the question of whether the merozoite invasion ligands actually
bind to heparin-like molecules in a physiological context remains to be an-
swered. Some of the proteins that have been shown to bind heparin, such as
the RH-family proteins (RH2, RH4, RH5), reside in the intracellular vesicular
compartments of the parasite, are only released for a very short time (approxi-
mately 30s) during the invasion process, and are thus unlikely to encounter
heparan sulfates. Furthermore, the proteins that have been shown to interact
with heparin have also been shown to have a specific receptor (for example,
BSG as the receptor of RH5 [88], and Complement receptor 1 (CR1) as the
receptor of RH4 [272]). This suggests that the ability of the many merozoite
proteins to interact with HS is a generic property of the proteins, and there
possibly exist specific cell surface receptors for some of these proteins other
than HS. Using the example of RH5, I demonstrated here that the contribution
from HS and the specific receptor can be experimentally separated. Therefore,
to use this approach for identifying specific receptors for merozoite proteins, it
is important to first identify a cell line where the binding of the proteins is not
completely dependant on the presence sulfated glycans, as it is likely that it
will be in those cell lines there exists a specific receptor for these proteins. In
this work I was unable to find such a cell line for the 11 merozoite proteins that
were tested.
The HS-binding behaviour was not limited to merozoite proteins as some
human proteins such as APP, APLP2 and G6B were also found to interact with
HS. All of these human proteins have been shown to bind to soluble heparin in
the past (see table 4.1), but the relevance of such binding behaviour in physio-
logical condition is still not understood. There are over 100 proteins that have
been described in literature to bind HS to carry out diverse cellular functions
such as cell adhesion, migration, regulation of enzyme activity, and protection
of proteins against degradation [271]. Members of the fibroblast growth factor
(FGF) family have been shown to interact with heparin with high-affinity (KD of
nM range) and this association has been shown to be physiologically important
for the signalling via FGF-FGF receptor(FGFR) complex, which is required
during development [273]. It has been suggested that HS chains provide a
linear domain over which growth factors can diffuse thereby increasing the local
100
CRISPR-Cas9 knockout screens for cellular recognition
concentration of the ligand so as to facilitate receptor-ligand interactions [271].
While such biologically relevant HS-mediated interactions do exist, there are
suggestions that the specificity of HS-mediated interactions in such situations
is determined by spatial and temporal expression of proteoglycans carrying the
HS chains; if the ligand is not exposed to HS proteoglycan, it cannot interact
even if it has that ability in principle [271]. Using the genetic screen approach
on cell lines, in which proteins that have the ability to interact with HS were
introduced to cell surfaces that bear HS, it was difficult to assess to what extent
such bindings were relevant in biological contexts. Therefore, I decided not to
focus on proteins that solely depended on HS for interaction at the cell surface.
To identify and eliminate proteins that only adsorbed to HS without binding
to a specific receptor, I designed a strategy to rapidly establish the extent
to which sulfated GAGs contributed to the observed binding events. The
approach I took was to test binding on an SLC35B2-deficient cell line (used as
a proxy for cells that lack HS), which provided clues as to the presence of a
specific receptor on the surface of the chosen cell line. In situations where the
binding was not largely dependent on the presence of SLC35B2, I was able to
identify the specific receptor in every case attempted. In the case of TNFRSF9,
I was also able to identify components of the p53 pathway to be important for
the interaction of this probe with TNFSF9. It is possible that TP53 acts as the
transcriptional factor responsible for the expression for TNFSF9 in these cell
lines and this hypothesis is consistent with a previous report demonstrating
the presence of TP53 binding sites in the promoter region of TNFSF9 [274].
This example showed the promise of this method in identifying the intracellular
pathways that can contribute to interactions occurring at the surface of the
cells.
In summary, in this chapter, I adapted the genome-scale screening system
to identify receptors and non-receptor cellular factors contributing to the inter-
action of cells with recombinant protein probes. Below I will highlight some
of the lessons learnt from adapting this strategy to use recombinant protein
probes:
• Recombinant protein probes can be used in this screening system to
identify both low and high affinity extracellular protein-protein interactions.
The method is also able to identify intracellular pathways that contribute
to the biology of the receptor.
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• It is important to be aware that observation of binding on a parental cell
line does not equate to the presence of a specific receptor as some
proteins tend to adsorb into HS present at the cell surface. The binding
behaviour of some proteins to HS in this system is not an indication that
such interactions also occur in physiological conditions.
• If a protein binds to a specific receptor but also adsorbs into HS, both
components can be identified using this method. In the example here,
such binding events were found to be additive and not dependent on
each other.
• The main limitation of this technique is that genes required for cell sur-
face interactions that are genetically redundant might be refractory to
identification. In the example of the screens in which heparan sulphate
was identified, specific proteoglycans that carry the HS-chains in the
cells were not identified. The reason for this could be the redundancy
in these classes of molecules. Cell surface HSPGs are composed of
the GPI-linked glypicans and the transmembrane syndecans. There are
four syndecans (SDC1-4) and six glypicans (GPC1-6) in mammals [250],
which can function equivalently on the cell line to provide HS chains; this
could have precluded their identification. That said, such screens do still
provide a wealth of information about the biology of the receptor, which
can then be used in subsequent follow-up studies to identify the precise
nature of the ligand-receptor interaction.
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IDENTIFICATION AND CHARACTERISATION OF IGF2R
AS AN ENDOSOMAL RECEPTOR FOR GABBR2
5.1 Introduction
This chapter describes the application of the genome-scale screening ap-
proach to identify the interaction between a mannose-6 phosphate receptor
(IGF2R) on the surface of HEK-293-E cells and the recombinant protein cor-
responding to the ectodomain of the B2 subunit of the gamma-aminobutyric
acid (GABA) type B receptor (GABBR2 or GABAB2). The interaction was
subsequently validated using biochemical approaches.
5.1.1 Introduction to GABA-B receptors
Communication between neurons occurs via the release of small chemical
molecules called neurotransmitters into the junction between two neuronal
cells (called synapses). Neurotransmitters are of two types (i) excitatory,
which increase the excitability of neurons, and (ii) inhibitory, which reduce
the excitability of neurons. Gamma-aminobutyric acid (GABA) is the major
inhibitory neurotransmitter of the mammalian central nervous system (CNS)
[275]. GABAB receptors are widely expressed metabotropic transmembrane
receptors for GABA that mediate slow inhibitory neurotransmission in the CNS
to control the excitability of neurons [276]. The GABAB (or GABAB) receptor is
composed of two subunits, GABAB1 and GABAB2, both of which are members
of the GPCR family and contain the characteristic GPCR seven transmembrane
(7-TM) regions. Both subunits also contain an extracellular domain called the
‘venus fly trap domain’ (VFTD), which acts as the binding site for GABA.
Functional GABAB receptors are generated through the combination of either
of the isoforms of the GABAB1 subunit (GABAB1a or GABAB1b) together with
the GABAB2 [277].
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Fig. 5.1 Schematics of GABAB receptors. Formation of functional GABAB recep-
tors requires dimerisation of the B1 and B2 subunits [278]. There are two isomers
of B1 subunits that differ by the presence of two sushi domains on the B1a but not
on the B1b subunit. GABAB1a/B2 are preferentially found presynaptically whereas
GABAB1b/B2 are mainly localised postsynaptically [279]. The subunits interact via the
coiled coil domains present on the C-terminus of the proteins. This interaction has
been shown to be required for the transport of the GABBR1 subunit to the plasma
membrane. The GABBR1 subunit contains an ER retention signal which is masked
when it interacts with the GABBR2 subunit, thereby allowing it to reach the cell surface.
The binding of GABA is medaited by the GABBR1 subunits whereas the GABBR2
subunit couples with the subset of heterotrimeric G-proteins (pertussis toxin sensitive
Gi/o family) to regulate voltage-gated Ca(2+) (Ca(V)) channels, G-protein activated
inwardly rectifying K(+) (GIRK) channels, and adenylyl cyclase activity [280].
Internalisation of GABAB receptors
The balanced expression of excitatory and inhibitory receptors in neurons
is crucial for normal brain function. Disruption to such balances has been
been implicated in a wide range of neurological disorders including anxiety,
depression, epilepsy and neuropathic pain [281]. Internalisation of GPCRs re-
ceptors has been most comprehensively studied in the context of β-adrenergic
receptors, the expression of which on the surface of cells is tightly controlled by
agonist desensitization. In this model, upon a prolonged stimulation of GPCRs
by an agonist, the agonist-bound GPCRs are phosphorylated by G protein-
coupled receptor kinases (GRKs), which leads to decreased effector coupling
and recruitment of arrestins and clathrins, in turn leading to the endocytosis
of receptors followed by recycling or degradation [282, 283]. However, unlike
the other GPCRs, GABAB are not GRK substrates [284, 285] and thus the
mechanisms by which the plasma membrane expression of GABAB receptors
are regulated have been suggested to follow other mechanism of internalisa-
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tion rather than the classical pattern of agonist-induced desensitisation and
internalisation1. While initial studies suggested that GABAB receptors are
stably expressed on the surface of cells with very low rate of constitutive inter-
nalisation [285, 290, 284], it is now generally accepted that GABAB receptors
are highly mobile and can undergo constitutive internalisation in both heterol-
ogous expression systems (including HEK293 cells) and cultured neurons
even in the absense of an agonist [289, 291, 292, 288]. The internalisation
of the receptor heterodimer has been reported to be carried out via clathrin-
and dynamin-dependent pathways. Internalised receptors are either targeted
to endosomes [289, 288] or degraded in the lysosomes [289]. Receptors
destined for endosomes have been reported to be recycled back to the surface
of the cells.
Several mechanisms mediated by post-translational modifications of het-
erodimer subunits have been proposed for the regulation of the expression of
GABAB receptors on the surface of cells. It has been suggested that sustained
activation of the N-methyl-D-aspartate (NMDA) receptor by glutamate causes
the activation of the AMP-dependent protein kinase (AMPK) and the protein
phosphatase 2A (PP2A). This in turn leads to the phosphorylation of serine
783 (S783) residue on the C-terminus of GABBR2 subunit, which causes the
change in the fate of internalised GABAB receptors—rather than being recy-
cled back to the surface of the cells, the receptors are instead directed towards
lysosomal degradation [293]. Another post-translational mechanism that is
known to contribute to receptor internalisation and regulation is ubiquitination.
The role of ubiquitination in GPCR internalisation is well-studied in case of
β-adrenergic receptors in which there exists an agonist-dependent ubiquitina-
tion of both β-arrestin and the receptor. It has been shown that ubiquitination
on β-arrestin and on β-adrenergic receptors serve distinct signals. While the
ubiquitination of β-arrestin is required for receptor internalisation, that of the
receptor is required for receptor degradation [294, 295, 296, 297]. Although it
is known that GABAB receptors do not engage β-arrestins, Lysine-63-linked
ubiquitination of the GABBR1 subunit and its interaction with USP14 (ubiquitin-
specific protease 14) has recently been reported to play a role in lysosomal
targeting of GABAB receptors [298, 299]. While these studies provide evi-
dence for ubiquitination mediated regulation of an amount of receptors present
1Studies regarding the effect of an agonist are conflicting as there are some studies that
have shown agonist-induced internalisation [286, 287] and others that show no influence of
an agonist on internalisation [288, 289].
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on the plasma membrane, the mechanism by which GABAB receptors are
constitutively internalised using clathrin-dependent endocytosis pathway still
remains unknwown. The GABBR2 subunit of the GABAB receptors has also
been suggested to play a regulatory role for mediating cell surface receptor
stability of GABAB receptors, but the precise mechanism for this is also not
known [292].
5.1.2 Introduction to IGF2R
IGF2R (also known as cation-independent mannose-6-phosphate receptor
(CI-MPR) or CD222) is a multifunctional membrane-bound glycoprotein. It is
mainly localised in the trans-Golgi network (TGN) and endosomes (90-95%)
with 5–10% of the receptor expressed on the plasma membrane [300]. IGF2R,
together with CD-MPR (cation-dependent mannose-6-phosphate receptor),
makes up the class of ‘P-type’ lectins that primarily function in sorting mannose-
6-phosphate- (M6P-) bearing glycoproteins from TGN to endosomes and
lysosomes (figure 5.2A, the schematic representation of IGF2R is shown in
figure 5.2B) [301].
Non-lysosomal targets of IGF2R
Apart from the transport of enzymes destined for lysosomes, IGF2R also
functions in regulating other cellular functions by interacting with multiple
non-lysosomal proteins. One of the first identified non-lysosomal protein
bound by IGF2R was the insulin growth factor II (IGF-II, hence the name
IGF2R). IGF2R has been suggested to be a ‘sink’ for excess IGF-II in the
extracellular fluid [301]. The interaction with IGF2R leads to internalisation
and subsequent degradation of IGF-II in the lysosomes. IGF-II does not
contain M6P modifications and binds to a site different to the M6P binding
sites of IGF2R. As IGF-II is important for cell growth, survival, and migration,
maintenance of correct levels of IGF-II in the extracellular space has been
shown to be crucial for normal growth and development of cells [302]. In
addition to IGF-II, IGF2R interacts with multiple non-lysosomal ligands in both
a M6P-dependent (such as Transforming growth factor-β precursor (TGFβ1),
Leukemia inhibitory factor (LIF), Proliferin, Granzyme B, CD26, Herpes simplex
virus glycoprotein D (HSV-glyD) ) and -independent (such as Retinoic acid
(RA), uPAR: urokinase-type (plasminogen activator) receptor, Plasminogen)
manner. A summary of the cellular context in which the some of the interactions
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with IGF2R occur, as well as the consequences of the interactions, is provided
in table 5.1 (reviewed in [300]).
Fig. 5.2 Schematics of mannose-6-phosphate cellular transport pathway and
structure of IGF2R. A. Newly synthesised enzymes such as soluble acid hydrolases
that are destined for the acidic compartments in cells are post-translationally modified
to contain M6P residues on their N-linked oligosaccharides in the golgi network
(represented with -P). These residues are recognised by cellular M6P receptors (CI-
MPR and CD-(cation-dependent)-MPR), which causes the receptors and their ligands
to cluster into clathrin-coated transport vesicles at the trans-Golgi-network (TGN).
Clathrin coated vesicles bud-out of the TGN and travel to an acidic late endosomal
compartment in which the low pH causes dissociation of the receptor–ligand complex.
The unbound M6PRs are then trafficked back to the TGN or trafficked to the plasma
membrane. In some cases, lysosomal enzymes that carry the sorting tag escape
the transport to the endosomes and are instead secreted. M6PRs (mainly IGF2R)
present on the surface of cells are required for the ‘secretion-recapture’ pathway
where such escapees are captured and are brought back into the cell via the clathrin
dependent endocytosis pathway. These proteins are also eventually transported to the
late endosomes (schematics is based on [303]). B. IGF2R is a 300 kDa glycoprotein
that contains 15 repetitive extracytoplasmic domains each with 147 amino acids that
share ∼14 % - 38 % sequence similarities. Monomeric receptors are found on the
membrane surfaces; however, weak dimeric complexes formed upon ligand binding
have also been reported. IGF-II binds to a site (domain 11) separate from the M6P
binding sites (domain 3 and 9) of IGF2R. The c-terminus of CI-MPR contains important
amino acid sorting signals (for example, GGA, Golgi-localized, gamma-ear-containing,
ADP-ribosylation factor-binding protein TIP47, tail-interacting protein; AP1 and AP2,
clathrin adaptor proteins) [303].
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Table 5.1 Non-lysosomal interaction partners of IGF2R
Ligand Context of interaction Ref
M6P bearing ligands
TGF-β The interaction leads to plasmin-mediated proteolytic activation of
the precursor to generate active growth factors at the cell surface
[304]
LIF Endocytosis and degradation in lysosomes
Proliferin Interaction induces endothelial cell migration and angiogenesis [305, 306]
CD26 Internalisation of CD26 and role in T cell activation [307]
Granzyme B Internalisation and induction of apoptosis [308]
HSV-glyD Facilitation of viral entry into cells and transmission between cells [309]
Non-M6P bearing ligands
IGF-II Internalisation and degradation in lysosomes [310, 311, 312]
RA Growth inhibition and/or induction of apoptosis [313]
uPAR Binds to IGF2R to convert plasminogen into plasmin [314, 315]
Plasminogen Activated by uPAR to form plasmin and consequently activate the
IGF2R bound TGF-β
[315]
5.1.3 Scope of this chapter
In this chapter I will describe the interaction that I identified between IGF2R
and GABBR2 with the genome-scale screening approach developed in chapter
4 using an avid GABBR2 (ectodomain of GABBR2 conjugated to streptavidin-
PE) as a screening probe. The interaction was subsequently validated using
targeted gene knockout and biochemical approaches.
5.2 Results
5.2.1 IGF2R is required for the binding of GABBR2 to HEK-
293-E cells
One of the proteins from the screening pipeline that was identified as binding
HEK-293-E cells in a SLC35B2 independent manner was the ectodomain of
gamma-aminobutyric acid (GABA) type B receptor subunit 2 (GABBR2) (figure
5.3A). To identify the cellular components contributing to this interaction, a
genome-scale screening approach was carried out and mutant cells that had
lost the ability to bind the GABBR2 ectodomain were sorted (figure 5.3B).
Enrichment analysis revealed a clear enrichment of gRNAs targeting IGF2R
together with genes involved in endosomal function and trafficking in the sorted
population (figure 5.3C). IGF2R is a known cargo receptor which transports
mannose-6-phosphate (M6P)-modified proteins between the TGN, endosomes,
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pre-lysosomal compartments, and the plasma membrane; it might therefore
provide a mechanism for the known internalisation and lysosomal degradation
of GABAB receptors through interactions with the GABBR2 subunit.
Fig. 5.3 A genome-scale screen using the ectodomain of GABBR2 identifies
IGF2R and genes involved in endosomal function and trafficking. A. Monomeric
biotinylated GABBR2 ectodomain conjugated to streptavidin-PE binds to HEK-293-E
cells in a SLC35B2-independent manner. B. Cells lacking the surface staining from
GABBR2 ecotodomain but expressing BFP fluorescence (from lentiviral transduction)
were collected. Approximately 800,000 cells were collected during this sort. C. RRA-
score rank-ordered genes identified from gRNA enrichment analysis from sorted
mutant cells that had lost GABBR2 binding activity. Enriched genes encoded the
IGF2R receptor and proteins involved in endo/lysosomal biology.
To investigate this further, I first validated the screen results using individual
gRNAs targeting IGF2R, which resulted in the loss of binding of the GABBR2
ectodomain (figure 5.4A). IGF2R expression on the surface of cells is known
to be dependent on lysosomal acidification, as cells treated with compounds
that increase lysosomal pH cause IGF2R to accumulate in endosomes, with
a consequent loss from the cell surface. This provides an explanation for
why genes known to be required for endosomal function (such as the compo-
nents or associated factors of the vacoular-type ATPases that pump protons
into the acidic compartments of the cells: ATP6VOD1, ATP6AP1, ATP6AP2,
ATP6V1A1, ATP6V1C1, VMA21 [316], and genes encoding for endosomal
trafficking proteins: VPS16, VPS18 and VPS39 [317]) were also enriched
[318]. One of the genes (WDR7 ) identified in this screen encodes for a poorly-
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characterised protein implicated to be involved in lysosomal acidification [319].
Consistent with the suggested role, WDR7 targeted HEK-293-E cells also
demonstrated a decrease in the surface level expression of IGF2R (figure
5.4B) and a corresponding partial loss in GABBR2 ectodomain binding (figure
5.4A) .
Fig. 5.4 Targeting IGF2R and WDR7 on HEK-293-E cells leads to the loss of
binding of GABBR2 ectodomain. A. Binding of GABBR2 was quantified on HEK-
293-E cells transduced with two gRNAs targeting different exons of IGF2R and one
gRNA targeting WDR7. A near complete loss of binding was observed on IGF2R-
targeted cells and a partial loss on WDR7 -targeted cells; targeted cells were main-
tained as polyclonal lines. B. Cells transduced with lentiviruses encoding individual
gRNAs targeting IGF2R and WDR7 show reductions in cell surface IGF2R levels.
Cells were transduced with lentiviruses encoding the indicated gRNAs and stained
12 days later with a mouse anti-human IGF2R mAb. Cells stained with secondary
antibody alone were the negative control and WT indicates untransduced cells as a
positive control. In both cases, a representative of three technical replicates is shown.
5.2.2 Plasma membrane expression of IGF2R is required
for the binding of GABBR2 ectodomain
I next set out to explore whether IGF2R was involved directly in the binding
of the GABBR2 ectodomain, or whether, it was playing an indirect protein
trafficking function in the cell, thereby assisting some other protein to the
surface of the cells to mediate the binding. To test whether the ectodomain of
IGF2R itself was required for the interaction with GABBR2, a IGF2R expression
plasmid was constructed in which the cytoplasmic region of the protein, which
contains the important amino acid sorting signals, was replaced with an eGFP
reporter protein and then displayed at the surface of human cells by transiently
transfecting the NCI-SNU-1 cell line. NCI-SNU-1 cells were chosen as they
110
CRISPR-Cas9 knockout screens for cellular recognition
exhibited very low levels of plasma membrane IGF2R compared to the HEK-
293-E cells and did not bind the GABBR2 ectodomain (figure 5.5A). The
NCI-SNU-1 cells transfected with the IGF2R-eGFP fusion protein but not the
control-eGFP fusion protein showed surface expression of IGF2R as indicated
by the presence of double-positive (GFP+/PE+) population when tested with
an anti-IGF2R mAb (figure 5.5B, left panel). Correspondingly, the binding
of the GABBR2 ectodomain could be conferred to the NCI-SNU-1 cells that
expressed the IGF2R-eGFP fusion protein but not the control-eGFP fusion
protein on the surface of cells (figure 5.5B). These data suggest that GABBR2
binding to cells was mediated by the ectodomain of IGF2R on the cell surface.
Fig. 5.5 Binding of GABBR2 can be conferred to NCI-SNU-1 cell line that do
not display IGF2R on their surface. A. NCI-SNU-1 cell line was tested for IGF2R
expression and GABBR2 ectodomain binding using an anti-IGF2R antibody and the
avid GABBR2 probe respectively; neither the expression of IGF2R nor the binding
to the ectodomain was observed. HEK-293-E cells were used as a positive control.
B. Gain of IGF2R-eGFP expression (left panel) and GABBR2 binding (right panel) in
cells transfected with a cDNA encoding IGF2R ectodomain. NCI-SNU-1 cells were
transfected with either a cDNA construct encoding the entire ectodomain of IGF2R
fused to a transmembrane (TM) region and an intracellular eGFP or a control TM-GFP
tagged receptor and tested for their ability to bind a fluorescently labelled GABBR2
binding probe; only the IGF2R-GFP positive cells and not the GFP negative or control-
TM-GFP bound GABBR2. In the case of anti-IGF2R antibody staining, a small fraction
of cells that were GFP positive were PE-negative, suggesting that not all expressed
IGF2R was displayed at the surface of the cells. In all cases, data is representative of
three technical replicates.
5.2.3 IGF2R ectodomain and GABBR2 ectodomain directly
interact
To further demonstrate that IGF2R and GABBR2 directly interact, I next ex-
pressed the entire ectodomain of IGF2R as a soluble beta-lactamase-tagged
‘prey’ and tested whether it could be captured specifically by a biotinylated
GABBR2 ectodomain ‘bait’ in a plate-based ELISA-style assay (schematic
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depicted in figure 5.6A). In the assay, biotinylated bait proteins are first immo-
bilised on a streptavidin coated mictotitre plate and β-lactamase tagged prey
proteins are added to the wells. Following wash steps, if an interaction with the
bait has occurred, the prey proteins will be captured in the corresponding wells
and this can be detected by addition of a β-lactamase substrate ‘nitrocefin’ the
hydrolysis products of which absorb at 485 nm. Using this assay, I observed a
specific capture of the IGF2R ectodomain by the GABBR2 ectodomain (figure
5.6B), demonstrating that the interaction between IGF2R and GABBR2 is
direct.
Fig. 5.6 Interaction between IGF2R and GABBR2 is direct. A. Schematic of plate-
based ELISA-style assay to test direct binding between ectodomains. The biotinylated
ectodomains are captured on streptavidin-coated plates and tested for direct binding
using a beta-lactamase-tagged ‘prey’ ectodomain. B. In the plate based assay, the
GABBR2 ectodomain was used as a bait and IGF2R ectodomain was used as a prey.
Positive control was the Cd200-Cd200R interaction; control ‘prey’ is an unrelated
ectodomain; positive (+) represents total capture of all preys with an anti-prey antibody
and negative (-) represents a tag only bait control. Data points are mean ± sem, n=3.
5.2.4 GABBR2 interacts with IGF2R in a M6P-dependent
manner
Given the known function of IGF2R to interact with multiple proteins in a
M6P-dependent manner, I next investigated whether the interaction that was
identified here also depended on the presence of M6P residues on GABBR2.
In a plate-based assay, the interaction between the ectodomains of GABBR2
and IGF2R could be prevented completely by the preincubation of IGF2R
with soluble M6P but not with a related monosaccharide, mannose (figure
5.7A). This suggested that the GABBR2 interaction with IGF2R was mediated
by the M6P binding domains of IGF2R. Furthermore, GABBR2 binding to
IGF2R was also dependent on the N-linked glycans as the interaction was
abolished by treating the GABBR2 ectodomain with PNGaseF (an enzyme that
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specifically removes N-glycans in a protein) (figure 5.7B). Together these data
demonstrate that the interaction between IGF2R and GABBR2 is dependent
on the M6P-modified N-linked glycans of GABBR2.
Fig. 5.7 Interaction between IGF2R and GABBR2 is dependent on the M6P-
modified N-linked glycans of GABBR2. A. The interaction between IGF2R and
GABBR2 can be completely inhibited by soluble M6P. The binding dependency on
M6P was established by tested by adding serial dilutions of mannose, M6P, or buffer
alone. B. Treating GABBR2 with PNGaseF ablates the interaction with IGF2R. Left
panel: The purified ectodomain of GABBR2-Cd4-bio was treated with PNGaseF for
the indicated times at 37 ◦C before aliquots were taken, resolved by SDS-PAGE
under reducing conditions and stained with Coomassie Blue. No further reductions
in molecular mass due to PNGaseF treatment occurred after eight hours incubation,
suggesting that the vast majority of glycans had been removed from the protein. Right
panel: The indicated biotinylated bait proteins were immobilised on a streptavidin-
coated microtitre plate and probed for interactions with the beta-lactamase-tagged prey
proteins. Prey binding was quantified by measuring the absorbance of the hydrolysis
products of nitrocefin — a β-lactamase substrate — at 485 nm. The known interaction
between Cd200-Cd200R was used as the positive control in the assay. Negative
control (-) was prey capture by a biotinylated Cd4 tag only control and positive control
(+) was total capture of all preys with an anti-prey antibody. Bars represent means ±
sem, n=3. In A and B, data is representative of three technical replicates.
These data provide evidence that IGF2R directly interacts with the ectodomain
of the GABBR2 receptor subunit via the M6P residues present on GABBR2;
they may therefore provide mechanistic insights for the known constitutive
internalisation of GABAB receptors.
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5.3 Discussion
In this chapter, I have demonstrated the utility of the genome-wide screening
approach developed in Chapter 4 by identifying IGF2R as a binding partner
for GABBR2 receptor. GABAB receptors are expressed abundantly in almost
all types of neurons and glia throughout the central nervous system and
mediate slow-acting control of neuron excitability by inhibiting neurotransmitter
release. This expression pattern overlaps with that of IGF2R, which is also
widely distributed throughout the nervous system with particular enrichment
in cortical areas, hippocampus and cerebellum [320]. The regulation of the
surface level of GABAB receptors by endocytosis is an important mechanism
to attenuate signal strength and can be modelled in HEK293 cells, where
GABAB receptors have been shown to rapidly and constitutively internalise
by the clathrin-dependent pathway to endosomes [289, 292]. The finding that
IGF2R can interact directly with the GABBR2 subunit of the GABAB receptor
complex provides a mechanism for the internalisation because IGF2R is itself
constitutively endocytosed and trafficked to the endosomal compartments
through clathrin-mediated uptake via ‘YSKV’ motifs in its cytoplasmic region
[321]. This is also consistent with the regulatory role for the GABBR2 subunit
in the uptake of the GABAB receptor complex, and the fact that antibodies
directed against the extracellular region, but not receptor agonists, can inhibit
GABAB receptor endocytosis [289]. A suggested physiological role of this
interaction is depicted in figure 5.8.
A similar role for IGF2R in interacting with M6P-bearing ligands to down-
regulate receptors from the cell surface has been shown for CD26 in activated
T-cells [307]. CD26 expressed on the surface of activated T cells (activated
with phytohemagglutinin), but not expressed on resting T cells was found
to be mannose-6-phosphorylated. One of the key questions, which has not
been addressed in this work, is the possible physiological mechanism by
which GABBR2 would be mannose-6-phosphorylated. To address this, it will
be important to first establish whether GABBR2 is constitutively mannose-6-
phosphorylated or whether it is a regulated process. One way of addressing
this experimentally would be to use the ectodomain of IGF2R to ‘pull-down’
endogenous GABBR2 from mouse (or rat) brain lysates. If GABBR2 exists
in a constitutively mannose-6-phosphorlated state, it should, in principle, be
possible to detect the interaction of IGF2R with endogenous GABBR2 using
such an approach.
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Fig. 5.8 Proposed mechanism of IGF2R mediated GABAB receptor internalisation. In this model, cell surface IGF2R associates with
M6P-modified N-glycans of GABBR2 subunit on the plasma membrane. The ‘YKSV’ motif on IGF2R then recruits adaptor protein complex 2
(AP2 complex), which is a plasma membrane-localised clathrin adaptor composed of α, β2, µ2, and σ2 adaptin subunits [321]. This is
consistent with the reported co-localisation of GABAB receptors with AP2 subunits in HEK293 cells [289, 322]. This is followed by clustering
of IGF2R and its cargo (GABAB in this case) into clathrin-coated vesicles (CCVs). Following internalisation and uncoating of the clathrin coat
proteins, the vesicles are fused with endosomes. The low pH of endosomes induces dissociation of cargo from IGF2R, thereby releasing
GABAB receptors into endosomal lumen. IGF2R is recycled back to TGN or to the cell surface, whereas, GABAB receptors are either
recycled back to the cell surface membrane or trafficked into lysosomes for degradation. This model is consistent with the observations in
HEK293 cells where constitutively internalised GABAB receptors have been shown to be targeted to endosomes from where they are either
recycled back to the cell surface or degraded in the lysosomes [289].
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The genome-scale approach here has once again demonstrated how this
method can be utilised to identify not only the receptor that directly inter-
acts with the recombinant protein probe but also provide valuable information
regarding the receptor biology. In the example here, I was able to identify
cellular components involved into intracellular vesicle acidification and trans-
port into endo/lysosomal compartments consistent with the known biology
of the IGF2R receptor. In addition, I was also able to identify WDR7 as an
important factor mediating the surface expression of IGF2R. Recently, it has
been shown that cells with RNAi mediated knock-down of WDR7 are unable
to re-acidify intracellular vesicles during recovery from compounds that re-
versibly block acidification (bafilomycin A1), suggesting a role for regulation
of vesicuar acidification for WDR7 [319]. The results here are consistent with
this observation and further reveal the role of WDR7 in surface expression of
mannose-6-phosphate receptors.
116
CHAPTER 6
DISCUSSION AND FUTURE DIRECTIONS
In this work, I have developed a genome-scale screening strategy using the
CRISPR-Cas9 knockout system to identify cellular components involved in
cellular recognition. The initial screens I carried out with mAbs as screening
probes provided a means to define the methodological parameters for the
genome-scale KO screening approach, so that the approach could be used
not only to identify the directly interacting receptors on the surface of the
cell, but also to reveal valuable information regarding the cell biology of those
specific receptors (such as essential roles for chaperones, enzymes required
for specific posttranslational modifications, and transcription factors). I then
adapted the screening system in order that the approach could also identify
both low- and high-affinity receptors of solubilised ectodomains of cell surface
proteins. Finally, I demonstrated the utility of the screening approach by
identifying IGF2R as a binding partner for GABAB receptors, providing a
mechanism for the internalisation and regulation of GABAB receptor signalling.
In the recent years, a number of genetic screens using the CRISPR-Cas9
system have been described to investigate complex biological questions, topics
of which ranging from gene essentiality, drug and toxin resistance, the hypoxia
response, and host factors required for invasion of viruses and bacteria (refer
to table 1 of [174]). In the context of cellular recognition, CRISPR-Cas9 based
genetic screens have already demonstrated their utility by the identification
of receptors and non-receptor host factors that are required for the entry or
survival of bacteria and viruses [181, 323, 324, 220, 183, 182]; host factors
required for resistance from pathogen toxins [173, 179]; and molecular mecha-
nisms that control expression of secretory and membrane proteins [186, 187]
(see table 6.1). The work here widens the applicability of a KO screening sys-
tem by utilising recombinant proteins that represent a broad range of cellular
contexts (both host and pathogen) to identify novel receptor-ligand interactions
and additional intracellular genes required for such associations.
117
118
Table 6.1 Summary of genome-scale KO screens using the CRISPR-Cas9 approach to study cellular recognition events
Cell line Phenotype/screen type Genes screened Primary finding(s) Ref
Virus-host interactions
RAW264.7 cells Host factors required for Murine
norovirus (MNV) (lethality screen)
87,987 sgRNAs targeting
19,150 mouse genes
Identification of CD300lf (also known as CLM2) as the
host receptor.
[324]
Huh7.5.1 cells Host factors required by DENV
serotype 2 and hepatitis C virus
(HCV) (lethality screen)
122,417 sgRNA targeting
19,052 human genes
Host OST complex is hijacked by the DENV virus to me-
diate viral RNA replication. HCV screen revealed genes
encoding for previously known host receptors (CD81,
OCLN, CLDN1) and a novel role of genes involved in
FAD biogenesis (RFK and FLAD1) for intracellular virus
replication.
[220]
293T cells Host factors required by West nile
virus (WNV) (lethality screen)
122,411 sgRNAs targeting
19,050 human genes
Initial identification of 12 genes involved in endoplasmic
reticulum-associated functions (carbohydrate modifica-
tion, protein translocation and signal peptide processing,
protein degradation, and heat shock response). Further
validation in other flaviviruses identified a requirement
of host signal peptide processing protein SPCS1 for
flavivirus protein processing and infection.
[183]
CD4+ T cell line
(GXRCas9)
Host factors required by CCR5-
tropic HIV-1 strain (lethality screen)
87,536 sgRNAs target-
ing 18,543 human genes
(+1,504 non-targeting con-
trol sgRNAs)
Identification of genes encoding for known receptors
(CD4 and CCRC5) and three novel host dependency
factors (TPST2, SLC35B2 and ALCAM). Tyrosine sulfa-
tion of CCR5 by SLC35B2 and TPST2 is crucial for the
cell surface expression of this HIV co-receptor. ALCAM
mediated cell aggregation and its loss confers strong
protection against cell-to-cell HIV transmission.
[182]
Table 6.1 – Continued on next page
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Toxin resistance screens
Mouse JM8 ESCs Clostridium septicum alpha-toxin re-
sistance (lethality screen)
87,897 sgRNAs targeting
19,150 mouse genes
Increased resistance to the toxin by inactivation of
B4galt7 and textitExt2 (enzymes required for Heparan
sulphate (HS) biosynthesis.
[173]
U937 cell line Staphylococcus aureus alpha
hemolysin toxin (lethality screen)
120,000 sgRNAs targeting
19,050 human genes and
1864 miRNAs
Identification of previously known receptor ADAM10
and three novel components (SYS1, ARFRP1 and
TSPAN14) that regulate the expression of ADAM10 on
the cell surface.
[179]
Bacteria-host interactions
HT-29 cell line Cytotoxicity of Vibrio parahaemolyti-
cus Type III secretion system (lethal-
ity screen)
74,700 sgRNAs targeting
18,675 human genes
Removal of host cell sulfation reduces bacterial adhe-
sion to cells and delays T3SS1-associated cytotoxicity;
fucosylation of surface glycans is required for T3SS2
mediated killing.
[181]
Cellular factors contributing to protein expression
BMDCs from Cas9
expressing mouse
Processes regulating induction of tu-
mor necrosis factor (Tnf) by bacte-
rial lipopolysaccharide (LPS) (FACS-
based screen)
125,793 sgRNAs target-
ing 21,786 genes + miR-
NAs + 1,000 non-targeting
sgRNA
Identification of the components of the OST complex,
Paf complex and other factors (e.g., Tti2, Ruvbl2,
Tmem258, Midn, Ddx39b, Stat5b and Pdcd10) as im-
portant regulators of Tnf expression.
[186]
Pancreatic cell line
BxPC-3
Constitutive and induced cell sur-
face PD-L1 expression (FACS-
based screen)
10-sgRNAs/gene target-
ing 20,500 human genes.
Identification of CMTM6 as the master regulator of PD-
L1
[187]
ALCAM:CD166 antigen, ARFRP1: ADP Ribosylation Factor Related Protein 1, BMDC: Bone marrow derived dendritic cells, PD-L1:
Programmed death-ligand 1, CMTM6: CKLF-like MARVEL transmembrane domain containing protein 6, CLDN1: claudin 1, FLAD1: FAD
synthase; OCLN: occludin, OST: oligosaccharyltransferase, SLC35B2: adenosine 3
′
-phospho 5
′
-phosphosulfate transporter 1; SPCS: signal
peptidase complex subunit, SYS1: Golgi trafficking protein, TPST2: protein tyrosine sulfotransferase, T3SS: Type III secretion system,
TSPAN14: Tetraspanin 14
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For the application of a genome-scale screening approach to identify re-
ceptors and receptor-specific pathways using soluble probes, the initial stages
of this work focused on testing a range of parameters with respect to sorting
thresholds, size of the gRNA mutant library, and the day of phenotypic se-
lections, which facilitated a better understanding of how the results from KO
screens could be influenced by the experimental design. Below, I highlight
some of the considerations for setting the screening parameters for genome-
scale CRISPR-Cas9 knockout screens.
6.1 Overview for screening parameters
6.1.1 Sorting strategy
All phenotypic selections in this work were carried out using a flow-cytometry-
based sorting approach. FACS-based screens are generally thought to have
an advantage over lethality screens for the identification of genes that have
intermediate phenotypes, as the quantitative nature of flow-cytometry allows for
the selection of cells with mutations that result in a partial as well as a complete
phenotype [325]. That said, the sorting threshold used during phenotypic
selections can influence the genes that are identified in this approach. When
determining the FACS sorting cutoff, it is important not only to consider the
stringency at which cells that show ‘true’ phenotypic changes are captured,
but also to collect sufficient cells from the ‘non-binding’ population such that a
wide range of gene perturbations that cause both weak and strong phenotypic
effects can be identified. The use of highly stringent sorting gates (e.g. 0.1%
of total population) can lead to a notable enrichment of very few genes with
strong effect sizes in the sorted population (as seen on the screen using an
anti-BSG mAb), but risks having insufficient representation of gRNAs to detect
genes with low effect sizes.
The use of a CRISPR-Cas9 based screening approach for the identification
of genes that have both strong and weak effects in regulating the expression
of a protein has previously been demonstrated in the context of expression
of tumor necrosis factor (Tnf) in mouse-derived primary dendritic cells upon
lipopolysaccharide (LPS) stimulation [186]. A FACS-based sorting strategy (5%
sorting threshold) was designed in the study in which cells within the mutant
population that were either refractory to Tnf expression or that induced Tnf
more strongly, were differentially collected and assessed for the cellular factors
that mediated the regulatory response. A large number of genes were identified
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in the screen as important for the regulation of Tnf expression upon LPS
stimulation; the highest ranking 176 (112 positive and 64 negative) candidate
regulators were chosen for targeted gene KO validation. Of the tested genes,
57/112 positive but only 4/64 negative regulators were correctly validated.
To reduce the high number of false-positive genes, the authors opted for a
secondary validation with a focused library, in which up to 10 gRNAs/gene were
designed for the top ranked 2,569 genes and a secondary pooled screen was
carried out, which was shown to have improved the specificity and sensitivity
of a pooled screen. This study demonstrated the way in which FACS-based
CRISPR-KO screens can be used to carry out comprehensive dissection
of genetic pathways contributing to protein expression in a defined cellular
context (for example, LPS induction). However, the screening approach also
highlighted the importance of secondary validation steps that are usually
required for high-confidence identification of regulatory genes when permissive
sorting thresholds are used. In the work described here, I sought to establish
the sorting parameter that would allow for a balance between identification
of genes that have weak effects and genes that could be identified with high
confidence without necessarily performing a secondary pooled screen. Based
on the data obtained from the antibody screens in this study, I determined that
collecting at least 300,000 to 500,000 cells at a 0.5-1% stringency threshold
from a high complexity library (500-1000× per gRNA) is generally appropriate
for the high-confidence identification of the directly interacting receptor and
additional genes related to the biology of the receptor from a single experiment.
In the screens carried out in this work, the phenotype selections were
carried out with a single sort. In the mAb screens described in chapter 3, I
observed that sorting the selected population just once rather than multiple
times is sufficient to identify both the epitope target and the cell pathways
responsible for surface expression. A more stringent approach to sorting
proceeds through iterative selections in which the mutant cells displaying the
phenotype of interest are enriched through multiple rounds of sorting. Such
approach have also been applied successfully in multiple loss-of-function
genome-scale screens [187, 235, 145]. Multiple rounds of selections are
usually desirable either when the signal-to-noise ratio of the desired phenotype
is low or when the aim of the screen is to identify mutants that have strong
phenotypes. When using an iterative selection approach for FACS-based
screens, it is important to consider that often the sorting process can cause
cell death (mainly caused by sheer force of the sorter); thus, not all collected
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cells will be represented in the next round of sorting. Again, this might not
greatly affect identification of genes with strong effect sizes, but this type of
highly stringent sorting approach might not be ideal when the screen is to be
used to investigate genetic pathways, where the representation of mutant cells
displaying weaker phenotype is low initially.
6.1.2 The timing of phenotypic selections
The timing of phenotypic selections can influence the genes that are identified
in genome-scale KO screens. As the number of days post transduction with
the lentivirus (for the generation of the KO library) increases, the overall
representation of the gRNAs targeting genes required for general cellular
proliferation is likely to decrease from the total mutant population. The longer
the mutant library is kept in culture, the more difficult it can be to investigate the
role of essential genes. In the screens carried out using mAbs, I specifically
observed the influence of screen timings in the identification of genes of the
SRP-dependent protein export pathway. The majority of proteins destined
for the plasma membrane are initially targeted to the endoplasmic reticulum
by the SRP-dependent protein translocation machinery [204]. Thus, genes
relating to this pathway are expected to be identified in screens designed
to study cellular recognition events. However, a number of genes in this
pathway are also known to be core-essential, which means that the likelihood
of cells lacking those genes being non-viable increases, the longer the mutant
library is cultured. This often led to the reduced representation of general
protein export pathway when selections were performed at late time points
(day 15-16) compared to early time points (day 9). This can be taken into
consideration while designing similar screens in the future; if the effect of
genes required for proliferation and viability is to be investigated in the context
of cellular recognition process, carrying out screens at an early time-point (day
9 post-transduction) would be generally appropriate. On the other hand, if the
approach is to be used to identify few targets with strong size effects rather
than general cellular pathways, it might be appropriate to perform screens at a
later time point (day 15-16 post transduction).
In loss-of-function screens, when the iterative selection approach is used to
enrich for mutant cells displaying the phenotype of interest over an extended
period of time, it also leads to the reduction in the representation of gRNA
targeting genes indispensable for cell proliferation and viability. An iterative
selection approach was recently described to identify host factors important for
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HIV infection [182]. In the study, a naturally susceptible T-cell line was serially
infected with HIV and the mutant cells refractory to infection were enriched over
a course of six weeks. Using this approach, a restrictive set of five host factors
(three novel factors; ALCAM, SLC35B2 and TPST2 and two known receptors;
CD4 and CCRC5) critical to the survival of HIV in host cells was identified.
All the identified factors were found to be dispensable for host cell viability;
thus the authors suggested that these factors could be attractive targets for
therapeutic intervention. This exemplifies how the sorting approach in terms of
stringency and screening end points can influence the genes that are identified
from a KO screen.
6.2 Potential of genome-scale KO screens using
mAbs for the study of receptor biology
The genome-scale KO screens carried out in this work using mAbs as screen-
ing probes demonstrated how such screens can be used to study the biology
of cell surface receptors. Similar use of mAbs in CRISPR-Cas9 KO screens to
investigate the cellular factors required for cell surface expression of membrane
proteins has been very recently applied by others for the identification of a
CKLF-like MARVEL transmembrane domain containing protein 6 (CMTM6) as
a critical regulator of programmed death-1 (PD-1) ligand 1 (PD-L1) in a broad
range of cancer cells [187]. In the study, a KO screening approach using an
anti-PD-L1 mAb as a screening probe was carried out, and cells refractory
to antibody staining of PD-L1 were found to be enriched in gRNAs targeting
CMTM6 in addition to PD-L1 itself. Further studies revealed the association
of CMTM6 with PD-L1 at the plasma membrane and in recycling endosomes,
where CMTM6 was found to protect PD-L1 from being targeted for lysosomal
degradation. This study further exemplifies how a genome-scale approach
using mAbs can be a valuable means to investigate the biology of cell surface
receptors.
In this work, the genome-scale KO screens carried out using mAbs in
some cases revealed potentially interesting novel factors (e.g., SPPL3 and
WDR48 in the screen with anti-BSG mAb; TNNT3 in the screen with anti-
GYPA mAb) that have not been previously reported to be associated with the
expression of the corresponding receptors. The precise roles of these factors
were not investigated in this work, but before further research is carried out, it
is important to first validate these genes using targeted gene KO approaches.
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Based on the known functions of these factors (e.g. SPPL3 as a regulator
of N-glycosylation [326]; WDR48 as a regulator of deubquitylating complex
[327, 328]; and TNNT3 as a factor known to bind tropomyosin, which is a
member of the erythrocytic membrane skeleton [225]), further studies can
be designed to investigate their roles in membrane expression (or antibody
epitope presentation) of the receptors.
6.2.1 Potential for the study of receptor biology in a high-
throughput manner
The screening strategy described here using mAbs as screening probes can be
adapted to be carried out in a high-throughput manner. From a single lentiviral
transduction of 80-100 million cells, I was usually able to generate mutant
libraries of sufficient size to carry out screens using 8-10 different probes.
This, combined with the ability to multiplex up to 15-20 samples in a single
sequencing (Hi-seq 2500 platform) run, will allow for up-scaling the throughput
of this screening platform. This can be further facilitated by the Cancer Cell
Line project and the cGAP facility at the Sanger Institute, which has generated
approximately 400 Cas9-expressing cancer cell lines. Most of these cell lines
are genomically well-characterised, which can facilitate the selection of a panel
of transcriptionally diverse cell lines to conduct genetic screens to study the
biology of a wide range of receptors. Using these resources, a systematic
approach can be devised, in which cell lines that express the receptor of
interest can be identified using transcriptomic analysis and screens can be
carried out using mAbs to identify cellular factors that are important for the
expression of the cell surface receptors. The approach could be carried out
for cell surface receptors, which are currently targets of antibody therapy, or
small molecule inhibitors in order to understand how the expression of the
therapeutically important receptors are regulated at the surface of cells.
6.3 Assessment of the approach to identify re-
ceptors of soluble protein ectodomains
In Chapter 4, I demonstrated the utility of a genome-scale CRISPR-Cas9
screening approach for the identification of directly interacting receptors on
the surface of cells for a panel of recombinant protein probes. I also found
that a general factor involved in several cell surface recognition events was
the role played by glycosaminoglycans (GAGs) (specifically HS), which form
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a major part of the cellular glycocalyx. An important discovery in this regard
was the observation that many recombinant proteins adsorb into HS without
necessarily binding to a specific receptor. Additionally, in the context of the
cellular binding assay described here, HS were also found to contribute to
binding in an additive rather than the specific receptor-dependent manner
for proteins such as RH5, and the individual contribution made by either the
specific receptor or HS could be dissected at a molecular level. When the
fractional contribution from adsorption into HS (as determined by comparing
the binding to the parental line with the binding on SLC35B2-KO version of the
line) was low (<20%), in every case I was able to identify the corresponding
interaction partner using this approach. This led to the development of a
two-step approach, in which every observed binding event on a parental line
was first tested to be mostly retained on a SLC35B2-KO version of the line
before proceeding to the genome-scale screening step. I believe that this will
provide extremely useful guidance to others using this approach in the future.
To further develop this approach, I have now generated six different cell
lines (HEK-293-E, NCI-SNU-1, HL-60, KBM7, HepG2 and HEL) that lack the
SLC35B2 gene. These cell lines can be used for the pre-screening step to
determine ligands suitable for this approach to identify novel receptors. Cur-
rently, this approach is actively being used in the laboratory to screen a panel
of approximately 70 recombinant proteins, representing diverse ligands from
both human and parasite surface proteins (e.g., megakaryocyte proteins, im-
mune regulatory proteins, sporozoite-stage proteins from P. falciparum, surface
proteins of Leishmania donovani). These ligands will be tested for binding
on the SLC35B2-KO cell lines and their corresponding parental versions; the
candidates that retain their binding on the SLC35B2 will be used as screening
probes to carry out genetic screens to identify receptors.
The adaptation of this technique to identify cell surface receptors for recom-
binant protein ligands in a high-throughput manner is limited by the number of
recombinant proteins that can be used as screening ligands. The limiting step
in the method is the pre-screening criterion in which proteins are only chosen
if they do not largely depend on HS for binding to the cell lines. Currently, it
takes up to two months to recombinantly produce 100 proteins and screen
them on the available cell lines (six cell lines and the corresponding versions
that lack SLC35B2 are available). However, binding to a given parental line
is not a common event in the first place, and the observation up to now has
been that it is more common to observe bindings dependent on SLC35B2 than
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without. Parasite proteins also seem to have a higher propensity of binding to
cells in a HS-dependent manner than without. In this work, I identified multiple
proteins of the P. falciparum merozoite that adsorb into HS. Similarly, recent
pre-screens carried out in the lab by Zheng Shan Chong and Amalie Couch
using 20 proteins of Leishmania donovani on six lines showed that seven
bound to at least one parental line but all seven out of seven bindings were
completely dependent on HS (as determined by testing binding on SLC35B2-
KO line and with soluble heparin blocking experiments). Of the approximately
200 proteins that have been screened, only 35 have shown binding to at least
one parental line and of these only 10 proteins have retained their binding
on the SLC35B2-KO version of the parental line. Of the 10 proteins that
have shown retention of binding, I have carried out genetic screens on five
proteins (CD226, EPHB1, TNFRSF9, LPHN1 and GABBR2); in every case,
I was able to identify the directly interacting receptor. Thus, this method is
not necessarily a high-throughput method but with the controls in place, it
has a very high success rate. In addition, because it does not require any a
priori assumptions to be made regarding the biochemical properties of the
cell surface receptor, and additionally identifies genetic pathways important for
the cell biology of membrane-associated proteins (for example, the function
of endosomal acidification in the transport of IGF2R and the role of p53 in
expression of TNFSF9), it has an advantage over biochemical or cDNA-based
gain-of-function approaches to study protein-protein interactions.
One potential way to improve this approach would be to screen the recombi-
nant proteins in the ‘biologically relevant’ cell lines. In this work I mainly utilised
HEK-293-E cells, because they are easy to transduce with lentiviruses and
can be grown in suspension culture, thus avoiding the need for enzymatic or
mechanical dissociation, which can alter the receptors on the surface of cells.
This makes HEK-293-E cells, and easily transducible suspension cell lines in
general, well-suited for genetic screens designed to study cellular recognition
processes. In addition, the initial study into the interaction between RH5 and
BSG suggested that physiologically relevant interactions, which occur at the
red-blood cell surface, can still be identified in this cell line. However, a better
approach would perhaps be to match the proteins to the cell line of related
biology. For example, the proteins of the macrophage-invading Leishmania
donovani parasite could be tested on macrophage-related cell lines such as
U937 and THP1, and the proteins of hepatocyte-invading sporozoites could be
tested on hepatocyte derived lines such as HepG2 and Huh7. The high activity
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Cas9-expressing cell lines and the corresponding SLC35B2-KO versions that
I have now generated represent cell lines from different origins, but this can
be further expanded, depending on the proteins that are to be tested. Testing
binding on biologically relevant cell lines in which there is possibly a higher
chance of a specific receptor being present could also decrease the number
of proteins that are identified to depend largely on HS for binding.
6.4 Interaction between IGF2R and GABBR2
Using the genetic screening approach developed in this work, I was able
to identify a novel interaction between the ectodomain of GABBR2 receptor
and a known cargo receptor IGF2R. Although the constitutive internalisation
of GABAB receptors using clathrin/dynamin dependent pathways has been
demonstrated in multiple studies [289, 292, 329, 330], the precise mechanism
of internalisation has remained unknown. The GABBR2 subunit itself contains
a known structural motif —Yxxϕ, where x can be any amino acid and ϕ
is a bulky hydrophobic residue)—that is required for recruitment of adaptor
proteins for clathrin-dependent endocytosis [331]; however, the mutation in
the critical tyrosine (Y) residue together with the hydrophobic leucine residues
has been shown to have no effect on internalisation [332]. In addition, the
C-terminus truncation of either the GABBR1a subunit or the GABBR2 subunit
has also been shown not to have an effect on the rates and extent of the
GABAB heterodimer internalisation in live HEK293 cells. Based on these
observations, researchers have suggested that the clathrin recruitment of
GABAB receptors is likely to be mediated by other regions of the proteins
[332]. The finding in this study that IGF2R, a known cargo receptor with a
well-defined internalisation sequence for recruitment of clathrin coats, directly
interacts with the ectodomain of GABBR2 potentially provides the missing
molecular explanation for the observed GABAB internalisation.
To validate the hypothesised function of IGF2R in internalisation of GABAB
receptors, further experiments can be carried out to address the following
topics:
• Effect of IGF2R-KO on internalisation of GABAB receptors: As HEK293
cells have been used as models in the past to study the internalisation of
GABAB receptors, I would conduct the preliminary experiments to test
the hypothesised function of IGF2R also in the HEK-293-E cell system.
To this end, I have generated an IGF2R-KO version of a HEK-293-E cell
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line. To validate that GABAB on the surface of cells is internalised by
IGF2R, parental HEK-293-E cells and cells lacking IGF2R can be trans-
fected with both components of the heretodimers and their constitutive
rate of internalisation can be compared. A number of endocytosis assays
that utilise antibody labelling of extracellular epitopes on receptors, recep-
tor biotinylation, and fluorescent-tagging techniques have already been
applied to study the mechanism of internalisation of GABAB receptors
in HEK293 cells [289, 292, 329, 330, 333]. Similar approaches could be
designed to assess the effect of IGF2R-KO on constitutive internalisation
of GABAB receptors.
• Regulation of mannose-6-phosphorylation on GABBR2: What causes
GABBR2 to be mannose-6-phosphorylated? Is it a constitutive or a
regulated process? I have conducted initial experiments in this re-
gard and prepared lysates from mouse brains. I intend to carry out
a pull-down experiment from this lysate using a recombinant biotinylated
IGF2R ectodomain that is conjugated to streptavidin-coated paramag-
netic beads for increased avidity. If the endogenous GABBR2 is consti-
tutively mannose-6-phosphorylated, it should in principle be possible to
observe this interaction using the biochemical pull-down approach. This
experiment would rely on the ability of the mouse GABBR2 to interact
with human IGF2R, but given that mouse GABBR2 is 98% identical to the
human version of the protein, it is likely that the interaction is conserved.
Based on the initial experiments in heterologous cells, further long-term
experiments can be designed to address how IGF2R functions in receptor
internalisation of neuronal GABAB receptors. Experiments with primary cul-
tured neurons have also shown rapid internalisation of GABAB receptors in the
absence of an agonist, which is in line with the findings in this work. GABAB
receptor internalisation is understood to be the main mechanism by which
signalling through this important class of inhibitory neurological regulators is
controlled; future work on this may therefore suggest new ways of neurotrans-
mission regulation, which may be useful in treating a wide range of neurological
disorders, including epilepsy and depression.
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6.5 Concluding remarks
In this work, I have described a genome-scale CRISPR KO approach to in-
vestigate the molecular basis of cell surface receptor biology and recognition
events. I have demonstrated how this method can be applied to identify directly
interacting receptors for commonly used probes such as monoclonal antibod-
ies and recombinant proteins, in addition to revealing the genetic pathways
important for the cell biology of membrane-associated proteins. It is a gener-
ally applicable approach that can be used to explore cellular signalling and
recognition processes in a wide range of different biological contexts, including
between our own cells (e.g. neural and immunological recognition), as well as
between host cells and pathogen proteins. Perhaps most importantly, because
this technique does not require any prior assumptions to be made regarding
the biochemical nature or cell biology of the receptors and provides an op-
portunity to study interactions mediated by cell surface receptors of unique
biology, such as glycans, glycolipids, and phospholipids, it has great potential
to make completely unexpected discoveries which would otherwise be very
difficult to achieve.
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APPENDIX A
Table A.1 Primers used for cloning IGF2R into protein expression vectors
Fwd=Forward, Rev=Reverse
Name Sequence 5’-3’ (restriction sites
are indicated in bold)
Purpose Restriction
site
IGF2R-Fwd GACTGCGGCCGCCACCATG
GGGGCCGCCGCCGGCCG-
GAG
Fwd primer for amplification
of IGF2R ectodomain
NotI
IGF2R-Rev CAGTGGCGCGCCGACTGCC
TGGCTCCGTTCTGAC
Rev primer for amplification of
IGF2R ectodomain
AscI
OL497 TGAGATCCAGCTGTTGGGGT Fwd sequencing primer -
OL4006 TCCCTGCAGGCTTTCCTCT
CCAAGGTTGAG
Rev sequencing primer -
Table A.2 Sequences of guide RNAs used in this study
Gene Oligos: Sense (S) and antisense (AS)- 5’-3’ gRNA ID from Human v1 library
BSG S: CACCGTCGTCAGAACACATCAACG
AS: AAACCGTTGATGTGTTCTGACGAC
BSG_CCDS12032.1_ex2_19:580670
-580693:+_9-4
SDC1 S: CACCGATGAGACCTCAACCCCTGC
AS: AAACGCAGGGGTTGAGGTCTCATC
SDC1_CCDS1697.1_ex2_2:20403694
-20403717:-_5-3
CD55 S: CACCGGGCCGTACAAGTTTTCCCG
AS: AAACCGGGAAAACTTGTACGGCCC
CD55_CCDS31006.1_ex1_1:207495775
-207495798:+_5-1
CD44 S: CACCGTACAGCATCTCTCGGACGG
AS: AAACCCGTCCGAGAGATGCTGTAC
CD44_CCDS31455.1_ex1_11:35198176
-35198199:+_5-2
EXTL3 S: CACCGGTCCATCCGTCCGCCAGTG
AS: AAACCACTGGCGGACGGATGGACC
EXTL3_CCDS6070.1_ex0_8:28574365
-28574388:-_5-3
SLC35B2 S: CACCGTCGGCGCAGCTACGAACAC
AS: AAACGTGTTCGTAGCTGCGCCGAC
SLC35B2_CCDS34462.1_ex0_6:44223027
-44223050:-_5-1
TP53 S: CACCGCAGTCACAGCACATGACGG
AS: AAACCCGTCATGTGCTGTGACTGC
TP53_CCDS11118.1_ex6_17:7578415
-7578438:-_5-1
IGF2R(4) S: CACCGCGGTCACTACGCATTCCAG
AS: AAACCTGGAATGCGTAGTGACCGC
IGF2R_CCDS5273.1_ex16_6:160468883
-160468906:-_5-4
IGF2R(5) S: CACCGACAACGACGGATACAGACC
AS: AAACGGTCTGTATCCGTCGTTGTC
IGF2R_CCDS5273.1_ex19_6:160477535
-160477558:+_5-5
WDR7 S: CACCGTGCGGAATGAATCACTAGC
AS: AAACGCTAGTGATTCATTCCGCAC
WDR7_CCDS11962.1_ex7_18:54358952
-54358975:-_5-5
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Table A.3 Summary of the screening parameters for all screens carried out in this
study. The table indicates the total number of cells screened within each library,
the day the selection was performed, the number of collected cells, and the sorting
threshold each for each indicated staining probe/cell line pairing used.
Cell line Staining
probe
Day of se-
lection
Number of
sorted cells
in the library
(x106)
Number of
collected
cells
Sorting threshold
(% of non-binding
cells selected)
HEK-293-E BRIC229 15 100 380,000 0.5
HEK-293-E BRIC126 9 80 280,000 1
HEK-293-E B6H12 9 80 200,000 1
HEK-293-E MEM6/6 16 60 40,000 0.2
HEK-293-E BRIC5 9 50 120,000 0.8
HEK-293-E P16 9 60 180,000 1
HEK-293-E RH5 9 80 200,000 0.7
HEK-293-E EBA181 14 70 420,000 1
HEK-293-E MSRP5 14 70 390,000 1
HEK-293-E APP 9 60 320,000 1.1
HEK-293-E APLP2 9 70 330,000 1
HEK-293-E G6B 15 100 800,000 0.75
HEK-293-E CD226 9 70 340,000 1.7
HEK-293-E EPHB1 9 70 300,000 1.4
HEK-293-E LPHN1 14 70 1,200,000 4.3
HEK-293-E GABBR2 14 125 780,000 2.3
NCI-SNU-1 SERA9 16 50 180,000 1
NCI-SNU-1 TNFRSF9 14 80 600,000 1
HEL BRIC256 14 50 300,000 1.7
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A.1 Protocol for PCR amplification of gRNAs from lentivi-
rally transduced cells for Illumina sequencing.
First PCR: This set up is for analysis of gRNAs from high complexity samples
(e.g. control samples).
Step 1: Set up the following PCR master mix and aliquot 50 µL to 36 wells.
Reagent Volume per reaction Master mix (x38)
Q5 Hot Start High-Fidelity 2× Master Mix 25 µL 950 µL
Primer (L1/U1) mix (10 µM each) 1 µL 38 µL
Genomic DNA (1 mg/mL) 2 µL 76 µL
H2O up to 50 µL up to 1900 µL
Step 2: Run the following PCR program.
Cycle number Denature Annealing Extension
1 98 ◦C, 30 s
2-26 98 ◦C, 10 s 61 ◦C, 15 s 72 ◦C, 20 s
27 72 ◦C, 2 min
Step 3: Collect 5 µL PCR product from each well (180 µL in total) and
purify using Qiagen PCR purification kit. Elute DNA into 50 µL EB buffer and
measure DNA concentration.
Second PCR
Step 4: Dilute the first PCR product to 40 pg/µL and set up one PCR
reaction per sample. The forward primer (PE 1.0) is common to all samples,
whereas the reverse primers are sample specific index primers (refer to table
A.4).
Reagent Volume per reaction
KAPA HiFi HotStart ReadyMix 25 µL
Primer (PE1.0/index primer) mix (5 µM each) 2 µL
First PCR product (40 pg/µL) 5 µL
H2O 18 µL
Step 5: Run the following PCR program.
Cycle number Denature Annealing Extension
1 98 ◦C, 30 s
2-15 98 ◦C, 10 s 66 ◦C, 15 s 72 ◦C, 20 s
16 72 ◦C, 5 min
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Table A.4 Primer sequences for amplifying gRNA and NGS.
Name Sequence 5’-3’ (restriction sites are indicated in
bold, * represents phosphorothioate)
Purpose
U1 ACACTCTTTCCCTACACGACGCTCTT-
CCGATCTCTTGTGGAAAGGACGAAACA
Forward primer for gRNA
amplification
L1 TCGGCATTCCTGCTGAACCGCTCTT-
CCGATCTCTAAAGCGCATGCTCCAGAC
Reverse primer for gRNA
amplification
PE1.0 AATGATACGGCGACCACCGAGATCTAC-
ACTCTTTCCCTACACGACGCTCTTCCGATC*T
Forward primer for Illu-
mina library preparation
iPCRTag1 CAAGCAGAAGACGGCATACGAGATAAC-
GTGATGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag2 CAAGCAGAAGACGGCATACGAGATAAA-
CATCGGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag3 CAAGCAGAAGACGGCATACGAGATATG-
CCTAAGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag4 CAAGCAGAAGACGGCATACGAGATAGT-
GGTCAGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag5 CAAGCAGAAGACGGCATACGAGATACC-
ACTGTGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag6 CAAGCAGAAGACGGCATACGAGATACA-
TTGGCGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag7 CAAGCAGAAGACGGCATACGAGATCAG-
ATCTGGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag8 CAAGCAGAAGACGGCATACGAGATCAT-
CAAGTGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag9 CAAGCAGAAGACGGCATACGAGATCGC-
TGATCGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag10 CAAGCAGAAGACGGCATACGAGATACA-
AGCTAGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag11 CAAGCAGAAGACGGCATACGAGATCTG-
TAGCCGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
iPCRTag12 CAAGCAGAAGACGGCATACGAGATAGT-
ACAAGGAGATCGGTCTCGGCATTCCTG-
CTGAACCGCTCTTCCGATC*T
Reverse indexing primer
for Illumina library prepa-
ration
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Fig. A.1 Enlarged version of figure 3.10B for better clarity of gene names
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Fig. A.2 Enlarged version of figure 3.12 for better clarity of gene names
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Fig. A.3 Enlarged version of figure 3.14A for better clarity of gene names
ChapterA
Fig. A.4 Genome-scale KO screen using an anti-CD58 mAb identifies CD58 as
the highest enriched gene in the sorted population. Gene-level enrichment anal-
ysis on a screen carried out using an anti-CD58 mAb. CD58 was identified as the
highest enriched gene. Two genes relating to general secretory were also identified
(highlighted in red). Only genes with FDR<0.05 are depicted.
Fig. A.5 Primary screen for binding of 11 merozoite proteins to six cell lines.
Biotinylated monomeric merozoite ectodomains conjugated to streptavidin-PE were
tested for binding six cell lines. The number in each grid represents the percentage of
cells that fell within the ‘binding’ gate, which was drawn on the histogram obtained from
control protein binding to the parental cell lines (example depicted in the right panel).
RH5 bound to all the tested cell lines, consistent with the expression of BSG in these
lines (as determined from antibody staining with anti-BSG antibody- data not shown).
HL-60 and HEL cells demonstrated restrictive binding profiles with clear binding only
to RH5. Five ligands, SERA9, EBA181, MSRP5 CyRPA and RAMA bound at least
three out of the six cell lines tested.
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CRISPR-Cas9 knockout screens for cellular recognition
Fig. A.6 Binding of merozoite proteins RAMA and CyRPA to HEK-293-E cells
can be completely blocked by soluble heparin. RAMA and CyRPA were identified
in the preliminary screen to bind to HEK-293-E cells in a SLC35B2-dependent manner.
Secondary validation with pre-blocking with soluble heparin (0.2 mg/mL) demonstrates
complete inhibition of binding by soluble heparin. RH5 is used as a control; binding of
RH5 is only partially blocked when pre-incubated with equivalent amount of heparin.
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Other functions
Fig. A.7 Summary of ‘overlapping factors’ identified in at least two out of six
screen that identified the HS-biosynthesis pathway. Apart from the identification
of multiple genes involved in biosynthesis of HS, these screens also revealed genes
involved in protein transport and secretion, cellular house-keeping genes, genes
involved in vesicular acidification, factors involved in global glycosylation in cells
(TMEM165, PTAR1), and genes encoding for proteins involved in tail anchoring
pathway (ASNA1, GET4). The screens with EBA181, MSRP5 and SERA9 were
conducted on day 15/16 whereas the screens with G6B, APP and APLP2 were
conducted on day 9: note that the representation of ‘core-essential’ genes (SLC61A1,
SRP19, ALG2, DPAGT1, GTF3C1, ATP6V1A, ATP6V0C, DBR1, CPSF4) on screens
carried out on later days is lower compared to the early time point screens.
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Table A.5 Summary of ‘other factors’ identified with FDR<0.05 in at least two out of the seven different screens carried out using mAbs.
Gene annotations are obtained from Uniprot.
Gene Function Identified in mAb targeting
ASCC3 Member of a family of helicases that are involved in the ATP-dependent unwinding of
nucleic acid duplexes
CD47 (BRIC125, BRIC126,
B6H12), ITGB1 (P16)
AHCY Adenosylhomocysteinase; important for transmethylation reactions CD58 (BRIC5), ITGB1 (P16)
HJURP Centromeric protein that plays a role in the incorporation and maintenance of histone
H3-like variant CENPA at centromeres
CD47 (B6H12), ITGB1 (P16)
CENPA Centromere protein A- Histone H3-like variant CD59 (BRIC 229), ITGB1 (P16)
CDIPT Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) GYPA (BRIC 256), ITGB1 (P16)
EEF2 Eukaryotic Translation Elongation Factor 2 CD58 (BRIC5), ITGB1 (P16)
EIF3D Eukaryotic Translation Initiation Factor 3 Subunit D CD58 (BRIC5), ITGB1 (P16)
GTF3C2 General Transcription Factor IIIC Subunit 2 CD47 (B6H12, BRIC126)
GTF3C4 General Transcription Factor IIIC Subunit 4 CD47 (B6H12), ITGB1 (P16)
NELFCD Essential part of the NELF complex- repress transcriptional elongation by RNA
polymerase II
CD59 (BRIC229), ITGB1 (P16),
CD58 (BRIC5)
NCBP2 Nuclear Cap Binding Protein Subunit 2 CD47 (BRIC125, B6H12)
PKMYT1 Member of the serine/threonine protein kinase family, which acts as a negative
regulator of entry into mitosis
CD47 (BRIC126, B6H12), CD58
(BRIC5), ITGB1 (P16),
EXOSC4 Exosome component required for RNA processing and degradation activities CD47 (BRIC126, B6H12), ITGB1
(P16)
EXOSC2 Exosome component required for RNA processing and degradation activities CD47 (B6H12), ITGB1 (P16)
DBR1 RNA lariat debranching enzyme that facilitates ribonucleotide turnover CD47 (BRIC125, BRIC126)
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Table A.6 Genes identified in KO screens (FDR<0.05) using recombinant proteins as screening probes. The genes are ranked according to
the RRA-score. Common gene refers to the genes identified repeatedly in screens using mAb (refer to table A.5). Gene annotations are
obtained from Uniprot and annotations on core-essentiality are obtained from http://www.hart-lab.org/Data/CEGv2.txt.
Genes Function Rank Notes
Recombinant biotinylated RH5 conjugated to streptavidin-PE
BSG Known receptor for RH5 1 -
SLC35B2 Transporter of PAPS, required for GAG-biosynthesis 3 -
DBR1 RNA lariat debranching enzyme that facilitates ribonucleotide turnover 4 Common gene
SLC16A1 MCT1 transporter known to be required for transport of BSG 4 -
C9orf114 Required both for chromosome alignment and for association of the centrosomes 5 Core-essential gene
CCT3 Molecular chaperone required for protein folding 6 Core-essential gene
RPL27A Encodes a ribosomal protein 7 Core-essential gene
SIN3A Transcriptional regulatory gene 8 -
PSMG4 Promotes assembly of the 20S proteasome 9 -
FTSJ3 Probable methyltransferase 10 Core-essential gene
ARPC4 Component of Arp2/3 complex 11 -
XRCC5 Involved in NHEJ DNA repair 12 -
SRPRB SRP Receptor Beta Subunit, general protein export 13 -
SRP19 Signal Recognition Particle 19, general protein export 14 Core-essential gene
ATRIP Essential component of the DNA damage checkpoint 15 -
GNB2L1 Translational regulation 16 Core-essential gene
SART3 Encodes for RNA-binding nuclear protein, recycling factor of the splicing machinery 17 Core essential gene
CENPM Centromere protein M 18 -
Recombinant pentameric CD226
PVR Known receptor for CD226 1 -
DPAGT1 Core-glycosylation in the ER 2 Core-essential gene
Table A.6 – Continued on next page
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Genes Function Rank Notes
Recombinant pentameric CD226 (continued)
PIK3C3 Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3, involved in multiple membrane
trafficking pathways
3 -
TOP1 Topoisomerase 4 Core-essential gene
SEC61A1 General protein transport pathway 5 Core-essential gene
PIK3R4 Phosphoinositide-3-Kinase Regulatory Subunit 4, involved in multiple membrane
trafficking pathways
6 -
GMPPB Core-glycosylation pathway 7 Core-essential gene
SPDYC Promotes progression through the cell cycle 8 -
ALG2 Core-glycosylation pathway 9 Core-essential gene
CHST8 Sulfotransferase: Transfer of sulfate N-acetylgalactosamine (GalNAc) residues in both
N-glycans and O-glycans
10 -
WDR62 invoved in centriole duplication 11 -
DBR1 RNA lariat debranching enzyme that facilitates ribonucleotide turnover 12 Common gene
Recombinant pentameric EPHB1
EFNB2 Known receptor for EPHB1 1 -
NDUFAF7 Arginine methyltransferase involved in the assembly or stability of mitochondrial
NADH:ubiquinone oxidoreductase complex
2 -
GTF2H3 General Transcription Factor IIH Subunit 3 3 -
DDX27 DEAD-Box Helicase 27, required for the formation of ribosomal 47S rRNA 4 -
NDUFA3 Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydro-
genase
5 -
LUC7L3 LUC7 Like 3 Pre-MRNA Splicing Factor 6 Core-essential gene
DR1 Down-Regulator Of Transcription 1 7 -
SPCS3 Signal Peptidase Complex Subunit, general protein transport 8 -
Table A.6 – Continued on next page
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Genes Function Rank Notes
Recombinant pentameric EPHB1 (continued)
RBM14 RNA Binding Motif Protein 14, a splicing modulator 9 Core-essential gene
SEC61G General protein transport 10 -
HSD17B7 Hydroxysteroid 17-Beta Dehydrogenase 7, biosynthesis of cholesterol 11 -
Recombinant pentameric LPHN1
TMEM165 Global glycosylation in cells 1 -
TENM4 Known receptor for LPHN1 2 -
SLC35B2 Transporter of PAPS, required for GAG-biosynthesis 3 -
PTAR1 Global glycosylation in cells 4 -
ACTR2 Component of ARP2/3 complex 5 -
MCMDC2 Minichromosome Maintenance Domain Containing 2 6 -
EBP Emopamil Binding Protein (Sterol Isomerase) 7 -
Recombinant biotinylated TNFRSF9 conjugated to streptavidin-PE
TNFSF9 Known interaction partner of TNFRSF9 1 -
CDKN2A Binds to MDM2 and blocks MDM2-induced degradation of TP53 2 -
TP53 Tumor suppressor protein containing transcriptional activation, DNA binding, and
oligomerization domains
3 -
CDC37 Molecular chaperone that forms a complex with Hsp90 4 Core-essential gene
DOHH Required for generation of hypusine, an essential post-translational modification only
found in mature eIF-5A factor
5 -
STK11 Serine/Threonine Kinase 11, able to phosphorylate TP53 6 -
DYRK1A Member of Dual Specificity Tyrosine Phosphorylation Regulated Kinase family 7 -
